ELAN - 1.000 % for the LONG-time - 500 Beiträge pro Seite (Seite 17)

[welke91]

MS-Patienten schreiben:

Our Opinion

• MS is a devastating disease that affects up to two million people worldwide.
• Effective MS treatment options are limited.

• We deserve the right to have the choice whether to take drugs to treat our disease or not to take drugs to treat our disease.

• If we choose drugs to treat our disease, then we want the right to choose which drugs to take.

• It is extremely important for patients to be fully informed as to the pros and cons of each treatment option.

• We all have an obligation to ourselves and our families to ensure that we are properly and fully informed.

• Many of us have injected ourselves with interferons or Copaxone®, and some of us have even had to resort to chemotherapy.

• Tysabri appears to be the most effective treatment option for MS, based on two years of clinical data, and we want the ability to choose Tysabri as our treatment option.

• We feel that a reasonably safe and effective treatment option should not be blocked or delayed by the FDA or the competing companies in the pharmaceutical industry that market the less effective and older treatment alternatives.

http://www.mspatientsforchoice.org/test.htm

[Nostarowie]

Thx werd ich tun.

[Poppholz]

in den USA sinkt der Kurs auf $13,79

[Poppholz]

$13,70

[Poppholz]

9.000 Stück zu $13,69 in den ASK geschmissen.

Hier stehen wir auch im Moment.

[zenman]

die amis kriegen schiss vor dem AC
es wird wohl ne gewinnmitnahmewelle geben

ich hatte eigentlich auf ne steigungswelle bis 8.03 getippt
tja
so kann man sich irren

[hechtbarsch]

ruhig Blut

nächste Woche wird alles gut

[bernie55]

[posting]20.423.593 von zenman am 28.02.06 15:17:51[/posting]es wird wohl ne gewinnmitnahmewelle geben


....Ne....

[Poppholz]

$13,65

[bernie55]

[posting]20.423.824 von bernie55 am 28.02.06 15:26:59[/posting]...erst down, dann wieder up.....

[Birgit.Tersteegen]

bloss nicht rausdrängen lassen!!HEFTIG!!

[bernie55]

[posting]20.423.593 von zenman am 28.02.06 15:17:51[/posting]...bist jetzt wieder draußen , Zenman ???

[Nostarowie]

Echt der wahnsinn der Kurs wird regelrecht bereinigt.
Mal sehen wo ein ende ist.
eben wieder 13,14.

[Birgit.Tersteegen]

DIE AMIS SPINNEN!

[hechtbarsch]

bestimmt stopp-loss-fishing,hab ich mal bei Rambus erlebt, das war echt der hammer, genauso schnell geht es dann aber wieder gen norden

[YoungRich]

[zenman]

nö
hab kein SL drinnen

gibt kein grund vorm 8.märz panisch zu verkaufen

[bernie55]

[posting]20.423.844 von bernie55 am 28.02.06 15:27:38[/posting]sorry......


down......up........down.....up.........down........up....up....up......up

[flow_solver]

Es gab ein Downgrade von Piper Jaffrey, nichts genaues weiss man.

[bernie55]

[posting]20.424.261 von flow_solver am 28.02.06 15:42:30[/posting]....also, das bekannte Spielchen !!!!!

[flow_solver]

Idiot Piper Says
by: tortoise2win (47/M)
Long-Term Sentiment: Strong Buy 02/28/06 09:43 am
Msg: 929232 of 929233

... best case is 10% of MS population will take Tysabri. That gives Ty a value of $9 per share according to Piper. All "fully reflected in price" per Piper. Rating is "market perform". Idiots!

[Poppholz]

$13,06

[eliasesteban]

hello @ all,da leg ich doch nochmal nach,wenn ich bedient werd

[bernie55]

13,33 USd...

[Birgit.Tersteegen]

..sagte ich schon dass NICT NUR die Römer spinnen??!!13,47

[Nostarowie]

Es ist ein gar grausiges Spiel.

nu sin mer wieder bei 13,41 heijeijeijeijeijei

[hechtbarsch]

stop loss fishing

was sonst, die alten drückeberger

[bernie55]

...Mensch , da wird wieder PINGPONG gezockt!!!!!

...ein aktueller Kurs entsteht, sofort wird auf der Sell Seite der gerade entstandene Kurs unterboten.....

...immer das selbe Spiel....aber wie lange können die BIGS das noch aufrechterhalten????

..aktuell 13,41 USD

[Bachalor]

[bernie55]

[posting]20.424.876 von Bachalor am 28.02.06 16:04:59[/posting]......ich weiß nicht, ob dein Schneeschieber heute helfen kann....

...heute sind die BIGS in USA dran und die schieben heute mit anderen Kalibern.....

[Bachalor]

[posting]20.424.941 von bernie55 am 28.02.06 16:07:28[/posting]meinst du so




ich schiebe mir einen wolf
und die wachsen schneller nach

[bernie55]

[posting]20.424.985 von Bachalor am 28.02.06 16:09:19[/posting]...so ungefähr, Bachalor....

[flow_solver]

Piper put out some survey results of 140 doctors and how the prescription rate of TY will be limited.

Ask yourself, "If I were a doctor and I was taking a SURVEY on my prescription plans for TY if it were reapproved, how would I answer?"

My own thinking is that I would answer as conservatively as possible to limit my exposure to ANY liability in the future - even though I may actually be more aggressive with my prescription writing of TY.

Just jumped on more calls.

Good luck all.

[Bachalor]

bin heute nacht erwischt worden

[Birgit.Tersteegen]

manchmal ist Börse wirklich strange...

hate to be optimistic...
by: yedistock 02/28/06 09:39 am
Msg: 929207 of 929623

But I think we go up a lot before the end of this week. When we have these unexplained "huge" drops, they are generally followed by a spike back up. Kind of a last shove to gain shares. What a stock we all own!

[Birgit.Tersteegen]

Long Term Capital Gain - Nothing More
by: viperdriver555 02/28/06 09:45 am
Msg: 929240 of 929653

This drop is simply from those people that were waiting to sell in order to qualify for the long term capital gains (which is today). We may see more of this over the next couple of days, particulary one year from the date that it sank to $3.00. This will pass and we will have a significant move up after that. Look at this as a buying opportunity. Good luck to all longs

[Birgit.Tersteegen]

hats changed? NOTHING THATS WHAT!
by: COBRAGENE
Long-Term Sentiment: Strong Buy 02/28/06 09:49 am
Msg: 929256 of 929664

MMs shaking the trees.
They know in 5 trading days they won`t be able to
touch these shares under $17

[Nostarowie]

Nu guckt doch ma das brutale downgap.



...das sollte doch wieder zugemacht werden.

[zenman]

aber heut sicher net

[Nostarowie]

Mist

[zenman]

wassn jetz ?


Piper price target reduction
by: dagcoams
Long-Term Sentiment: Strong Buy 02/28/06 12:18 pm
Msg: 929712 of 929724

The news release hit Ameritrade news at 6:10 am. Price target reduced from $15.00 to $14.00. I would love to hear their rational as to why

hier steht KZ 14 $

hatte doch heut mittach was von 9 $ gelesen

[Birgit.Tersteegen]

[posting]20.428.564 von zenman am 28.02.06 18:25:17[/posting]ob 14 /9 oder 0--alles QuatschmitSosse!

Ich glaube ich verlege mich aufs Häkeln (allerdings konnte ich das noch nie....)

[flow_solver]

@zenman

Ja, die 9 Dollar sieht Piper allein für Tysabri, die weiteren 5 Dollar zum Kursziel 14 Dollar sind für das Restgeschäft (Nano etc.). Also alles im Lot, wahrscheinlich hats wegen dieser missverständlichen Meldung viele Leute so gesehen, dass das Kursziel insgesamt 9 Dollar sind!. Gut gemacht, muss man den Jungs schon lassen.

[zenman]

habs inzwischen im forbes gelesen

Elan`s Tysabri Valued At $9 Per Share
Peter Kang, 02.28.06, 12:25 PM ET

Piper Jaffray trimmed the price target on Elan and said a recent survey of neurologists indicate that a return of Tysabri is "more than accounted for" in the current stock price.

Tysabri is a treatment for multiple sclerosis drug that was pulled from the market by Elan (nyse: ELN - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) in early 2005 due to safety issues. A U.S. Food and Drug Administration advisory committee will meet next week to discuss a potential re-entry of the drug.

"The results from our freshly finished survey suggest that Tysabri will have limited and likely restricted use," wrote Piper analyst Deborah Knobelman in a client note issued Tuesday. "At most, doctors expect to use it in 10% of MS patients."

The analyst lowered the price target on Elan to $14 from $15.

"Based on these survey results, our NPV [net present value] on Tysabri shows that the value of Tysabri is $9 per share and has been more than accounted for in the current stock price," the analyst said.

Of the 140 neurologists in the survey, 92% believed Tysabri could be a valuable therapy but 59% said Tysabri should not return given the risks of progressive multifocal leukoencephalopathy (PML), a brain infection, which resulted in the deaths of two Tysabri patients last year.


der abverkauf is wohl
weil die neurologen schiss vor PML ham
daraus wird wohl eine zurückhaltung bei der verschreibung
an die patienten geschlossen
oder
man befürchtet
die neurologen auf der AC
werden ebenfalls höchst vorsichtig und zurückhaltend
bzgl. rückkehr TY sein


Knobelman maintained a "market perform" rating on Elan

[[KERN]Codex]

Ich hoffe ihr habt nun endlich CEL SCI, da knallen demnächst die Korken

[Birgit.Tersteegen]

[posting]20.430.045 von zenman am 28.02.06 19:20:00[/posting]Also Zen,Bernie,Nosta,Poppi,Hecht,Mikel,Bacha and all:Für die Anhörung müssen wir aber mal ALLE geistigen guten Kräfte in Elans Richtung lenken...

[Birgit.Tersteegen]

Guckt Euch mal das Orderbuch an,70000im Ask unter 13.Ich staune!!

[hechtbarsch]

ich bin mit positiver Energie dabei.

Es ist halt wie im Leben ein ewiges auf und ab.

heute geht es mal abwärts, aber bald geht es wieder nach Norden.

hb

[Birgit.Tersteegen]

[posting]20.431.400 von hechtbarsch am 28.02.06 20:13:12[/posting]Danke-brauche Trost!

[YoungRich]

Was ist bloss loos ?

[YoungRich]

[Birgit.Tersteegen]

[posting]20.431.567 von YoungRich am 28.02.06 20:20:38[/posting]eigentlich nichts-Massenpanik nach Analysteneinschätzung von 14$

Good thing we have a WS insider as CEO
by: noweinteam (40/M/chicago) 02/28/06 02:23 pm
Msg: 930061 of 930062

So we get the story out and analysts get the facts they need and don`t do biased statistically skewed `surveys`.
Yep, good thing.

[flow_solver]

Es geht mehr um diese Meldung, und die verbreitet Panik!!

briefing.com
by: xjcomxxx 02/28/06 02:24 pm
Msg: 930064 of 930072

13:59 BIIB Biogen Idec and Elan: Tysabri suppresses immune system as much as HIV, study finds - Bloomberg (47.93 -2.17) -Update-

[hechtbarsch]

naja das Marktumfeld ist heute auch sehr schwach, mal sehen wann mehr kauforders reinkommen. ab und zu kommen schon mal paar 10.000er blöcke.

[zenman]

hast du die vollständige meldung ?

[zenman]

scheisse

Bloomberg story - "Fly"
by: bunnygoodknows (58/M/San Diego, CA) 02/28/06 02:35 pm
Msg: 930134 of 930142

BIIB

1:57 PM
Hot Stocks: Biogen Idec-BIIB Tysabri suppresses immune system as much as HIV-Bloomberg
BIIB and ELN`s Tysabri can deplete immune-system cells as much as HIV, researchers found. The amount of immune-system cells in spinal fluid of patients given Tysabri fell as low as levels seen in people infected with the virus that causes AIDS, according to a study led by neurologists from the University of Texas Academy of Neurology.

[YoungRich]

1:57 PM
Hot Stocks: Biogen Idec-BIIB Tysabri suppresses immune system as much as HIV-Bloomberg
BIIB and ELN`s Tysabri can deplete immune-system cells as much as HIV, researchers found. The amount of immune-system cells in spinal fluid of patients given Tysabri fell as low as levels seen in people infected with the virus that causes AIDS, according to a study led by neurologists from the University of Texas Academy of Neurology. (FLY) [GOTO]

[flow_solver]

@Pinvestment ist eigentlich immer gut informiert

TEVA abstract is a fraud
by: pinvestment 02/28/06 02:40 pm
Msg: 930164 of 930179

remember that normal people have CSF lymphocyte counts of 0-5. Thus elevated numbers seen in MS patients go down when tysabri is started - therefore tysabri makes peoples CSF lympho counts go to normal - the TEVA abstract says they look like AIDS patients - but they really also look like normal patients - also note that blood lymphocyte levels are normal

TEVA is handing ELN shares to you on the cheap - be wise

[Nostarowie]

Was für eine Megagülle.

[[KERN]Codex]

Tysabri can deplete immune-system cells as much as HIV, researchers found

SCHEISSE

[[KERN]Codex]

Jetzt wird Tysabri geshortet und das Treffen in Dubai fällt nicht flach

Immer das positive draus ziehen

[Birgit.Tersteegen]

Versteht jdm genaues--was bedeutet Pins Erwiderung?

Ein Fall für Cyberhexe!

[Nostarowie]

Das Gap wird heut definitiv NICHT mehr dicht gemacht.
Mein Immunsystem is auch geschwächt.

[flow_solver]

Das ist der Bericht, sogar von deutschen Wissenschaftlern, den hat eine Biotech-Analyst dann bei Bloomberg reingestellt.


http://www.abstracts2view.com/aan/search.php?search=do&query…



S32.001] Immune Surveillance in Multiple Sclerosis Patients Treated with Natalizumab

Olaf Stuve, Christina Marra, Keith R. Jerome, Linda Cook, Seattle, WA, Petra D. Cravens, Sabine Cepok, Elliot Frohman, Ted Phillips, Gabriele Arendt, Dusseldorf, Germany, Bernhard Hemmer, Marburg, Germany, Nancy Monson, Michael K. Racke, Dallas, TX

OBJECTIVE: To test whether treatment of multiple sclerosis (MS) with natalizumab, an antibody against VLA-4, interferes with central nervous system immune surveillance, leukocyte cell numbers and cellular phenotypes in cerebrospinal fluid (CSF) and peripheral blood (PB). BACKGROUND: Natalizumab was recently associated with development of progressive multifocal leukoencephalopathy (PML), a demyelinating disorder of the CNS caused by JC virus (JCV) infection. DESIGN/METHODS: Cell numbers and cellular phenotypes in CSF and blood were analyzed in MS patients treated with natalizumab, untreated MS patients, patients with other neurological disease (OND), and HIV-infected patients. JCV DNA in the CSF and PB of these patient cohorts was quantified by kinetic PCR. RESULTS: CSF total leukocyte counts, CD4+ and CD8+ T cells, CD19+ B cells and CD138+ plasma cells were significantly lower in natalizumab-treated MS patients compared with OND patients and untreated MS patients. Natalizumab therapy decreased the CD4:CD8 ratio in the CSF to levels similar to that of HIV-infected patients. JCV DNA was not detected in natalizumab-treated patients. Six months after cessation of therapy, low lymphocyte counts in the CSF persisted, whereas the CD4:CD8 ratio normalized. The patient with the highest total leukocyte, CD4+ and CD8+T cell counts in the CSF experienced a clinical relapse. CONCLUSIONS/RELEVANCE: These data suggest that a low CSF CD4:CD8 ratio in natalizumab-treated patients may confer an increased risk of developing PML in these patients.
Category - MS and Related Diseases
SubCategory - Clinical Science

Wednesday, April 5, 2006 3:45 PM

[[KERN]Codex]

birgit und co

Boah ich könnt echt kotzen

[zenman]

quick thoughts
by: nangasimon (36/M) 02/28/06 03:27 pm
Msg: 930445 of 930468

the survey
very odd, inconsistent. How can it be a valuable therapy, but not marketable? We know that more studies can`t provide reassurance. 6% thought they would use it first line, and they are bound to be MS prescribers - high users. I think this is remarkbale. 10% of all MS at this stage is very positive. I can`t help but think that
1. an answer is being reported in a misleading way
2. many polled were not MS prescribers.
...its all spin

Second the abstract
I dont see the conspiracy but to conclude that the immunosuppression is the same as AIDS is just not justified. For starters they didnt say the HIV comparison was AIDS. PML kicks in at very low CD4 counts. The ratios were compared and not total counts. It really is impossible to conclude anything from the abstract at all...I found it interesting as a handle on a biomarker of PML risk, but nothing more. It simply cant tell us about the true risk for patients

In conclusion, and I have never been convinced of this before, CLEAR manipulation and SPIN.

The FDA will see through this rubbish

[Birgit.Tersteegen]

Wir sollten erstens NICHT panisch agieren und zweitens medizinisch klären was das bedeutet und drittens uns bewusst werden dass hier Politik mit im Spiel ist,der wir nicht auf den Leim gehen sollten.

Welke und Cyberhexe :Könnt Ihr was sagen dazu??

Wieso steht eigentlich 5.4.2006 unter dem Artikel??

[eliasesteban]

ich sag nur keine panik,die wollen wie schon gesagt nur noch mehr aktien-billig-profitgeier-schandmäuler,ich lass mich nicht verrückt machen,das wird sich auch relaxen!das teilchen geht ja auch schon wieder stetig up,warum?guts nächtle!schlaft euch gut aus und morgen sieht die welt wieder anders aus,die panik kommt vom vielen kursstarren.

[zenman]

another important topic
by: pinvestment 02/28/06 03:38 pm
Msg: 930504 of 930510

BIIB rituxan for RA news should be out after the close or tomorrow morning - rituxan is the current year reigning champ for numbers of PML cases caused ( per FDA AERs database) - if it is okayed then you can pretty much guess that tysabri is in great shape

so tomorrow should be even more interesting

as usual i feel bad for the people that got scammed by TEVA - just like the people that got scammed by krasner et al last year

[hechtbarsch]

Kurs fängt sich 12,86 usd

[Nostarowie]

Hab mir grad nochma den 5Jahrchart angesehen,
beruhigend wie ein Fischglas.




hey das ist hier normal, Zacken gehören zu dem Papier wie zur Krone vom König Rollo.

[zenman]

Teva abstract and Pinvest
by: pokerden1 (34/M) 02/28/06 03:43 pm
Msg: 930537 of 930561

Here is a link to back up what pinvestment has already stated about the lymphocytes in CSF (cerebral spinal fluid).

Scroll a third of the way down under the heading "Cell Count" You will see that normal CSF has upto 5 WBC (white blood cells) per ml...and in fact elevated levels imply and infection.

Under "Cell Differential" they make the statement:
"Up to 50 monocytes per mm3 are seen in about 25 percent of patients with multiple sclerosis."

http://64.233.179.104/search?q=cache:kwQgbM3SvvsJ:www.aafp.o…


soll sich welke und hexi mal anschauen

[hechtbarsch]

@ nostarowie

das ist ein großes "W" - siehst du doch auch so-oder?

[Birgit.Tersteegen]

Jetzt wird wieder gedrückt-- hat eigentlich Teva mit diesem Artikel zu tun??

[Birgit.Tersteegen]

TEVA misinformation -thats all this was
by: pinvestment 02/28/06 03:36 pm
Msg: 930494 of 930628

I think you can be pretty sure that Dr. Racke will write anything he wants for some $$$$$. I think that is called a sellout - funny thing is that most docs probably completely understand why he did it - and they probably know that he can`t be stupid enough to write something like that without getting paid for it

[Nostarowie]

Jetzt wo Du es sagst...


...und was rauchst Du?

[Birgit.Tersteegen]

[posting]20.433.774 von Nostarowie am 28.02.06 22:02:24[/posting]ich trinke gleich!!
Bin seit 4 Monaten Nichtraucherin....gut dass jetzt keine Packung im Haus ist....

[Nostarowie]

Balls of Steel
by: odz500 (46/M/N. Ireland)
Long-Term Sentiment: Strong Buy 02/28/06 04:03 pm
Msg: 930645 of 930648

..required!

[Nostarowie]

Kein Alkohol ist auch keine lösung Birgit.

N8 @all geh nun auch zum Kühlschrank...

[Birgit.Tersteegen]

Der Black monday ist scheinbar genau ein Jahr her.Na Bravo!

Habe heute einiges verkauft--ich stocke Elan morgen noch ein bisschen auf!

[Birgit.Tersteegen]

[posting]20.434.012 von Nostarowie am 28.02.06 22:12:51[/posting]Stimmt-auf Elan und Uns !Prost!Kann nur besser werden!

[Birgit.Tersteegen]

About the 140 doctors in the poll
by: stillholdun (40/M/Dallas TX)
Long-Term Sentiment: Strong Buy 02/28/06 03:45 pm
Msg: 930550 of 930699

It was original supposed to be 160 doctors, but Teva told the "pollster" from Piper to stop at 140, because it was imperative that she get the report out today, to coincide with anniversary of BM.

And Teva also got the clown doctor from Texas to release his "Tysabri causes Aids" research to also come out on 2/28.

I mean, how fucking comical is this already?

Further, ELN and Biib both have PR depts, IR depts, accounting depts., etc, but what I seldom see mentioned here is that they both have LEGAL departments as well. Doesn`t some of this crap present a potential LEGAL action against these bastards?
---------------------------------------------------------

genau:Alle Analysten hinter Gitter (zumindest bis Ty auf dem Markt ist...)

[welke91]

Birgit Glückwunsch wollte dich nicht darauf ansprechen mit dem Rauchen!

Am Anfang diesen Tages habe ich euch doch geschrieben, das Tysabri in Verbindung mit immunsupprimierten Medikamenten das JC-Virus aktiviert!

NIX neues! und die Lachen sich eins in die dicke Hose!

Bla Bla schon wieder ein Todesfall? Ha HA diesmal eine clevere Alternative es auf medizinische Art zu versuchen!

grüße

[welke91]

Krimi Al á carte !

Elan Announces the Suspension of Trading of Its Shares Commencing March 7, 2006 For Up to Two Days
Tuesday February 28, 4:30 pm ET
Suspension of Trading Due to Two Day FDA Advisory Committee Meeting to Review Tysabri

bbbbbbbbbuuuuuuuuuuuuuhhhhhhhhhhhhhh wollen die mich schoken?

[Birgit.Tersteegen]

[posting]20.434.390 von welke91 am 28.02.06 22:37:47[/posting]Welke,war das denn der Inhalt dieser angeblichen Studie?Dass imunsuppr.Medikamente + Ty problematisch sind war doch eh klar.....

Hot Stocks: Biogen Idec-BIIB Tysabri suppresses immune system as much as HIV-Bloomberg
BIIB and ELN`s Tysabri can deplete immune-system cells as much as HIV, researchers found. The amount of immune-system cells in spinal fluid of patients given Tysabri fell as low as levels seen in people infected with the virus that causes AIDS, according to a study led by neurologists from the University of Texas Academy of Neurology.

[zenman]

was heisstn das genau ?

[zenman]

#8083 mein ich

[Birgit.Tersteegen]

Es wird doch suggeriert dass Ty die Immunabwehr genauso schwächt wie der HIV-Virus,oder??

[Birgit.Tersteegen]

[posting]20.434.531 von zenman am 28.02.06 22:49:27[/posting]dass die Aktie während der Anhörung vom handel ausgesetzt wird!Ist ja nix "schlimmes"...

[welke91]

Auf so etwas lass ich mich nicht ein!

4 Todesfall? z.b. war genau son dreck!

elan haben die weltweit 4 besten Prof. die sich mit dem JC-Virus auskennen angagiert um ihnen bei der Safety-Studie zu unterstützen!

Jetze will ein irrer Doktor von wem Poyper Jefferson wissen was los ist?

ich glaube nicht dran auch wenn ich unter gehe jetzt ist der handel am 7 März ausgesetzt besser kann kein Fallschirmsprung sein!

Hat jemand die Nummer von der Hexe!

Ich bezweifle dieses Statement!

grüße

[Birgit.Tersteegen]

unglaublich die ganze Geschichte,der Artikel ist alt und wir haben die Zusicherung des CEO "Not IF,but WHEN"

Re: Bloomberg article...yes very old
by: nyanal11113
Long-Term Sentiment: Strong Buy 02/28/06 04:34 pm
Msg: 930765 of 930853

Article was published probably 6 months ago..non-event.

Long ELN

[Birgit.Tersteegen]

[posting]20.434.587 von welke91 am 28.02.06 22:54:22[/posting]Ich habe die Bordhexe schon per BM gebeten,sich im Bord zu erklären....

Wir sind hier echt im Haifischbecken gelandet....Aber wir können ja gut schwimmen und tarnen...

[Birgit.Tersteegen]

SEC WILL SOON REQUEST THE SURVEY
by: inflation_profff 02/28/06 04:41 pm
Msg: 930792 of 930880

LIST AND DOCUMENTED INFO FROM PJ.

PJ WILL BE SERVED THE PAPER WORKS TO COMPLY WITH SEC PROB.

IF PJ MADE UP THE STORY WITHOUT THE TRUETH, PJ NEED TO BE JAILED FOR LONG TIME....

IF TEVA PAID PJ TO GENERATE BOGUS ISSUE, TEVA SHOULD BE JAILED AND FINED FOR BILLIONS OF DOLLARS.

[welke91]

Für ganze zwei Tage

Administration (FDA) Advisory Committee meeting to review Tysabri, commencing March 7, 2006, for up to two days.
kann man Elan wahrscheinlich nicht handeln

RISIKO ich liebe das!

[Birgit.Tersteegen]

LL SURVEY RESULTS CAN BE SKEWED ...
by: cyberflash8
Long-Term Sentiment: Strong Buy 02/28/06 04:54 pm
Msg: 930850 of 930890

If only 27% of doctors have prescribed Tysabri, then the 73% were not even qualified to answer that survey in an objective manner. WHY? Because they never had any first-hand experience with Tysabri and have never seen the results.

it`s Bullcrap!

[Birgit.Tersteegen]

FDA HAS APPROVED TYSABRI de facto
by: hunglikeahorz (33/M/NC)
Long-Term Sentiment: Strong Buy 02/28/06 05:05 pm
Msg: 930901 of 930905

The AC is a political show that legitimize the FDA`s decision by hearing MS patients say `what a miracle drug Tysabri is`. But the fact is - FDA has already approved Tysabri for 5000 patients. And all the analyst from Piper J, ML, etc. (and even Krasner) ... all these bitchy analyst ADMIT THAT FDA WILL BRING TYSABRI BACK.

Today, 28 million shares just went from the frightened small traders and investors to the hands of big smart institutional buyers. Sad, but that`s what today really is about.

[welke91]

DAns ganze heute war eine groß angelegte Scheisse! Sory aber könnte sein!

Ist ja bekannt das mit dem Immunsystem,..jetzt wissen irre Leutz die wollen nicht gehandelt werden am 7 März bumbs da machen wir uns mal schnell auf die Socken die Leute zu verwirren, so dass wir noch günstiger an die Aktien herrankommen.

PANIK mehr nicht 2 Tage nicht handeln hu hu was wenn doch nicht Ty zugelassen wird huu hu hu dreck was mach ich

Börse is RISIKO no Risk no FUN!

einfach genial jetzt trennen sich Spreu vom Weizen!

ds gibt ein guaddes Bier

[welke91]

Noch eins zur Beruhigung, damit ihr gut schlafen könnt!

FDA stop hold on clinical Trials!

grüße wird schon;-)

[Birgit.Tersteegen]

[posting]20.434.813 von welke91 am 28.02.06 23:14:25[/posting]Prost und guts nächtle!!Nur die Harten.....

[Wouw]

Würde mich auch sehr interessieren, was Cyberhexe zu #8063 sagt. Die nächsten Tage werden sehr spannend.

[Birgit.Tersteegen]

Whose turn tomorrow?
by: stox (44/M/Westmont, Illinois)
Long-Term Sentiment: Strong Buy 02/28/06 05:24 pm
Msg: 930963 of 930963

Serono maybe?

And who will launch the MOAB on next Monday?

Gentlemen, this mean WAR!!!!

I truly hope ELN`s PR department is ready for it.
---------------------------------------------------------

Here`s a Sample of the Survey BS
by: cyberflash8
Long-Term Sentiment: Strong Buy 02/28/06 05:24 pm
Msg: 930962 of 930965

PJ: Doctor, do you think Tysabri is good for MS patients?

92% said yes. YES, YES, YES.

PJ. Doctor, would you prescribe Tysabri to your patients?

- YES it depends on their condition of course.

PJ: What if they are taking other meds like Avonex or steriods or they are immuno- supppressed aready - like AIDS patients. Would you still prescribe Tysabri?

- NO, if you are talking about patients in serious immunosuppressed conditions.

PJ: so you`re answer is a NO ? So, that`s what I will put in the survey, doc?

- YES. Assuming that`s the patient`s condition

[Birgit.Tersteegen]

Does anybody have the PJ Survey?
by: Mr10001 (55/M/Michigan)
Long-Term Sentiment: Hold 02/28/06 05:31 pm
Msg: 930980 of 930980

Love to see the raw data, and the questions in the survey.

Also 159 were surveyed, how many responded?

Sounds like a game of liars poker to me.

[Birgit.Tersteegen]

Hey Bangaluru: NBV+1.1555 Million share
by: darrelldemello 02/28/06 05:45 pm
Msg: 931017 of 931018

was posted earlier...


4.01pm NBV +1.1555 Million shares
by: darrelldemello 02/28/06 04:08 pm
Msg: 930661 of 931011

at close today pps $13.71

Buy Volume = 11,438,500 shares

Sell Volume = 10,283,000 shares

Indeterminate Volume = 6,426,300 shares

NET BUY VOLUME = +1,155,500 SHARES

Comment:
1. The indeterminate volume is very high today ... at the time when the pps was brought down, many large volume buys were going through at pps levels below the bid ... but higher than the offer ... many large instis have picked up mucho quantities of shares ...

2. Tomorrow could be total capitulation in the morning ... forced margin calls etc ... then in the afternoon starts the rise in anticipation of the AC...


Have a good evening, folks!!!

JMHO.

[Birgit.Tersteegen]

Letzter:

Re: bloomberg article...TEVA?? WTF??
by: dougdenv 02/28/06 05:47 pm
Msg: 931026 of 931039

If I were counsel for BIIB or ELN (or the SEC for that matter), I would aggressively seek more info about the Bloomberg article and its sources, timing, etc., as this sort of premature "highlights?" publication seems quite unusual, and its substance, without supporting documentation, strikes me as inflammatory and unfounded. Yes, there is sometimes a connection between PML and HIV, but comparing Tysabri immunosupression with typical HIV is a huge stretch.

Contrast this with the PJ survey. Any of us could conduct a poll among known friendly or otherwise uninformed neuros (and, as one who has experienced it first hand, there are more than you might think), then ask leading questions to produce the answers that confirm the desired result. We in the general public, just reading the headline, would never know the true facts, perhaps to our detriment.

The machinations of Wall Street have been around forever and will not change anytime soon. That may indeed affect ELN`s PPS prospects, but that is out of our control. As are the the efforts by Tysabri competitors to diss its efficacy and safety record. Why not defend your medication on its merits, or STF up? Wall Street is a cesspool, but am beginning to think that pharma is at least as dirty, and when lives are at stakes, no less. This just stinks!

[welke91]

Alle gut verkraftet?




Noch mal so zur Verdeutlichung, PML kommt immer dann zum Vorschein wenn das Immunsystem geschwächt ist!

Wir hatten nur Todesfälle bei Patienten, bei denen das Immunsystem geschwächt war durch Interferonen oder andere Immunblocker.

Hier wurde in drei Fällen dieses beobachtet bei 2000 + MC Trial Patienten!
Wieviel HIV Patienten haben wir? Wollen die mich verarschen

Und warum schließen die das nur auf Tysabri und nicht auf die Kombi?
Weil sie billig an die Aktien wollen!

grüße

[Birgit.Tersteegen]

Moin

Re: to hold or not to hold ....
by: Norwoodone 03/01/06 01:04 am
Msg: 932005 of 932020

pull yourself together ... leave your emotions at the door .. think

1- BOD have mucho 12 dollar options
2- gillespee buys 3 million dollars worth
3- t rowe owns 12 million shares
4- feinberg has 18% of his fund in tysabri
5- the data is the best around for ms
6- 1 pml in 1000 says nejm MILD
7- trials have restarted
8- msers are demanding & begging for tysabri 9- nejm article appears positive
10- pin has broken it all down in layman terms
11- pin says slam dunk
12- inconceivable says km
13- this is biotech, this is normal
14- this is eln this is normal
15- extrapolating the disability curve is big, srs said it and i heard elsewhere it`s in nejm
16- did i mention remylination, wouldn`t that be nice
18- did you see the video of the young lady on the ms site, this is not about headaches
19- did you ever hear of Paliperidone Palmitate IM long acting injectable
20- don`t forget europe
21- gambling is gambling, the odds are clearly in our favor
22- if your time horizon is 1 month or less then maybe you should sell
23- additionally a little bit of advise, SUCK IT UP KID!

[Birgit.Tersteegen]

Battle Plan Updates
by: ragingpig6 02/28/06 11:42 pm
Msg: 931912 of 932020

Those, who blindly argue that there is no Battle Plan or conspiracy, please explain the following FACTS since the AC was scheduled:

1. Message board FUDS: FDA requiring addition clinical trials, approvable letter, NMSS survey, BBB floods, GTRT calls and …….(on going)

2. Merrill Lynch lowered Ty chance of return from 80-100% to 50-70%. (2/16)

3. Merrill Lynch’s reduction of 5.5M shares holding made public. (2/16)

4. Lehman Bros said ELN is overvalued. (2/16)

5. BMJ: Dr. Abhijit Chaudhuri said, “The use of Ty cannot be justified because the risk of PML is high and the long term efficacy of the drug is unknown.” (2/17)

6. LA Times: Dr. Steinman and Dr. Annette Langer-Gould e-mailed to FDA to screw Ty, "We are concerned that not only were patients put at risk by Tysabri, but we feel that the risk was absolutely unnecessary to assume." (2/18)

7. Newsinferno.com trashed Ty by regurgitating LA Times, BMJ and NY Times (2/18)

8. The Philadelphia Inquiry regurgitated the LA Times story (2/21)

9. Burt Adelman created more FUDs against Ty’s launch (2/22)

10. WSJ trashed Ty and quoted the same Dr.Gould (2/24)

11. On 2/22, I predicted, “Jeff Krasner is still lurking but it is a matter of when and not if he will join in for the attack soon.” He did join the attack TODAY! (2/25)

12. Piper Jaffray pans on BM anniversary. (2/28)

13. TEVA smears by distributing UT abstract which has NOT been accepted by a scientific journal yet. (2/28)

My computer said the odds for the above to occur at random in such a tight window are 2,780,379,500 to 1. Come on Barron’s and NY Times. We need the final straws.

To the attackers: Is money your real motive for the attack? If so, I feel sorry for you in compromising your moral judgement for something that you couldn`t possibly take it with you. Many years from now before you die, you will regret what you have done to the MS patients and will never rest in peace.


PS. If TEVA’s abstract fails to receive acceptance, I would be happy to take it off their hands ‘cause I need some toilet papers. When that happens, I’ll really feel sorry for my arse.

[welke91]

die Hexe kann das besser sagen:

Man bedenke, dass in der Monotherapie bei Tysabri bisher keine PML-Fälle aufgetreten sind...und schwerwiegende Nebenwirkungen gab es bisher ledoglich im Plazebobereich

[welke91]

ENCORE Studie 510 Patienten!
Safety Studie MS 2000 Patienten
drei Fälle von denen keiner ausschließlich Tysabri zugeordnet werden kann

[welke91]

gefunden auf Bloomberg...

...die wahrscheinlich richtige Erklärung der PML-Erkrankung in der Kombitherapie (Ty+Avonex):

Durch das Interferon (Avonex) wird die Eliminationshalbwertszeit von Natalizumab erhöht, wodurch dessen Konzentration von Infusion zu Infusion ansteigt. Dies wiederum führt über die Zeit zu einer vollständigen Absättigung der Rezeptoren an den T-Zellen mit Natalizumab, so dass keine T-Zellen die Blut-Hirnschranke passieren können. Dieser Zustand erst ermöglicht eine Aktivität des JC-Virus im Nervengewebe.
Ohne Interferone erfolgt keine Akkumulation von natalizumab, so dass immer noch genügend T-Zellen die Blut-Hirnschranke durchqueren um die Aktivität des Virus unter Kontrolle zu halten.

dank an HEXE!

[Birgit.Tersteegen]

Welke,Danke!

Was war denn überhaupt der Bezug zu HIV,hab ich nicht verstanden.....

[welke91]

[posting]20.435.955 von Birgit.Tersteegen am 01.03.06 08:20:25[/posting]NUn das ist eindeutig kompletter Blödsinn!

Tysabri ist in der Mono noch sicherer als Pfannenkuchen essen

Es wurde darauf angesprochen das Tysabri das Immunsystem schwächt mehr sogar als AIDS und somit das PML Risiko steigt.

Dem kann nicht sein, hier die Nebenwirkungen von der Mono!

Nebenwirkungen bei der Monotherapie im Plazebobereich

Table 3. Adverse Reactions in Study 1 (AFFIRM)
Adverse Events (Preferred Term)

TYSABRI® n=627 Studienteilnehmer vs. Plazebo n=312

Kopfschmerzen 35% bei Tysabri vs. 30% bei Plazebo
Müdigkeit 24% vs. 18%
Gelenkschmerzen 15% vs. 11%
allergische Reaktionen 7% vs. 3%
Harndrang 7% vs. 5%
Brustbeschwerden 4% vs. 2%
lokale Blutungen 3% vs. 1%
Rigors 3% vs. 1%
Ohnmacht 2% vs. 1%

In der Mono keine PML-Fälle und wenn Tysabri das Immunsystem schwächen sollte würde es ja im Nebenwirkungsprofil stehen oder?

grüße

[flow_solver]

Der Bezug zu HIV war lediglich, dass man in einer vergleichenden Studie festgestellt hat, dass die Immununterdrückung bei Verabreichung von Tysabri eine gleiche Wirkung erzielt wie das HIV Virus. Pinevestment hat aber prompt erklärt, dass die Analyse anhand der Blutbestandteile das Bild falsch verzerrt.

[flow_solver]

Hier noch ein weiterer Kommmentar aus dem Elan-Board, der auf einige sehr positive Studien zu Tysabri in einem wissenschaftlichen Journal hinweist.

NEJM OUT TODAY NOT TOMORROW
by: defenderyou 02/28/06 09:12 pm
Msg: 931598 of 932047

Just got call from my gastro doc who summarised the three articles for me. NEJM VOL 354 #9 is OUT TODAY!!!!!!

He said that once this is in the press ELN will soar!! (hope he is right?). Now what is in these articles we have all heard before, but here is a summary from the notes I took listening to him as I dont get the NEJM

Article 1 by Chris H Polman: Randomised controlled trial for Nat... for ..Relapsing MS patients
-- 942 patients, 637 on TY, 325 Placebo - Conclusions: TY reduced relapse rate significantly and 92% fewer lesions with Nat vs Placebo

Article 2 (author - forgot) Nat and Avonex for MS.... Conclusions: Combined much better than Avonex; disabilty porgression much better combined than with Avonex

Article 3: (Author Tarek Ayonsry): Valuation of Patients treated with TY for PML. Conclusions: Risk is very mild of 1 in 1000!!!!!

Sorry that I dont have better synopsis - but the doc called me and was excited as hell. he says these are great articles that have been passed through the acid test with peers and w/o a doubt TY is fantastic and that the PML risk of TY is minimal!!!!!

No we all know this and much of this has been said. BUT its now in the NEJM. Vol 354 #9 and its published. The press should pick this stuff up tomorrow and I cant believe that ELN wont go up on the back of this final confirmation.

He also pointed out hat when Remicade first came out the surveys that were done were just if not more negative than the one we got slapped with today.Look at Remicade today!!

Maybe someone can get the articles on line - BUT THEY ARE OUT!!

[welke91]

The amount of immune-system cells in spinal fluid of patients given Tysabri fell as low as levels seen in people infected with the virus that causes AIDS


Das die Menge der Immunzellen in der Rückenmarkflüssigkeit
bei Patienten die mit Tysabri behandelt worden sind starkt abfällt auf dem gleichen Level geht, das mit Aids vergleichbar wäre!

[welke91]

BIIB and ELN`s Tysabri can

"CAN"

@flow
Der Bezug zu HIV war lediglich, dass man in einer vergleichenden Studie festgestellt hat, dass die Immununterdrückung bei Verabreichung von Tysabri eine gleiche Wirkung erzielt wie das HIV Virus.

TYSABRI unterdrückt nicht die Immunantwort!kruzifix nochamal

Was für ne Studie??? es gab ein HOLD verdammisch!

Wirkung von HIV, wäre bitte vorsichtig damit umgehen!

so und nun schluss Kaufen Leutz kaufen!

[flow_solver]

@Welke,

sorry! Habe gerade gelesen, dass es nur ein Abstract eines eingereichten Papers ist, dass noch nicht akzeptiert wurde. Wir befinden uns hier in einem wirtschaftlichen Krimi, wie ich es selten erlebt habe. Es wird mit allen Mitteln gekämpft.

[welke91]

[posting]20.436.390 von flow_solver am 01.03.06 08:59:40[/posting]wenn ich fluche hat das nix mit dir zu tun, mich bricht das langsam alles an,

Krimi ist das echt!
Schering und alle anderen lachen sich eins !

grüße auf steigende kurse

[YoungRich]

Guten Morgen

Was macht Irland, jemand Realtime ?

Tx
Young

[welke91]

@ flow

http://www.boston.com/business/technology/biotechnology/arti…
Was ist mit Mrs. Smith die gar nicht an MS erkrankt war und trozdem mit Tysabri behandelt wurde?

Krimi

[Birgit.Tersteegen]

Muss leider gerade arbeiten,habe Kauforder eingestellt!Lasst Euch nicht verarschen!!Gruss bis später!

[Poppholz]

Hallo Zusammen,

ich bin auch am überlegen gewesen, noch weitere Aktien zu kaufen, habe das Vorhaben aber erst einmal auf Eis gelegt, da die momentane Verkaufsaktionen, in meinen Augen, absolut irrational sind.

Da mir ein solches Umfeld nicht gefällt habe ich keine neuen Aktien geordert.

Habe aber auch keine meiner Aktien verkauft.

[Nostarowie]

...hauptsache gesund...was so zum fallen gebracht wird muß wieder steigen.

[Birgit.Tersteegen]

[posting]20.438.937 von Nostarowie am 01.03.06 11:13:51[/posting]Du sagst es ,Nosta--darauf trinken wir dann ein Gläsle mehr zusammen!!
Ich finde,es werden hier nicht sonderlich viele Aktien geschmissen;die Meisten scheinen das Spiel zu durchschauen!

Grüsse Birgit

[Birgit.Tersteegen]

this User | Report Abuse
ThisIsMS - Frontpagenews
by: schaakjan (59/M)
Long-Term Sentiment: Buy 03/01/06 03:08 am
Msg: 932058 of 932101

Interesting new Research Abstracts on Tsyabri (Natalizumab)

While Tysabri is scheduled to get its day in "court" soon -- the FDA Advisory committee meeting will be meeting in early March to decide whether the public will have access to the therapy in the near future-- the American Academy of Neurologists has revealed the schedule for its annual meeting.

Included are numerous new-- and fascinating-- studies on Tysabri. This is a long post, as there is simply too much good information to condense fully. Please click "read more" to read this intriguing and important information.

The Effects of Natalizumab Monotherapy on Multiple Measures of Disability Progression in MS Patients: This one is potentially huge. Of particular interest is the reduction in T1-hypointense lesions, also known as "black holes" which are areas of the brain that are irreversibly damaged. Previously, Copaxone has been shown to reduce these as well, but to a lesser extent than what has been seen with Tysabri in previously announced results (though remember it is difficult to compare trial results directly due to myriad variables.

"OBJECTIVE: To report the effects of natalizumab monotherapy (TYSABRI) on multiple measures of disability and burden of disease in patients with relapsing multiple sclerosis (MS). RESULTS: Over 2 years of treatment in AFFIRM, natalizumab delayed the onset of sustained disability progression by 42% compared with placebo...In addition, natalizumab reduced disability progression as measured by change from baseline in MSFC...the percentage of patients who reached an EDSS of 4.0 (5% vs. 13%...) or an EDSS of 6.0 (2% vs. 6%...), and mean (standard deviation) change in EDSS (0.04 0.86 vs. 0.41 1.09...). Furthermore, natalizumab reduced T2 lesion volume...and the number of new T1-hypointense lesions...over 2 years...

CONCLUSIONS/RELEVANCE: Natalizumab monotherapy reduces disability progression and suppresses changes on MRI that represent, in part, irreversible axonal damage in MS."

" target="_blank" rel="nofollow ugc noopener">http://www.thisisms.com/index.html

[Birgit.Tersteegen]

Davy ...
by: paddystocks 03/01/06 03:59 am
Msg: 932069 of 932104

Elan (ELN US)
Jitters provide opportunity
Previous close: $12.70 Target: $18.00 (31/01/06; previously $13.00, issued 09/08/05) Analyst: [e-mail]
It is hardly surprising that Elan shares have been a little jittery ahead of the important advisory panel meeting scheduled for
March 7th–-8th. After advancing strongly through the end of last year, the stock is now down 9% year-to-date and has in
fact underperformed Biogen Idec by 24% since the end of January. The absolute differential in their respective market caps
now stands near to its highest level since Tysabri was suspended a year ago.
With the approval of Rituxan the only major Biogen-related newsflow in recent times, we believe that this differential offers a
near-term trading opportunity. Elan shares are some 24% off 12-month highs and 29% off our SOTP target of $18,
notwithstanding encouraging signs on the FDA’s attitude to Tysabri and the increased profile of its AD research programme.
If we take it that a return for Tysabri can occur, its commercial potential is the key issue. Our peak revenue estimate of
$1.6bn assumes a patient take-up of approximately 80,000, or 10% of the total available MS population in the US and EU.
Given anticipated label restrictions, and as the monitoring burden is assessed, our near-term forecasts assume a modest initial
take-up: our 2006 forecast revenues are $70m, implying average patient numbers for the period of approximately 3,000.

[[KERN]Codex]

Danke für euer Engagement

[Birgit.Tersteegen]

Wichtig und verständlich zu der Affaire von gestern--also Teva ,als Konkurrent,hat die Finger DIREKT im Spiel und hat die Zusammenhänge völlig verdreht:SUPER;zum ersten Mal verstehe ich was....(na ja vielleicht nicht zum allerersten Mal...)

NCB ...
by: paddystocks 03/01/06 04:03 am
Msg: 932070 of 932105

• A report on Bloomberg regarding an abstract to be presented at AAN (American
Academy of Neurology) in April 2006 highlights that the level of immune cells in the
central nervous system (CNS) following Tysabri treatment are as low as those seen in
AIDs patients.
• Tysabri specifically works by blocking the movement of immune cells into the central
nervous system and the dose of Tysabri administered to patients is expected to block
c.80% of the immune cells moving into the CNS. In multiple sclerosis patients the
immune system in the brain is over-activated and reducing the level of immune cells
present in the brain with Tysabri treatment effectively dampens down the immune
system in the brain as intended. Clearly the HIV virus also attacks the immune cells
directly and results in reduced immune cell levels but the connection between
Tysabri and HIV ends there.
• This report on Bloomberg highlights that the abstract was circulated yesterday to the
media by Teva (manufacturer of Copaxone).
• Elsewhere Elan shares will be suspended for the duration of the advisory panel
meeting on 7th-8th March 2006.
• Click Here to access the Elan page on NCB’s online Irish Equity Stock Guide
Orla Hartford [phone] [e-mail]

[zenman]

NCB - Full Report
by: powershares (M/Ireland)
Long-Term Sentiment: Strong Buy 03/01/06 05:28 am
Msg: 932100 of 932106

Elan Corporation: Tysabri Abstracts at AAN

• A report on Bloomberg regarding an abstract to be presented at AAN (American Academy of Neurology) in April 2006 highlights that the level of immune cells in the central nervous system (CNS) following Tysabri treatment are as low as those seen in AIDs patients. We have included the abstract referred to in the Bloomberg report below and the detail from the abstract highlights that Tysabri treatment decreased the CD4:CD8 ratio (this indicates the level of immunosuppression) in the CSF to a level similar to HIV treated patients. Very importantly JC virus DNA was not detected in the Tysabri treated patients.

• Tysabri specifically works by blocking the movement of immune cells into the central nervous system and the dose of Tysabri administered to patients is expected to block c.80% of the immune cells moving into the CNS. In multiple sclerosis patients the immune system in the brain is over-activated and reducing the level of immune cells present in the brain with Tysabri effectively dampens down the immune system in the brain. Clearly the HIV virus also attacks the immune cells directly and results in reduced immune cell levels.

• Overall the conclusion in this abstract is that a low CD4:CD8 count in Tysabri treated patients may confer an increased risk of patients developing PML. In the absence of the full data it is difficult to assess this. Our view has been that with c.20% residual immunesurveillance in the CNS following Tysabri monotherapy treatment, adequate immunesurveillance remains to fight opportunistic infections such as the JC virus. With combination treatment (Tysabri and AVONEX) therapy, the level of immunesurveillance is reduced further leaving patients potentially at risk of JC virus infection and PML (see attached report). The focus of the advisory panel meeting on 7th-8th March will be to ensure that an appropriate risk management strategy can be implemented to monitor patients on Tysabri treatment.

• There are a number of other abstracts related to Tysabri that will be presented at AAN including the 2-year clinical data and the data from the safety extension study following Tysabri`s withdrawal (http://am.aan.com/scientific/abstracts.cfm).

• Elsewhere Elan shares will be suspended for the duration of the advisory panel meeting on 7th-8th March 2006. The share price performance over the coming days will be strongly influenced by commentary ahead of this meeting.


Abstract
To test whether treatment of multiple sclerosis (MS) with natalizumab, an antibody against VLA-4, interferes with central nervous system immune surveillance, leukocyte cell numbers and cellular phenotypes in cerebrospinal fluid (CSF) and peripheral blood (PB)...RESULTS: CSF total leukocyte counts, CD4+ and CD8+ T cells, CD19+ B cells and CD138+ plasma cells were significantly lower in natalizumab-treated MS patients compared with Other Neurological Disease (OND) patients and untreated MS patients. Natalizumab therapy decreased the CD4:CD8 ratio in the CSF to levels similar to that of HIV-infected patients. JCV DNA was not detected in natalizumab-treated patients. Six months after cessation of therapy, low lymphocyte counts in the CSF persisted, whereas the CD4:CD8 ratio normalized. The patient with the highest total leukocyte, CD4+ and CD8+T cell counts in the CSF experienced a clinical relapse. CONCLUSIONS/RELEVANCE: These data suggest that a low CSF CD4:CD8 ratio in natalizumab-treated patients may confer an increased risk of developing PML in these patients."

[Cyberhexe]

[posting]20.436.850 von Birgit.Tersteegen am 01.03.06 09:27:57[/posting]@Birgit
ich habe ebenfalls nachgekauft und meinen Investitionsgrad wieder auf 110% erhöht - entgegen jeder Vernunft versteht sich...

Die Absicht ist eindeutig: Natalizumab in haarsträubenden Winkelzügen mit dem HIVirus gleichsetzen, dadurch die Verunsicherung bei potentiellen Konsumenten steigern und die eigenen Absatzchancen erhöhen.
Da es sich hiebei jedoch nicht um ein belangloses Konsumgut sondern um eine bisher nicht wirklich therapierbare Krankheit handelt, die mitunter ein langes qualvolles Sterben der Betroffenen zur Folge hat , ist ein derartiges Vorgehen gegenüber dem bisher einzig massgeschneiderten Wirkstoff aus ethischer Sicht verwerflich.
Man bedenke, dass Natalizumab mehr als doppelt so wirksam ist als die am Markt etablierten Wirkstoffe und dies bei einem Nebenwirkungsprofil im Plazebobereich (bei den etablierten Wirkstoffen sind die Nebenwirkungen mitunter beträchtlich, insbesondere die eingeschränkte Lebensqualität durch Müdigkeit usw.).
PML ist zudem bisher nur in Zusammenhang mit immunsupprimierenden Wirkstoffen - Avonex=Interferon bei der SENTINEL-Studie bzw. in der ENACT-Studie nach immunsupprimierender Vorbehandlung mit Azathioprin - aufgetreten. In nicht immunsupprimierten Organismen ist PML in Zusammenhang mit Natalizumab bisher nicht aufgetreten. Der Analogieschluss von HIV und Natalizumab ist vor diesem Hintergrund ja geradezu lächerlich.

Hut ab Birgit....wir lassen uns keinen Bären aufbinden!
good luck
ch

[Birgit.Tersteegen]

[posting]20.439.657 von Cyberhexe am 01.03.06 11:48:02[/posting]Danke Hexchen--gut dass wir Dich an Bord haben;ich kenne mich zwar mit der Seele der Menschen aus aber bei Fragen der Gehinflüssigkeit hörts echt auf...

Die Mischung der demagogischen Einzelmassnahmen der Konkurrenz hat jedenfalls Wirkung gezeigt-und ich finde auch, dass das mehr war als der "Anstand"erlaubt!!

Also nach wie vor :Keep cool and stay long!Gruss!

[Poppholz]

aus dem BOSTEN GLOBE:

Doctors wary of Biogen MS drug, survey says Shares of firm, partner Elan fall sharply on report
By Jeffrey Krasner, Globe Staff | March 1, 2006

Shares in Biogen Idec Inc. and Elan Corp. fell sharply yesterday after a Wall Street analyst published the results of a survey suggesting doctors will be reluctant to prescribe the companies` multiple sclerosis drug, Tysabri, if the Food and Drug Administration approves its return to the market.

Deborah Knobelman, an analyst at Piper Jaffray, polled 140 neurologists in advance of an FDA meeting next week at which doctors, specialists, and patients will discuss allowing sales of Tysabri. In a note to clients, Knobelman said 59 percent of the doctors said it is too soon to bring the drug back. Only 6 percent said they would prescribe Tysabri before trying alternate treatments.

Doctors also said they would use Tysabri to treat only about 10 percent of their MS patients.

Biogen Idec shares fell $2.85, or about 6 percent, to close at $47.25. Elan shares fell $1.25, or 9 percent, to $12.70.

Biogen Idec of Cambridge and Elan of Ireland developed Tysabri together and started selling it in November 2004. Three months later, they suspended sales after two patients using it in a clinical trial contracted a rare brain disease. One of those patients died, and the company later discovered a separate case in which a patient in a trial also died of the disease. The companies have since conducted an extensive safety review that did not uncover any other cases.

Shares in the companies may also have been affected by a Bloomberg News report highlighting a scientific paper to be presented at an upcoming neurology conference that claims Tysabri can affect the immune cells of a patient in much the same way as HIV. Biogen Idec declined to comment on the study, noting that the scientific abstracts posted on the website of the American Academy of Neurology are under embargo until they are presented at the conference, which is scheduled for April 1-8.

``The article is definitely under embargo," said Robin Stinnett, a spokeswoman for the academy.

Before problems surfaced, Tysabri was expected to become a blockbuster drug generating as much as $3 billion in annual sales. Sales predictions have dropped considerably, and some analysts suggest the drug may become more of a niche treatment.

Dr. Burt Adelman, Biogen Idec executive vice president of development, said that if Tysabri sales resume, the company doesn`t expect sales to grow as rapidly as when it was introduced.

``We`ve always said the marketplace will be cautious and there will be early adopters and there will be late adopters," Adelman said.

The FDA advisory committee considering Tysabri will meet next Tuesday and Wednesday. The panel typically votes at the end of such meetings and its recommendation is usually adopted by the agency. A decision on Tysabri`s return could come later in March.

Elan yesterday said it would suspend trading in its shares during the two-day meeting.

Separately yesterday, Biogen Idec said the FDA approved its cancer drug Rituxan for use in treating patients with rheumatoid arthritis. Adelman said the drug would be used to treat the 30 to 40 percent of patients who don`t respond to standard treatment, known as TNF inhibitor therapy.

``We are actively developing the drug for broader use," he said.

Jeffrey Krasner can be reached at [e-mail].

© Copyright 2006 Globe Newspaper Company.

[Birgit.Tersteegen]

[posting]20.440.699 von Poppholz am 01.03.06 12:39:59[/posting]Auch das wieder eine Art Politik zu machen:Er fügt nichts neues hinzu--wiederholt nur den Schmarn von gestern--ohne eigene Stellungnahme.

[Birgit.Tersteegen]

Nochmal-damit wir alle es verstehen


AAN abstract: What`s the big deal?
by: markettwain (32/M/Metairie, LA) 03/01/06 07:07 am
Msg: 932136 of 932137

Immunosuppressant drugs are supposed to suppress the immune system!! Duh! That means it`s working.

The LA Times headline: "Tysabri Said to Deplete Immune-System Cells"

Sounds bad if you don`t know any better.

The abstract from AAN reaches the conclusion that Tysabri users MIGHT be at a higher risk for PML, caused by JCV. But,

THEY FOUND ABSOLUTELY NO JCV DNA IN TYSABRI PATIENTS IN THIS STUDY!!!!!

-REPEAT-

THEY FOUND ABSOLUTELY NO JCV DNA IN TYSABRI PATIENTS IN THIS STUDY!!!!!

************************************
Here`s their conclusion: We found no JCV whatsoever, but we`re pretty sure those patients were more at risk for it. Did we mention AIDS?
************************************

Don`t forget, Teva paid to have this distributed. People see Tysabri and AIDS in the same sentence and freak out.

AIDS means you are immunosuppressed, Tysabri works by suppressing the immune system. That is the extent of the similarities.


http://www.latimes.com/business/la-fi-tysabri1mar01,1,377581… lines-business

[zenman]

UPDATE 1-Ireland`s Elan shares fall on research report
Wed Mar 1, 2006 7:32 AM ET
(Adds further analyst comment, Serono share price, details)

DUBLIN, March 1 (Reuters) - Shares in Irish drug maker Elan Corp (ELN.I: Quote, Profile, Research) (ELN.N: Quote, Profile, Research) fell on Wednesday after research on the firm`s key product was interpreted by the market as negative, but some analysts shrugged off the report and said the stock would rebound.


Elan -- the fate of whose suspended multiple sclerosis (MS) drug Tysabri is critical to its future -- was down 6.4 percent at 10.47 euros by 1215 GMT on a slightly weak Dublin market <.ISEQ>, having dropped 9 percent in early trade.

Shares in Serono, the maker of a leading MS drug that had been seen under threat from Tysabri competition, rose 1.2 percent to 936.40 Swiss francs.

Dublin traders said Elan had already been suffering on Tuesday on the back of a U.S. broker report suggesting the use of Tysabri might be limited if it returned to the market.

"Then there was a story last night about a medical study on the effect of Tysabri on the immune system that caused a bit of a panic, but if you know about the drug that`s just the way it works, " one dealer said. "It was a bit misleading."

The abstract referring to Tysabri -- by researchers at the University of Texas -- had been posted on the American Academy of Neurology`s (AAN) website ahead of a presentation on April 5.

"The authors disclosed that the amount of immune-system cells in spinal fluid of patients on Tysabri are at levels similar to those in people infected with AIDS," Kepler Equities analyst Denise Anderson said in a note to clients, adding the real concern lay elsewhere.

"While the headlines of the study may sound scary, the main issue on whether or not to allow Tysabri back on the market is the risk of developing ... the condition that lead to suspension of sales of the drug," she said.

Dublin-based Goodbody Stockbrokers analyst Ian Hunter said the research was not fresh news.

"As the action of Tysabri is, by nature, immuno-suppressant, some degree of depetion in immune cells would be expected," he said.

"We remain comfortable the drug will return to the market as more than just a second line treatment."

Elan pulled Tysabri -- developed with U.S. partner Biogen Idec (BIIB.O: Quote, Profile, Research) -- from the market last year following the death of a patient.

The product is due for a two-day review by the U.S. Food and Drug Administration (FDA) on March 7 and 8, during which Elan will suspend trading of its shares.

Tysabri is key to restoring Elan`s fortunes after a brush with bankruptcy in 2002

[Birgit.Tersteegen]

NA Also--schön zurückrudern...

Ich hoffe ,dass TEVA auf ihren Intrigen sitzenbleiben-und auf ihren Produkten auch.

Aber:Wieso meldet sich die IR-Abteilung von Elan nicht--wäre doch ganz unverfänglich!

[Birgit.Tersteegen]

THE PERFECT STORM
by: mazurek2050
Long-Term Sentiment: Hold 03/01/06 07:59 am
Msg: 932190 of 932192

Ironic may be an understatement, How can all this BAD NEWS come together in ONE day..??
GOOGLE says not much more room in SEARCH; Cramer gets a TICKET, ELAN makes NO defensive statement to guard their position,,Then short activity is being called into question by overstock.com and ELAN is also mentioned in a briefing about ILLEGAL shorting and questionable statements from TV JOURNALISTS.
ALL of this amounts to a major HAIRCUT for the shares..So we hit LAST year ALL over again and here We sit "viewing the PERFECT STORM" ALL I can say is I wish it was 1 year from now and We could look back..!!
This would certainly make a GREAT movie script.Hurricane ELAN just destroys entire fortune during perfect storm..My take I`m staying and rebuilding and it just MAY take a year,because i`m not giving up My SHARES.
God bless All and good fortune.
Patience is a virtue or is it a fortune..??????

[Poppholz]

in USA wird wieder mit großen Blöcken gedrückt.

erster Kurs liegt bei $12,50

[Poppholz]

auf jeden Fall werden die Orderpositionen bei diesen Kursen deutlich größer:

8:32:36.733 S 2,700 12.6000

8:32:34.000 S 1,000 12.6000

8:32:24.801 B 1,300 12.6000

8:32:24.280 B 1,000 12.6000

8:31:43.913 S 200 12.6000

8:31:13.214 S 100 12.6000

8:31:05.162 S 2,500 12.6000

8:31:05.153 S 2,100 12.6000

[speedy001]

unter € 10- ein kauf ??? bin neu, warum gedrückt könnten ja auch schlechte nachrichten kommen ???

[Birgit.Tersteegen]

[posting]20.443.154 von speedy001 am 01.03.06 14:53:11[/posting]lesen hilft!

[Poppholz]

[posting]20.443.154 von speedy001 am 01.03.06 14:53:11[/posting]lies dir einfach diesen Thread und den von Cyberhexe durch.

Danach solltest Du Dir ein eigenes Bild machen können.

Jeder sollte für seine Kohle selbst verantwortlich sein.

(falls es hilft, wir sind alle noch investiert)

[Poppholz]

da werden immer wieder große Blöcke geschmissen.

Und noch keine Reaktion von ELAN.

Die haben wahrscheinlich Angst mit irgendeiner Reaktion die FDA zu verärgern, (oder sind selbst am einsammeln).

[Poppholz]

Biogen steht übrigens mit 6% im PLUS.

[Birgit.Tersteegen]

300 Stück zu 14,40 von 871331 gekauft!und wenn es weiter südlich geht,kommen die nächsten 300....

[Birgit.Tersteegen]

1 Million Shares in 3 Minutes
by: rpnhoo (47/M) 03/01/06 09:33 am
Msg: 932401 of 932404

what an interest ;-)

[Birgit.Tersteegen]

Geht up!

[Poppholz]

wir sind grün.

[Poppholz]

[posting]20.444.259 von Birgit.Tersteegen am 01.03.06 15:33:16[/posting]Gratuliere!

ich bleibe bei meiner Einstellung, keine weiteren Aktien zu kaufen.

Da ich bereits daneben gelegen habe, dass die Aktie überhaupt so tief fallen könnte, lass ich es lieber sein.

Wenn die Aktie doch noch weiter fallen sollte (gibt zwar keinen Grund, aber den gab es die letzten Wochen auch schon nicht), würde es mir doch ein wenig weh tun.

[zenman]

ELN/BIIB News from San Diego U-T (1/2)
by: rowerx1 03/01/06 09:50 am
Msg: 932463 of 932475

http://www.signonsandiego.com/news/business/20060301-9999-1b…

Good detail on TEVA`s repulsive behavior in this - Rx1

Drug`s approval dwarfed by worries over another
By Penni Crabtree
UNION-TRIBUNE STAFF WRITER
March 1, 2006

Shares of Biogen Idec fell about 6 percent yesterday despite the biotechnology company gaining regulatory approval for a new use for its top-selling cancer drug, Rituxan, as a treatment for rheumatoid arthritis.

The additional approval for Rituxan – a drug developed by San Diego`s former Idec Pharmaceuticals and co-marketed with South San Francisco`s Genentech – was overshadowed by speculation about the fate of another Biogen Idec drug, the multiple sclerosis drug Tysabri. A key advisory committee of the Food and Drug Administration will deliberate next week about whether to recommend Tysabri`s return to the market.

The drug, co-marketed by Cambridge, Mass.-based Biogen Idec and Irish drugmaker Elan Corp., was withdrawn last year after it was linked to a rare but often fatal brain disorder called progressive multifocal leukoencephalopathy, or PML. The disease is caused by the activation of a virus that is commonly found in healthy adults but usually remains dormant; three patients who took Tysabri developed PML, and two of them died.

A flurry of news – reports by wary Wall Street analysts that downplayed Tysabri`s ultimate utility and a negative scientific paper on Tysabri circulated by a rival drug company – contributed yesterday to the companies` stumbling stocks.

Shares of Elan, which like Biogen Idec maintains a research hub in San Diego, fell 9 percent, or $1.25, to close at $12.70. Biogen Idec`s share price lost $2.85 to close at $47.25.

A report yesterday by Piper Jaffray analysts speculated that Tysabri`s use by physicians will be limited if the product returns to the market. A survey of 140 neurologists found that only 10 percent would prescribe Tysabri for their patients, and then only for those who fail other available treatments.

A summary of a research paper, posted on the Web site of the American Academy of Neurology, concluded that Tysabri can deplete immune-system cells as much as HIV. PML typically afflicts AIDS patients because they have weakened immune systems.

Tysabri`s effect on the immune system might similarly increase patients` risk of contracting the PML-associated virus, the researchers said in the study. The study will be presented at the academy`s annual meeting April 5 in San Diego.

Teva Pharmaceutical Industries, the Israel-based maker of a rival multiple sclerosis drug, Copaxone, circulated copies of the abstract yesterday to the media through an outside spokesman. That action raised hackles at Elan, which is counting on Tysabri`s return to shore up its fragile fortunes.

“Other competitors will try to do everything they can to bring about criticism,” said Lars Ekman, head of research and development for Elan. “These are speculative exercises done by the competition, positioned and designed to undermine a new drug.”

Biogen Idec spokeswoman Amy Brockelman said it would be “inappropriate” for the company to comment because of the American Academy of Neurology`s policy to embargo the data until it is presented at the April 5 meeting.

The risk of contracting the rare brain disorder can be managed by monitoring patients and not giving it to those with impaired immune systems, according to the companies.

“This is an immunosuppressant drug and it suppresses the immune system,” said David Blaustein, who owns shares of Elan and manages health care investments at Suttonbrook Investments in New York. “It means the drug is working. It doesn`t mean Tysabri equals AIDS .”

[Poppholz]

[posting]20.444.259 von Birgit.Tersteegen am 01.03.06 15:33:16[/posting]300 Stück zu 14,40?

zu 14,40 hätte ich Dir auch noch einige verkauft.

Biete Dir sogar noch welche zu 14,30 an.

[[KERN]Codex]

12,55$

[Birgit.Tersteegen]

[posting]20.445.065 von Poppholz am 01.03.06 15:59:48[/posting]Poppi-das war ein Freudscher....es waren natürlich 10,40....aber die sind eben viiiiiiiiiiiiiiiiiiiiiiiel zzuuuuuuuuuuuuuuuuuuuu billig!

Irgendwann setzt sich die Wahrheit durch--ich hoffe nächste Woche!!

[Poppholz]

wenn das so weiter geht, dann haben wir auf jeden Fall wieder einen der besten Tage bezüglich "gehandelte Aktien".

In den ersten 15 Minuten waren es in USA bereits ca. 2.7 mio Stück gewesen.

[Nostarowie]

Was mich porös macht ist das ich nicht selbst nach meinem prognostizierten fallenden Dreieck gehandelt hab...

...ich fühle mich sooo schlecht.

Nuja fahrn wir halt die Achterbahn mit.

[Birgit.Tersteegen]

[posting]20.445.309 von Nostarowie am 01.03.06 16:08:11[/posting]porös--wie rieselt es schon???

Achterbahn fahren ist doch ganz lustig--ab und an wirds einem mal schlecht-aber das legt sich dann wieder....

[Birgit.Tersteegen]

Die gesamte Konkurrenz hat Angst vor Ty´s Zulassung...

Elan in THE GUARDIAN today ! link
by: watawn (31/M/ie)
Long-Term Sentiment: Strong Buy 03/01/06 10:09 am
Msg: 932527 of 932529

GSK know the damage TYSABRI will do to Serano...This means much more than that NEURO survey !!!!

http://www.guardian.co.uk/frontpage/story/0,,1720637,00.html


GlaxoSmithKline eased 22p to £14.46 amid fresh talk that it is considering a bid for Swiss biotech company Serono. However, analysts said GSK or anyone else was unlikely to make a move for Serono until next week`s ruling by the US regulator the food and drug administration on Elan`s multiple sclerosis treatment, Tysabri.

If the regulator allows Tysabri to return to the market with no restrictions it could pose a serious competitive threat to Rebif, Serono`s biggest-selling drug.

[Birgit.Tersteegen]

THIS IS WHAT WE BELIEVED, TY WILL
by: inflation_profff 03/01/06 10:24 am
Msg: 932561 of 932577

TAKE OVER ALL REBIF PAITIENTS IN ONE YEAR.

99.99% PATIENT WILL CHOOSE TY, 6 MONTHS AFTER THE RELOUNCH.

TEVA AND OTHERS, WILL SHRINK TO MINIMUM.

WE HAVE A TARGET OF 12BILLIONS REV FOR TY ON THE 2ND YEAR, WITH NO PML.

[Poppholz]

$12,94

?
?
?
?
?

?

Ich bin ja misstrauisch.

[Birgit.Tersteegen]

13!

[Poppholz]

$13,01



(sollte die Drückerei zu Ende sein?)

[Poppholz]

$13,08

und da sind die 10.000 Blöcke zum drücken wieder.

(wurde schon nervös)

[Nostarowie]

Ja doch doch, der Begriff Achterbahn ist angemessen

RT$13,02 grad

[Birgit.Tersteegen]

Das Orderbuch ist sehr spannend.Gerade 80.000er Block-und weg.

[Birgit.Tersteegen]

Re: The NEJM pdf files are out
by: hunglikeahorz (33/M/NC)
Long-Term Sentiment: Strong Buy 03/01/06 10:46 am
Msg: 932623 of 932627

Once the PDFs ae downloaded by media ... that`s it ...

We blow past $15-$17 before the AC ... Monday! Friday even.

[diddlhase]

[posting]20.440.186 von Birgit.Tersteegen am 01.03.06 12:13:07[/posting]Hallo Birgit,
ich verfolge ja den Thread schon einige Zeit und bin selbst investiert! Nun habe ich eine interessante Zeile von Dir gelesen:"ich kenne mich zwar mit der Seele der Menschen aus" Schön.. ich bin schon einige Zeit am überlegen, was genau ist die Seele des Menschen?? Mit einem Wort würde ich es als "das innere" bezeichnen! Ach das sind ja 2 Wörter!!
Ich versuche genauso ruhig zu bleiben wie ihr, mal sehen wie lang wir das durchhalten!!

[Nostarowie]

13,16
Elan,s Nervenschonendes Ferien-Freizeit-Tradeparadies.
..werde morgen ma die PR-Abteilung in Irland anrufen.

"Geld riskiert und mehr erlebt"

sollte dann kleingedruckt auf der Packung stehen.

[Birgit.Tersteegen]

[posting]20.446.591 von diddlhase am 01.03.06 16:51:53[/posting]Die Seele ist ein Mysterium ---und man sucht sich so Pfade dadurch-auch spannend...
----------------------------------------------------------
Was unser Schätzchen betrifft:

ich habe auch schon mal besser geschlafen als letzte Nacht...

Aber für mich hat sich gezeigt,dass es nur eine Blase der Konkurrenz war und jetzt bin ich wieder wohlgemut...

Am Tag Schokolade und abends Wein....Carepaket für Elanaktionäre...

[Birgit.Tersteegen]

[posting]20.446.713 von Nostarowie am 01.03.06 16:56:50[/posting]gute Idee!!Ausserdem wollen wir Schmerzensgeld!!

[Nostarowie]

Yepp das bring ich in Deinem Namen mit an....

...aber da wird der Kurs wahrscheinlich wieder fallen

[Birgit.Tersteegen]

[posting]20.446.960 von Nostarowie am 01.03.06 17:06:04[/posting]Also ich würde auf das Schmerzensgeld evtl.verzichten wenn ich im Gegenzug deren IR-Abteilung cochen dürfte (gegen gutes Honorar,versteht sich...)

[Poppholz]

dpa-afx
Aktien Frankfurt: Fester - MAN stärkster DAX-Wert
Mittwoch 1. März 2006, 14:58 Uhr

FRANKFURT (dpa-AFX) - In einem von Zurückhaltung geprägten Handel haben die deutschen Aktien am Mittwoch überwiegend leicht zugelegt. Für den Leitindex DAX ging es um 0,57 Prozent auf 5.829,29 Punkte nach oben. Auch der MDAX (Xetra: Nachrichten) der mittelgroßen Werte entwickelte sich freundlich und stieg um 0,16 Prozent auf 8.370,36 Punkte. Der Technologieindex TecDAX baute seine Gewinne aus und legte um 0,47 Prozent auf 746,98 Punkte zu.
Händler sprachen von einer Erholung, nachdem die deutschen Aktien am Vortag gegen Handelsende sehr stark verloren und damit übertrieben auf die Verluste in den USA reagiert hätten. Insgesamt verlaufe der Handel sehr ruhig, sagte ein Marktteilnehmer.

DAX (Xetra: Nachrichten) -Gewinner waren MAN-Aktien mit plus 3,54 Prozent auf 54,75 Euro. Die Analysten von Societe Generale (Paris: FR0000130809 - Nachrichten) hatten die Aktien des Maschinenbauers und Nutzfahrzeugherstellers zum Kauf empfohlen. Auch die Aktien der Deutschen Bank (Xetra: 514000 - Nachrichten) legten nach einem positiven Analystenkommentar um 0,97 Prozent auf 93,35 Euro zu. Merrill Lynch (NYSE: MER - Nachrichten) hatte das Kursziel von 104 auf 114 Euro erhöht.

Schlusslicht waren die Aktien von Volkswagen (Xetra: 766400 - Nachrichten) (VW) mit minus 1,30 Prozent auf 57,90 Euro. Händler verwiesen auf das Sparprogramm "For Motion". "VW versucht zwar zu sparen, aber Preisnachlässe und Währungseffekte scheinen den Großteil zu verschlingen." Für Unsicherheit sorge zudem, dass die Vertragsverlängerung von VW-Chef Bernd Pischetsrieder nicht sicher sei. Es sei "wirklich eine offene Frage", ob der Vertrag verlängert werde, sagte Ferdinand Piech dem "Wall Street Journal Europe" in einem Interview (Mittwoch).

Die Aktien von Schering stiegen um 2,27 Prozent auf 61,69 Euro. "Elan (Dublin: DRX.IR - Nachrichten) kann sein Konkurrenzprodukt gegen Multiple Sclerose noch nicht auf den Markt bringen, das ist gut für Betaferon von Schering", sagte ein Marktteilnehmer.

was soll denn jetzt eine solche Schlussfolgerung?

Linde (Xetra: 648300 - Nachrichten) -Aktien gewannen 0,51 Prozent auf 66,79 Euro. Händler begründeten die Gewinne mit Spekulationen über ein am morgigen Donnerstag bevorstehendes freundliches Übernahmeangebot der Wiesbadener für den britischen Industriegase-Konkurrenten BOC . Das Gebot soll demnach bei 1.630 bis 1.640 Pence je BOC-Aktie liegen.

T-Online gaben um 1,28 Prozent auf 7,70 Euro nach. Der Internetanbieter rechnet in diesem Jahr bestenfalls mit einem stagnierenden Reingewinn. Im vergangenen Jahr hatte T-Online unter dem Strich 203,8 Millionen Euro verdient./mw/sc

[zenman]

gibt en mords-steiles W bis GAP-schluss bei 14
nich unbedingt heute
aber bis freitag

[Poppholz]

in 1,5 Stunden fast 8 mio Aktien in den USA gehandelt.

Das geht noch richtig was heute, wenn die Käufer so beibleiben.

[Birgit.Tersteegen]

[posting]20.447.193 von Poppholz am 01.03.06 17:15:04[/posting]auch diese Schlussfolgerung ist nur Politik!

[Birgit.Tersteegen]

aus Globes online-der selbe Quatsch von gestern-allerdings ist der letzte Absatz interessant....

MS drug Tysabri severely harms immune system - study
Tysabri competes against Teva’s Copaxone. Biogen Idec and Elan’s shares are down 5-6% in New York and Europe.
Yuval Mendelson 1 Mar 06 14:31
Is the return of multiple sclerosis (MS) drug Tysabri in greater doubt? Tysabri, made by Biogen Idec (Nasdaq: BIIB) and Elan Corp. (NYSE; Dublin: ELN; LSE: ELA), was taken off the shelves in December 2004 after some patients using the drug died.

After year in which Teva Pharmaceutical Industries Ltd.’s (Nasdaq: TEVA; TASE: TEVA) Copaxone, Tysabri’s competitor, enjoyed relative quiet, it seemed that Tysabri’s path back to the shelves was getting shorter. Next week, a US Food and Drug Administration (FDA) panel is due to approve new clinical trials for Tysabri by Biogen Idec and Elan, which could have put the drug back on the shelves within a few months.

A new study, published today, could become a major obstacle for Tysabri’s return. Carried out by two University of Texas neurologists, the study found that Tysabri affected patients’ immune system. The study took blood samples from MS patients who had taken Tysabri experienced a significant deterioration in their immune systems, to levels seen in AIDS patients. It should be stressed that MS treatment includes suppressing the immune system.

Tysabri’s future now appears quite bleak. In a survey of 140 neurologists, only 10% recommended their patients take Tysabri, especially if other treatments are ineffective.

It should be emphasized that the study was sent to a scientific journal for publication, but it has not yet been accepted for publication, said one of the researchers. Teva yesterday circulated a synopsis of the study through an external New York spokesman.

Biogen Idec and Elan’s shares fell 5-6% in trading in New York and on European bourses yesterday and today.

Published by Globes [online], Israel business news - www.globes.co.il - on March 1, 2006

[Birgit.Tersteegen]

Drug`s approval dwarfed by worries over another
By Penni Crabtree
UNION-TRIBUNE STAFF WRITER

March 1, 2006

Shares of Biogen Idec fell about 6 percent yesterday despite the biotechnology company gaining regulatory approval for a new use for its top-selling cancer drug, Rituxan, as a treatment for rheumatoid arthritis.

The additional approval for Rituxan – a drug developed by San Diego`s former Idec Pharmaceuticals and co-marketed with South San Francisco`s Genentech – was overshadowed by speculation about the fate of another Biogen Idec drug, the multiple sclerosis drug Tysabri. A key advisory committee of the Food and Drug Administration will deliberate next week about whether to recommend Tysabri`s return to the market.

Advertisement
The drug, co-marketed by Cambridge, Mass.-based Biogen Idec and Irish drugmaker Elan Corp., was withdrawn last year after it was linked to a rare but often fatal brain disorder called progressive multifocal leukoencephalopathy, or PML. The disease is caused by the activation of a virus that is commonly found in healthy adults but usually remains dormant; three patients who took Tysabri developed PML, and two of them died.

A flurry of news – reports by wary Wall Street analysts that downplayed Tysabri`s ultimate utility and a negative scientific paper on Tysabri circulated by a rival drug company – contributed yesterday to the companies` stumbling stocks.

Shares of Elan, which like Biogen Idec maintains a research hub in San Diego, fell 9 percent, or $1.25, to close at $12.70. Biogen Idec`s share price lost $2.85 to close at $47.25.

A report yesterday by Piper Jaffray analysts speculated that Tysabri`s use by physicians will be limited if the product returns to the market. A survey of 140 neurologists found that only 10 percent would prescribe Tysabri for their patients, and then only for those who fail other available treatments.

A summary of a research paper, posted on the Web site of the American Academy of Neurology, concluded that Tysabri can deplete immune-system cells as much as HIV. PML typically afflicts AIDS patients because they have weakened immune systems.

Tysabri`s effect on the immune system might similarly increase patients` risk of contracting the PML-associated virus, the researchers said in the study. The study will be presented at the academy`s annual meeting April 5 in San Diego.

Teva Pharmaceutical Industries, the Israel-based maker of a rival multiple sclerosis drug, Copaxone, circulated copies of the abstract yesterday to the media through an outside spokesman. That action raised hackles at Elan, which is counting on Tysabri`s return to shore up its fragile fortunes.

“Other competitors will try to do everything they can to bring about criticism,” said Lars Ekman, head of research and development for Elan. “These are speculative exercises done by the competition, positioned and designed to undermine a new drug.”

Biogen Idec spokeswoman Amy Brockelman said it would be “inappropriate” for the company to comment because of the American Academy of Neurology`s policy to embargo the data until it is presented at the April 5 meeting.

The risk of contracting the rare brain disorder can be managed by monitoring patients and not giving it to those with impaired immune systems, according to the companies.

“This is an immunosuppressant drug and it suppresses the immune system,” said David Blaustein, who owns shares of Elan and manages health care investments at Suttonbrook Investments in New York. “It means the drug is working. It doesn`t mean Tysabri equals AIDS.”

The spate of negative Tysabri news managed to steal the spotlight from the Rituxan approval late yesterday for rheumatoid arthritis. The drug, already approved for some forms of non-Hodgkin`s lymphoma, generated $1.8 billion in U.S. sales last year.

With the new use in rheumatoid arthritis, Rituxan is expected to generate $300 million to $500 million more in annual revenue for Biogen Idec and Genentech to divide, according to some Wall Street analysts.

Nikki Levy, a spokeswoman for Genentech, said one course of Rituxan as an arthritis treatment, which lasts for six to nine months, will be priced at about $9,088.

Rituxan is an engineered protein, or monoclonal antibody, that targets B cells. In rheumatoid arthritis, those B cells manufacture antibodies that attack the body`s joint linings, causing painful inflammation and swelling.

Rituxan was approved for use in arthritis patients who don`t have an adequate response to a class of drugs known as TNF inhibitors. Those drugs include Amgen`s Enbrel, Johnson & Johnson`s Remicade and Abbott Laboratories` Humira.

About 2 million Americans, mostly women, suffer from rheumatoid arthritis, and about 30 percent of patients treated with anti-TNF drugs don`t get adequate relief.

Bloomberg News contributed to this report.

Penni Crabtree: [phone]; [e-mail]









Q

[Birgit.Tersteegen]

t`s hard to believe
by: tazzsnapper 03/01/06 12:07 pm
Msg: 932894 of 932933

and I`ll be called a pumper for saying it, but ELN was $29 with Ty before (GREAT alz and nano news since then). After Ty is back we should jump above $25 --- yes I`m saying we could see a 100% gain from these levels in 1 week. What are the chances Ty will be back -- I would say pretty damn good.
-----------------------------


I would say :YES!

[[KERN]Codex]

Da haben einige richtig fett gesammelt

[Birgit.Tersteegen]

[posting]20.448.897 von [KERN]Codex am 01.03.06 18:28:06[/posting]und-Du auch??

[Birgit.Tersteegen]

Orderbuch spricht für linke Tasche-rechte Tasche,1775 Stück mehrfach....d.h. sie sammeln und drücken noch.Wir haben also hier die Evolution von Jäger und Sammler zu Jäger und Drücker-na immerhin...

[Birgit.Tersteegen]

Dieser Artikel triffts!


Tysabri: As Bad as AIDS?

By Bill Mann (TMF Otter)
March 1, 2006

Elan (NYSE: ELN) shareholders are a certifiably nervous lot these days. In a week, the Food and Drug Administration will hold hearings on whether -- and under what circumstances -- it will allow Tysabri, a treatment for multiple sclerosis that Elan developed and co-markets with Biogen IDEC (Nasdaq: BIIB), to return to the market. When the two companies voluntarily pulled the drug following reports linking it to two deaths from progressive multifocal leukoencephaly (mercifully abbreviated PML) last year, Elan`s share price tanked by more than 70%. When another case came to light -- this time with a patient taking Tysabri as a monotherapy -- the losses from the peak increased to 90%.

Elan seemed cooked. Tysabri was its great hope. But there was no denying a few things: Tysabri was more effective in treating MS than anything else was on the market, the two cases of PML presented themselves in patients who were using Tysabri in combination with other drugs, and MS sufferers and many neurosurgeons alike were clamoring for its return to the market. In November, the FDA put Tysabri on priority review, and next week, they`ll hold the meeting. To say that a lot rides on the outcome of this meeting for Elan shareholders is an understatement. The stock has risen 300% from its April lows, but recent weakness in the shares suggests that some shareholders are hedging their bets or are selling entirely.

So when a University of Texas report came out on Feb. 28 stating that Tysabri can deplete immune-system cells by the same level as the HIV virus, Elan shares went into a complete tailspin, dropping more than 14% at one point, before recovering to finish down only 7% at the close.

However, Bloomberg said on Wednesday that this report, which has yet to be accepted by a medical journal, was circulated by a spokesman for rival MS drugmaker Teva Pharmaceutical (Nasdaq: TEVA). If this is true, I believe it`s a pretty dastardly deed -- not so much because a study showing that Tysabri lowers the immune system as much as HIV does is slanderous, but because doing so shows that Teva is willing to try to influence proceedings before the FDA meeting by introducing additional doubt for the safety of Tysabri. It also shows that the company considers the drug to be a legitimate threat to its own MS treatment, Copaxone.

Let`s face it -- HIV is scary, a true hot button if there ever was one. But the report doesn`t say that Tysabri is as dangerous as HIV. It says that it lowers immune systems to similar levels. Well, hello! Tysabri is an immunosuppressant. This is how the drug combats MS. Essentially, Tysabri sequesters the immune system to keep it from destroying the central nervous system. The challenge is to keep the immune system from dropping too low. This, incidentally, is why most PML cases exist in people who have full-blown AIDS. The virus that causes PML exists in an estimated 70% of the general population but remains latent.

Now, imagine that -- an immunosuppressant that suppresses the immune system! None of this implies that suppressing the immune system isn`t an extremely dangerous thing to do. But it also happens to be the most effective way to treat a debilitating and deadly disease.

This is not to cast aspersions on the original Texas research, which may turn out to be bulletproof. But Tysabri is a drug administered once a month by doctors, who, one would assume, observe and adjust dosing as needed. But while the study may have its clinical use in helping make Tysabri (and future MS treatments) safer, the link to HIV in the public domain is spurious. You might as well say that helium is as dangerous as hydrogen because it also makes balloons float.

Makes you wonder why Teva`s representative went to such an effort to make the study known, doesn`t it?

Biogen is a Motley Fool Stock Advisor recommendation.

Bill Mann doesn`t even play a doctor on TV. He does hold shares of Elan Pharmaceuticals. Bill is the co-advisor of the Motley Fool Hidden Gems newsletter, in which he and Tom Gardner monthly recommend stocks that the market has ignored, mistreated, and misunderstood. A 30-day guest pass is a click away!

[Birgit.Tersteegen]

NEJM - Tysabri Mono Trial
by: powershares (M/Ireland)
Long-Term Sentiment: Strong Buy 03/01/06 02:01 pm
Msg: 933140 of 933158

In conclusion, our study provides evidence that natalizumab significantly reduces the progression
of disability and the occurrence of clinical relapse and suppresses the formation of lesions as visualized by MRI in patients with relapsing multiple sclerosis. Moreover, our data indicate that efficacy is realized early and persists throughout the treatment period. Within the 30-month valuation period of this trial, natalizumab monotherapy had an excellent safety and tolerability profile. Continued assessments of long-term treatment with natalizumab will better define the safety profile of this effective therapy and establish its place in the arsenal of treatments for relapsing multiple sclerosis.

[mikel_ann]

Was denkt ihr wo wir stehen, wenn Ty nicht zugelassen würde ?

[Birgit.Tersteegen]

[posting]20.453.094 von mikel_ann am 01.03.06 21:21:15[/posting]Da denke ich gar nicht dran!

[mikel_ann]

Hm, nein das kann ich nun nicht akzeptieren.

Zumindest die Möglichkeit besteht.

Recht haben und bekommen sind bekanntlich auch 2 Paar Schuhe.

[YoungRich]

Also ich bin heute mit 2/3 meiner Position raus, meine Nerven machen dies nicht mehr mit

Bald wisen wir mehr :-) Vielleicht wars falsch, vielleicht auch nicht ...das ganze Spiel erinnnert mich langsam zu sehr an Roulette (rot oder schwarz)

Grüsse Young

[Birgit.Tersteegen]

[posting]20.453.623 von YoungRich am 01.03.06 21:45:37[/posting]wahrscheinlich bleibst Du dann young -aber nicht unbedingt rich--....ich bin schon älter---dann werd´ich vielleicht rich--we will see !

[Birgit.Tersteegen]

Recommend this Post - This post has 15 recommendations Ignore this User | Report Abuse
MS`er
by: gvgiants
Long-Term Sentiment: Strong Buy 03/01/06 04:02 pm
Msg: 933430 of 933436

I have been on the sidlines for several years. Yes, I own Elan and I bought it because of Tysabri. I have tried the other drugs, copaxane, Beta Serone and rebif. I have tried other options that I won`t bore you with. I had two infusions of Ty and I felt tingling in my toes. My feet are completly numb, I try and related it by describing the feeling as a deadness of my feet. It works! I am not the only one who feels this way. If PML were to come my way, so be it. MS sucks thats all I can say. I believe in this drug becuase I have taken it. I have followed its development for years and looked forward to its release. For the people wanting to make money on us MS`ers so be it, I wan`t to too. I do not work for Elan or the idiots who short this stock. Elan will prevail becuase it works. Teva is out for the money, well so are we. For me however, the benefit will be by getting better. Sorry for the length. I will not post again.

[YoungRich]

Birgit, was (wieviel) ist schon rich :-)
Hauptsache man ist gesund

Schönen Abend

Young (noch nicht rich)

[Birgit.Tersteegen]

M.S. medication breakthrough
by: semiconductress2004
Long-Term Sentiment: Buy 03/01/06 05:25 pm
Msg: 933610 of 933610

Local TV news station in Connecticut is running this story.

http://www.wtnh.com/Global/story.asp?S=4569990

Best wishes to all the MSers.


(WTNH, Mar. 1, 2006 5:00 PM) _ There is new hope for the thousands of Americans suffering from M.S.

* by Dr. Mike Rosen

A novel drug, called Tysabri, has been shown in new studies to prevent the progression of the disease.

But does it come with a life-threatening side effect?

For patients like, Audrey Greenfeld, who suffers from relapsing multiple sclerosis, any new treatment is a welcome one. “I was diagnosed almost fifteen years ago. I basically have no strength in my right side, and it just kept getting worse,” says Audrey.

With relapsing M.S., the symptoms come, go, and come back, and gradually worsen over time.

The disorder is characterized by intermittent development of inflamed areas of the brain and spinal cord that result in plaques which destroy nerve signal transmission.

Dr. Fred Lublin of Mt. Sinai Medical Center says, “It can produce all sorts of potential problems blindness in one eye, double vision, numbness, tingling, weakness in one arm, one leg, both legs.”

The best treatments including interferon, often fall short. Audrey has tried everything…to no avail.

But now, this new treatment called Tysabri may be, not a cure, but a big answer in battling relapsing M.S.

A new study shows Tysabri, when used alone, reduced relapse rates after one year of use by 68 percent. And it decreased the risk of a steady worsening of diseasem by 42 percent.

Dr. Lublin, who co-authored the study published in the latest New England Journal of Medicine, says, “So we know the drug is effective and we are happy with the efficacy but we don’t know what the real risk is.”

The big concern: in another study, when Tysabri was combined with interferon, there were two cases of PML—a deadly viral brain infection.

The drug was withdrawn from the market voluntarily.

“I stopped walking two years ago so but I figured ok ill get it when it becomes available and I got approval from my insurance company and I had one infusion and I had no side effect. So I was very excited and then two weeks after I got my infusion they took it off the market,” recalls a disappointed Audrey.

But Tysabri alone has not been shown to cause PML.

So two weeks ago, the FDA once again allowed studies on the drug. And next week, an fda advisory panel will consider approval of Tysabri for relapsing M.S.

“They will review the efficacy data, the safety data that has been collected since the drug was taken off the market,” states Dr. Lublin.

Tysabri may be the answer for Audrey. “I would love to walk again, but if I cant I just don’t want it to get worse it is getting to the point where I am not going to be able to live with not doing anything so I’ve got to stop it from getting worse,” she exclaims.

Tysabri may alone provide benefit for two other diseases, Crohn’s disease and rheumatoid arthritis.

There was, before the voluntary withdrawal of the drug by its maker, four months of open availability; during that short time span, 7,000 patients received it commercially, showing there is a huge unmet need for M.S. patients.

[Birgit.Tersteegen]

Moin----Heute ist Elan bei Yahoo aufder ersten Seite mit einem Artikel über u.a. die Ergebnisse der Studien





Studies Find Withdrawn MS Drug Effective

By STEPHANIE NANO, Associated Press Writer 2 hours, 6 minutes ago

NEW YORK - A promising multiple sclerosis drug that was suspended from the market because three people developed a rare brain disease now appears relatively safe and quite effective, three studies found.
ADVERTISEMENT

What keeps you from eating right?

I`m tired of salads
No time to cook
Don`t know how

The research in Thursday`s
New England Journal of Medicine comes days before government hearings on whether to allow sales of the drug, Tysabri, to resume.

Tysabri (pronounced ty-SAH-bree) was withdrawn a year ago by Biogen Idec Inc. and Elan Corp. PLC, only months after it had been approved. The
Food and Drug Administration last month agreed to allow testing to resume after the company said no more cases of the brain disease had emerged.

The new studies found that Tysabri alone or with standard interferon treatment cut the rate of relapse by as much as two-thirds after two years and reduced the number of people whose MS got worse, compared to those on a dummy treatment or interferon alone.

The studies "confirm that this drug is a significant advance for MS treatment," said Dr. Allan H. Ropper of Boston`s Caritas St. Elizabeth`s Medical Center, who wrote an editorial in the journal.

Multiple sclerosis, a disease of the central nervous system, afflicts about 350,000 Americans and is more common among women than men. There is no cure and the cause is unknown. Symptoms include trouble seeing and walking. The most common form causes periodic flare-ups of symptoms.

Tysabri was highly anticipated because it works in a different way than existing drugs, which offer only modest help. It blocks destructive immune cells from leaving the bloodstream and entering the brain to inflame and damage nerve tissue.

Patients clamored for the drug when it went on sale, with about 7,000 getting treatment in the first three months.

Then a woman who had gotten Tysabri and interferon for three years died of the brain disease, progressive multifocal leukoencephalopathy, or PML, and a second participant contracted it. Sales of the drug were suspended and tests halted.

A Crohn`s disease patient in a Tysabri test for the painful bowel disorder also died of the brain ailment, which is caused by a common virus that is usually dormant. It is most often seen in those with weak immune systems, such as
AIDS patients.

An independent committee that included
National Institutes of Health scientists reported in the journal that a review found no other cases of the brain infection in other study volunteers. They put the odds of getting PML at 1 in 1,000.

In one study of 942 people, nearly twice as many on a dummy treatment got worse over two years. The Tysabri group had 68 percent fewer relapses.

In the second study of 1,171, the rate of relapse was cut in half when Tysabri was added to interferon. A quarter more patients got worse on interferon alone.

The researchers have received fees or support from the makers of Tysabri and include Biogen Idec employees.

The lead researchers said they will soon resume testing Tysabri and would give it to the neediest patients if it went back on the market.

"I think it`s up to the doctor, together with the patient, to decide whether to use it," said the Cleveland Clinic`s Dr. Richard Rudick, who led the combination study.

One of the many MS patients who want it is Steve Triedman, 47, a graphic designer in Providence, R.I. He got the study drug for more than two years and had no relapses. Without it, he has had several episodes and has problems with his balance, though he still plays tennis.

"When we are out, it`s not a question of what will I knock over, but when," he said.

Mary Morin had only two Tysabri monthly infusions before it was pulled, but she is eager to get more. The 43-year-old woman, who works as a physical therapy assistant, said she did not realize how much Tysabri had helped until her daughter noticed her walking had improved.

"It makes you feel for once you aren`t focused on the fact that you have MS," said Morin, who lives in Northwell, Mass.

Dr. Lawrence Steinman of Stanford University School of Medicine, who helped develop Tysabri, said he would be reluctant to use it now, although he thinks the FDA should approve its sale with stern warnings.

"If I had any alternatives, I would not use it," he said. "MS is a bad disease, but it`s not like lung cancer or a disease where you`d take lethal risks to treat it."

___

[Birgit.Tersteegen]

Forbes schreibt dazu

Studies Suggest Controversial Multiple Sclerosis Drug Is Safe
03.01.06, 12:00 AM ET

WEDNESDAY, March 1 (HealthDay News) -- New data on a controversial multiple sclerosis drug pulled from the market a year ago found that the drug actually appears to be effective and safe, at least for the short term.

However, the researchers can`t yet say the medication is risk-free.

Three patients taking the drug, Tysabri (generic name natalizumab) had developed progressive multifocal leucoencephalopathy (PML), a progressive, neurodegenerative disease. Two of those patients died, one with multiple sclerosis (MS) and one with Crohn`s disease. In the aftermath of these events, questions were also raised about the drug`s effectiveness.

A U.S. Food and Drug Administration advisory committee will no doubt take this updated picture into account when it considers allowing Tysabri back on the market at a meeting March 7 and 8.

"The efficacy data was very encouraging and the extra year of follow-up during which people who had taken Tysabri were evaluated did not reveal any additional cases of PML, which is also very encouraging," said Dr. John Richert, vice president for research and clinical programs at the National Multiple Sclerosis Society. "The issue now is for the FDA to evaluate all of the efficacy data and all of the risk data and come up with the wisest decision possible."

The makers of Tysabri -- Biogen Idec Inc. and Elan Corp. PLC -- were also pleased with the findings.

"The two-year data from two Phase III clinical trials of Tysabri, among the largest ever in MS, alongside findings from a comprehensive safety evaluation, underscore the compelling efficacy of Tysabri in MS and the extensive nature of the safety evaluation -- both will be used to further define the benefit-risk profile," said Davia Temin, spokeswoman for Elan. "The two-year data along with the safety evaluation are part of regulatory filings currently under review with the FDA and EMEA. The FDA has granted Priority Review to the Tysabri sBLA [biologic license application] and we anticipate action in late March."

Tysabri was pulled from the market on Feb. 28, 2005, after reports that three patients taking it had developed PML. The suspension took place just three months after the FDA had granted accelerated approval of the drug for the treatment of relapsing forms of MS.

In February of this year, the U.S. Food and Drug Administration announced that Biogen and Elan could resume clinical trials for MS patients who were previously treated with the drug under an investigational study.

According to the National Institute of Neurological Disorders and Stroke, multiple sclerosis is an unpredictable disease of the central nervous system that can range from relatively benign to somewhat disabling to devastating. Most MS patients experience their first symptoms between the ages of 20 and 40, and most suffer muscle weakness in their extremities and difficulty with coordination and balance. These symptoms may be bad enough to hamper walking or even standing; in worst cases, MS can produce partial or complete paralysis.

Tysabri is a monoclonal antibody, engineered to attach itself to white blood cells called lymphocytes and prevent them from entering the brain, where they do damage that causes the disabling symptoms of MS. Tysabri had also been used to treat Crohn`s disease.

The new findings appear in three papers in the March 2 issue of the New England Journal of Medicine.

The first trial, involving 942 patients, found that Tysabri reduced the risk of progression of disability by 42 percent over two years and the rate of clinical relapse at one year by 68 percent. The drug also reduced the accumulation of brain lesions, which are hallmarks of the disease.

The second trial found that, when combined with interferon beta-1a, Tysabri reduced the risk of relapse by 55 percent. The combination therapy also reduced the risk of progression of disability by 24 percent over two years. This study involved 1,171 patients.

Finally, and perhaps most encouraging, the third study found no additional cases of PML among 3,116 patients who had taken Tysabri.

"We concluded that at this particular time there is no evidence that there are more PML cases," said Eugene Major, co-author of the third paper and chief of the laboratory of molecular medicine and neuroscience at the U.S. National Institute of Neurological Disorders and Stroke.

The risk is still high, however, Major said. "One in 1,000 is substantial. Questions remain about risk," he said.

"There probably is some definite risk of PML in people who are on Tysabri," added Richert, of the National Multiple Sclerosis Society. "What`s not clear yet is whether or not people on Tysabri also have to be otherwise immunosuppressed or immuno-modulated with other medications in order to have that risk."

The National Multiple Sclerosis Society conducted a survey of about 800 people with MS to gauge their views on Tysabri and has given this data to the FDA to consider at the upcoming advisory committee meeting. Many people said they wanted more information on Tysabri before making a decision on whether they would be willing to take it.

The society feels much the same way, Richert said. "Rather than proselytize for or against approval, our emphasis has been make sure that the FDA conducts as thorough an evaluation as humanly possible and comes to the wisest decision possible," he said. "We did give them names of people to testify but they have not told us who, if anyone, from our list they have chosen."

More information

For more on MS, visit the National Multiple Sclerosis Society.

[Birgit.Tersteegen]

147 Artikel sind im Moment verfügbar über die Ergebnisse--na,wenn das nicht hilft.....

http://news.google.com/nwshp?tab=wn&ned=us&topic=m

[Birgit.Tersteegen]

Der ist auch guuuuuuuuuuuuuuuut;ach ist das FEIN!!



I don`t care how many times this gets
by: odz500 (46/M/N. Ireland)
Long-Term Sentiment: Strong Buy 03/02/06 01:46 am
Msg: 934406 of 934420

..posted. Up Élan

http://news.yahoo.com/s/nm/20060302/hl_nm/tysabri_ms_some_ri…

NEW YORK (Reuters Health) - Tysabri, a drug made by Biogen Idec and Elan Pharmaceuticals, significantly reduces the rate of disease progression in patients with relapsing multiple sclerosis (MS), according to the results of two trials reported in this week`s New England Journal of Medicine.

"The available drugs for MS, interferon and Copaxone, have been shown in trials to reduce relapse rate by one third," Dr. Richard A. Rudick, of the Cleveland Clinic Foundation in Ohio, told Reuters Health. The two current trials show that "the effectiveness of Tysabri was very excellent," far better than that of the other available drugs.

However, a review of more than 3000 patients treated with Tysabri (which is known as natalizumab, generically) in clinical trials revealed that the drug is associated with a small risk of a serious neurological disease called progressive multifocal leukoencephalopathy or PML.

Tysabri was approved by the US Food and Drug Administration in November 2004 for the treatment of MS, but it was suspended in February 2005 after PML cases were reported.

In one of the new studies, Dr. Chris H. Polman, from the VU Medical Center in Amsterdam, and his team recruited 942 patients with relapsing remitting MS, who were randomly assigned to receive natalizumab every 4 weeks or an inactive placebo injection.

After 2 years of treatment, compared with placebo, natalizumab was associated with a 42 percent decrease in the risk of a sustained progression of disability and 59 percent reduction in the risk of relapse. The active treatment also reduced the number of new or enlarging MS lesions in the brain by 83 percent.

In the second trial, Dr. Rudick and his colleagues enrolled 1171 MS patients who had at least one relapse during a 12-month period while they were being treated with interferon. Patients were randomly assigned to natalizumab every 4 weeks or placebo while continuing on interferon.

Combined treatment over 2 years resulted in a 24 percent decrease in the risk of sustained disability progression, a 55 percent reduction in rate of relapse, and an 83 percent reduction in new or enlarging lesions, compared with interferon alone.

After the three original cases of PML were reported in patients being treated with natalizumab, Dr. Eugene O. Major, from the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland, and colleagues established an independent committee to evaluate suspected cases of PML in 3417 patients exposed to natalizumab in recent clinical trials.

Forty-four patients with possible PML were referred to the committee. PML was ruled out in 43, and 1 case was classified as indeterminate. The three previously reported cases did seem to be actual PML.

When the FDA suspended Tysabri, "patients were devastated," Rudick said. "Imagine being 1 of 7000 patients for whom current therapies are of little benefit and starting a new drug that is known to be a significant advance, then having it suspended abruptly because of this question about safety. We had patients crying in our offices."

[Birgit.Tersteegen]

Importance of 3 NEJM articles
by: creedster_99
Long-Term Sentiment: Strong Buy 03/02/06 01:35 am
Msg: 934401 of 934428

For those who don`t really understand, The NEJM is the "A Number One" respected medical Journal in the world.

To get these articles accepted and in print all together and immediately before the AC is either a very cleverly arranged event or a gift from God.

The ABSOLUTELY STELLAR RESULTS will now be seen by tens of thousands of doctors who knew nothing about Tysabri before. The decrease in relapses and new Gad enhancing T2 lesions results are mind-blowing.

The abstract from the AAN showing decrease in disability progression vs placebo at the p<0.0001 level will make people`s heads spin!

Folks, there is just no better, more respected journal out there than the NEJM. If they "give their blessing" as they have done here and the results are this great many, many people will ahve the opportunity to read about Ty for MS this weekend and will be informed and prepared for next weeks AC.

I previously said chance of AC approval was 99%. This should go a long way to satifying the other 1% of doubters.

Thank you Elan, thank you patient subjects, thank you NEJM, thank you.

[Poppholz]

Elan`s Tysabri Monotherapy Cuts MS Progression-Journal

03-01-06 05:15 PM EST
LONDON -(Dow Jones)- Biogen Idec Inc.`s (BIIB) and Elan Corp. PLC`s (ELN) multiple sclerosis drug Tysabri used as a monotherapy cut the risk of disability progression by 42%, according to the results of two phase III trials and one safety evaluation study published in the New England Journal of Medicine Wednesday.

The results also showed that treatment with Tysabri, whose generic name is natalizumab, led to a 68% reduction in the annualized relapse rate compared with the use of a placebo.

A second trial studying Tysabri`s use with Avonex, another multiple sclerosis treatment sold by Biogen, reported that the drug had a significant effect on disability progression, relapse rate and brain lesions compared with Avonex alone.

The two-year data from the phase III trials were previously presented at medical meetings during 2005.

Touted as a potential blockbuster and major breakthrough in the treatment of multiple sclerosis, Tysabri was withdrawn from sale in February 2005 after being linked to three cases of an often fatal brain infection called progressive multifocal leukoencephalopathy, or PML.

Two patients died of the condition, while a third survived, but was significantly impaired.

An independent adjudication committee, established as part of the safety evaluation and whose findings are published in the journal, has concluded that there were no new confirmed cases of PML in patients treated with Tysabri.

An accompanying editorial to the three articles stated that the data shows the efficacy of the drug when taken during a two-year period and provides reassurance that the risk of PML is small with relatively brief use.

"Beyond these findings, clinicians and patients are left wondering if and when natalizumab will be made available and what precautions might be taken to prevent the emergence of the ... causative agent of PML," the editorial said.

The U.S. Food and Drug Administration has removed the clinical hold it placed on Tysabri at the time of its withdrawal and Biogen is expected to resume trials of Tysabri in the coming weeks.

In a two-day meeting set to start March 7, an FDA advisory committee will decide on whether the drug should return to the market and what limits should be set on its use if it does.

Elan`s shares will be suspended for the duration of the meeting.

Journal Web site: http://www.nejm.org

-By Elena Berton, Dow Jones Newswires; 44 20 7842 9267; elena.berton@ dowjones.com


(END) Dow Jones Newswires
03-01-06 1715ET
Copyright (c) 2006 Dow Jones & Company, Inc.



http://news.morningstar.com/news/DJ/M03/D01/200603011715DOWJ…



heute wird ein Dunkelgrüner Tag.

[Poppholz]

heute sollten wir wieder über € 12,00 schließen.

[Birgit.Tersteegen]

[posting]20.458.020 von Poppholz am 02.03.06 09:37:22[/posting]JAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAa!

[Poppholz]

auf der Insel sind wir bereits über €11,-

[Poppholz]

02.03.2006 09:34
Elan cites positive results from 2-yr Phase III trial on Tysabri in MS

LONDON (AFX) - Elan Corporation PLC (Nachrichten) and Biogen Idec Inc said they have had positive two-year results from the two Phase III clinical trials evaluating TYSABRI (natalizumab) for patients with relapsing forms of multiple sclerosis (MS), as well as data from the comprehensive safety evaluation.

Data from AFFIRM and SENTINEL, among the largest ever Phase III MS trials, provide compelling evidence of the benefit of TYSABRI, the companies said.

Currently available MS therapies often do not adequately control the disease for many patients, creating a significant unmet need that TYSABRI may help address, they added.

[e-mail]
slm

[Poppholz]

Der Link zu dem Artikel:

http://www.iii.co.uk/news/?type=afxnews&articleid=5568012&su…

[Poppholz]

Tysabri Study Results Published

By Althea Chang
TheStreet.com Staff Reporter
3/1/2006 6:58 PM EST
Click here for more stories by Althea Chang


Biogen Idec (BIIB:Nasdaq - commentary - research - Cramer`s Take) and its partner Elan (ELN:NYSE ADR - commentary - research - Cramer`s Take) said data from two late-stage clinical trials of the multiple sclerosis drug Tysabri have been published in the New England Journal of Medicine.

Results included those from the phase III trial dubbed Affirm, which examined Tysabri used by itself, and a phase III trial called Sentinel that studied Tysabri used with the Biogen Idec MS drug Avonex.

According to the Affirm trial, Tysabri used alone reduced the risk of an MS patient`s disability worsening by 42% and showed a 68% reduction in the rate of relapse each year when compared with a placebo. Treatment with Tysabri also resulted in significant and sustained reductions in brain-lesion activity, according to the companies.

The Sentinel trial found that Tysabri plus Avonex had a significant effect on hampering the progression of MS, the relapse rate and brain-disease activity vs. Avonex alone.

Last year, Tysabri was pulled from the market after it was linked to a potentially fatal brain disease called progressive multifocal leukoencephalopathy. In all, three cases of the condition were found, but safety evaluations uncovered no additional episodes of PML.

A Food and Drug Administration advisory committee is scheduled to meet for two days next week to decide whether the drug can again go on sale.

Biogen`s shares tacked on 5 cents to $47 in after-hours trading Wednesday, and Elan rose 11 cents to $13.10.

[Poppholz]

NIH:No New Cases Of Brain Disorder With Tysabri

03-01-06 05:15 PM EST

WASHINGTON -(Dow Jones)- An independent review that found no new cases of a rare brain disorder linked to the death of a patient taking the multiple- sclerosis drug Tysabri may have an impact on the decision of regulators to return the drug to the shelves.

The review, led by the National Institutes of Health, will be published in the March 2 edition of the New England Journal of Medicine. The companies that make Tysabri, Biogen Idec Inc. (BIIB) and Elan Corp. PLC (ELN), have previously reported that the NIH review found no new cases of PML. Clinical studies of the drug, which were presented last year at various medical conferences, will also be published in this week`s New England Journal.

The Food and Drug Administration will take recommendations from a panel of outside medical experts meeting next Tuesday and Wednesday to review whether Tysabri, also being studied in the treatment of the intestinal illness Crohn`s disease, should be returned to the market.

Tysabri was pulled off the market last February after two patients developed a brain disorder called progressive multifocal leukoencephalopathy, or PML. One patient died, and a third patient was later discovered to have PML.

The meeting was extended by a day because dozens of MS patients are expected to testify in favor of bringing Tysabri back to the market. The FDA is expected to make a final decision by the end of March. Clinical studies have suggested the drug is more effective at treating MS than current treatments.

Earlier this month, the FDA said the companies could make Tysabri available to patients who were receiving the drug as part of preclinical studies. Biogen and Elan said they would begin a new clinical study "in the coming weeks" and it would be open to patients who participated in the earlier clinical studies of the drug.

Multiple sclerosis is a chronic disease of the central nervous system which affects the brain, optic nerves and spinal cord. About 400,000 Americans have the disease, according to the Multiple Sclerosis Society.

The independent panel that reviewed Tysabri was chaired by Eugene Major, acting director of the Basic Neurosciences Program at the National Institute of Neurological Disorders and Stroke and an expert on the so-called JC virus linked to PML. The JC virus doesn`t cause noticeable symptoms in most people who are infected; however, in people whose immune systems are compromised, the virus can cause PML. Tysabri alters the immune system in order to suppress the progression of MS.

The panel reviewed more than 3,000 patients treated with Tysabri who underwent a detailed clinical history, physical exam and brain magnetic resonance imaging scans. Some patients` cerebrospinal fluid was tested for evidence of the JC virus. A total of 44 patients were referred to the review panel because of clinical findings of possible PML. But further investigation revealed that none of the patients had PML.

Major and other panel members, which include David B. Clifford of the Washington University School of Medicine in St. Louis and Tarek Yousry of the Institute of Neurology, Queens Square in London, said they can`t say what the long-term risk of developing PML is in patients treated with Tysabri. For now, they estimate the risk at about 1 in 1000 among patients who had been treated with the drug for an average of 18 months.

"Even under close evaluation, PML remains a rare disease," Major said. "But as we alter the immune system, we need to understand what unintended effects it might have."

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; [e-mail].

http://news.morningstar.com/news/DJ/M03/D01/200603011715DOWJ…

[Poppholz]

Tysabri: As Bad as AIDS?
By Bill Mann (TMF Otter)
March 1, 2006

Elan (NYSE: ELN) shareholders are a certifiably nervous lot these days. In a week, the Food and Drug Administration will hold hearings on whether -- and under what circumstances -- it will allow Tysabri, a treatment for multiple sclerosis that Elan developed and co-markets with Biogen IDEC (Nasdaq: BIIB), to return to the market. When the two companies voluntarily pulled the drug following reports linking it to two deaths from progressive multifocal leukoencephaly (mercifully abbreviated PML) last year, Elan`s share price tanked by more than 70%. When another case came to light -- this time with a patient taking Tysabri as a monotherapy -- the losses from the peak increased to 90%.

Elan seemed cooked. Tysabri was its great hope. But there was no denying a few things: Tysabri was more effective in treating MS than anything else on the market, the two cases of PML presented themselves in patients who were using Tysabri in combination with other drugs, and MS sufferers and many neurologists alike were clamoring for its return to the market. In November, the FDA put Tysabri on priority review, and next week, they`ll hold the meeting. To say that a lot rides on the outcome of this meeting for Elan shareholders is an understatement. The stock has risen 300% from its April lows, but recent weakness in the shares suggests that some shareholders are hedging their bets or are selling entirely.

So when, on Feb. 28, a University of Texas report stated that Tysabri can deplete immune-system cells by the same level as the HIV virus, Elan shares went into a complete tailspin, dropping more than 14% before recovering to finish down only 7% at the close.

However, Bloomberg said on Wednesday that this report, which has yet to be accepted by a medical journal, was circulated by a spokesman for rival MS drugmaker Teva Pharmaceutical (Nasdaq: TEVA). If this is true, I believe it`s a pretty dastardly deed -- not so much because a study showing that Tysabri lowers the immune system as much as HIV does is slanderous, but because doing so shows that Teva is willing to try to influence proceedings before the FDA meeting by introducing additional doubt for the safety of Tysabri. It also shows that the company considers the drug to be a legitimate threat to its own MS treatment, Copaxone.

Let`s face it -- HIV is scary, a true hot button if there ever was one. But the report doesn`t say that Tysabri is as dangerous as HIV. It says that it lowers immune systems to similar levels. Well, hello! Tysabri is an immunosuppressant. This is how the drug combats MS. Essentially, Tysabri sequesters the immune system to keep it from destroying the central nervous system. The challenge is to keep the immune system from dropping too low. This, incidentally, is why most PML cases exist in people who have full-blown AIDS. The virus that causes PML exists in an estimated 70% of the general population, but remains latent.

Now, imagine that -- an immunosuppressant that suppresses the immune system! None of this implies that suppressing the immune system isn`t an extremely dangerous thing to do. But it also happens to be the most effective way to treat a debilitating and deadly disease.

This is not to cast aspersions on the original Texas research, which may turn out to be bulletproof. But Tysabri is a drug administered once a month by doctors, who, one would assume, observe and adjust dosing as needed. But while the study may have its clinical use in helping make Tysabri (and future MS treatments) safer, the link to HIV in the public domain is spurious. You might as well say that helium is as dangerous as hydrogen because it also makes balloons float.

Makes you wonder why Teva`s representative went to such an effort to make the study known, doesn`t it?

[Poppholz]

[posting]20.458.782 von Poppholz am 02.03.06 10:09:13[/posting]sorry, hatte Birgit schon gepostet.

(ist aber so schön, dass der ruhig doppelt kommen darf)

[Poppholz]

MS drug Tysabri severely harms immune system - study

Tysabri competes against Teva’s Copaxone. Biogen Idec and Elan’s shares are down 5-6% in New York and Europe.
Yuval Mendelson 1 Mar 06 14:31

Is the return of multiple sclerosis (MS) drug Tysabri in greater doubt? Tysabri, made by Biogen Idec (Nasdaq: BIIB) and Elan Corp. (NYSE; Dublin: ELN; LSE: ELA), was taken off the shelves in December 2004 after some patients using the drug died.

After year in which Teva Pharmaceutical Industries Ltd.’s (Nasdaq: TEVA; TASE: TEVA) Copaxone, Tysabri’s competitor, enjoyed relative quiet, it seemed that Tysabri’s path back to the shelves was getting shorter. Next week, a US Food and Drug Administration (FDA) panel is due to approve new clinical trials for Tysabri by Biogen Idec and Elan, which could have put the drug back on the shelves within a few months.

A new study, published today, could become a major obstacle for Tysabri’s return. Carried out by two University of Texas neurologists, the study found that Tysabri affected patients’ immune system. The study took blood samples from MS patients who had taken Tysabri experienced a significant deterioration in their immune systems, to levels seen in AIDS patients. It should be stressed that MS treatment includes suppressing the immune system.

Tysabri’s future now appears quite bleak. In a survey of 140 neurologists, only 10% recommended their patients take Tysabri, especially if other treatments are ineffective.

It should be emphasized that the study was sent to a scientific journal for publication, but it has not yet been accepted for publication, said one of the researchers. Teva yesterday circulated a synopsis of the study through an external New York spokesman.

Biogen Idec and Elan’s shares fell 5-6% in trading in New York and on European bourses yesterday and today.

Published by Globes [online], Israel business news - www.globes.co.il - on March 1, 2006

http://www.globes.co.il/serveen/globes/docview.asp?did=10000…

[speedy001]

ja gester zu 10,40 und 10,50 nachgekauft

[Poppholz]

vielleicht platzt heute schon der Knoten:

Ankündigung eines Kursaussetzens 5 Tage vorher beurteile ich positiv.

Die Investoren, die die Gewinne nach einem Jahr mitgenommen haben, werden sich zum Großteil wieder in ELAN investieren, da die Pipeline gut aussieht und somit auch die Zukunft des Unternehmens.

Die Shorties müssen auch wieder rein und ab dem 07. März wird es auf jeden Fall teurer sein als heute.

Also schön festhalten.

[Poppholz]

auf der Insel sind wir bereits über €11,20.

[Poppholz]

vom Boston Globe:

Two studies of Tysabri see little risk
By Reuters | March 2, 2006

Tysabri, withdrawn last year because of fears it might cause an often-deadly brain disorder, slows the progression of multiple sclerosis and seems to pose little risk, two studies showed yesterday.

Sign up for: Globe Headlines e-mail | Breaking News Alerts The studies were financed by the drug`s manufacturers and come as a US Food and Drug Administration panel is to meet on March 7 to discuss whether Tysabri should go back on the market.

The drug, also known by the generic name natalizumab, was removed by Cambridge-based Biogen Idec Inc. and its marketing partner Elan Corp. of Ireland, just over a year ago after three patients developed a rare brain disease.

The studies, published in this week`s New England Journal of Medicine, reported no new cases of the brain disease.

Researchers in the first study found that Tysabri cut the likelihood of a relapse by 68 percent in 627 patients, compared to the 315 patients who got a placebo.

The second study looked at volunteers who had suffered a recent relapse despite treatment with interferon beta.

Among 582 patients receiving just interferon, 32 percent did not have a relapse after two years. The rate was 54 percent among 589 who also got Tysabri.

© Copyright 2006 Globe Newspaper Company.

http://www.boston.com/business/healthcare/articles/2006/03/0…

Positiv?

Die müssen sich vertan haben. Der Artikel ist bestimmt nur aus versehen live gestellt worden.

[Birgit.Tersteegen]

Den Brief an die Konkurenz Teva,die durch gezielte Falschinformationen den Kursrutsch ausgelöst hat,finde ich
C O O L!



My message to Teva
by: holidaywish1
Long-Term Sentiment: Strong Buy 03/02/06 04:08 am
Msg: 934455 of 934613

Sent this out tonight. I don`t expect a response...LOL

"I am a person with Multiple Sclerosis. I chose Copaxone for my therapy.I have used Copaxone for one year. It`s not working.

I have watched the development of Tysabri (Elan,plc. Biogen Idec) since it started. I was excited about people with Multiple Sclerosis having another choice of therapy, especially those for whom none of the current therapies are effective.

Now I find that a week before the FDA Advisory Committee meeting on March 7th and 8th, your company PAID to have an article distributed that equates MS patients using Tysabri to patients with HIV. I will not quote that article as I know you are fully aware of what it says.

Your company`s vision statement includes the following: "... and our focus on customers and patients." Yet in one fell swoop you cut the legs out from under the very patients you say you focus on by disseminating garbage about a competitor`s drug.

I am sure that you have received many complaints about this but I felt the need to comment on the unethical behavior displayed. I want you to know that I was planning on staying on Copaxone until the studies were all in on Tysabri. However, after this shameful, disgusting attempt to scare the hell out of people with NO other options, I have decided to refuse my 90 dose delivery of Copaxone on March 3rd.I will no longer be taking Copaxone. I will be one of those people who stand up against liars. I will be one of those people who will take Tysabri. I will be checking every label on every medication I am prescribed from now on. If the label says Teva on it, I will be asking for an alternative drug even if I have to pay for it out of my own pocket.

Maybe the next time some damned fool throws out an idea like this in a board meeting, someone from your company will show some ethics and refuse to sink to the outstanding low that you are at now.

By the way? The site reactions never go away. Copaxone sucks.

Thanks from a former user of Copaxone.

[zenman]

ELAN hält dagegen mit veröffentlichung der studienergebnisse

[zenman]

PM akt 13,69

ASK allerdings jetz 13,63

[speedy001]

11,25

[Birgit.Tersteegen]

Bloomberg: Tysabri Is Worth (the) Risk
by: tekn0wizz (38/M/NL)
Long-Term Sentiment: Strong Buy 03/02/06 06:04 am
Msg: 934498 of 934625

[ http://www.bloomberg.com/apps/news?pid=10000103&sid=aAfbIuTX… ]

Biogen, Elan`s Tysabri Is Worth Rare, Fatal Risk, Patients Say

March 2 (Bloomberg) -- Michael Barron, a 48-year-old former operator of a nuclear power plant, was so crippled by relapses in his multiple sclerosis that he couldn`t stand up without help. The drug Tysabri allowed him to take walks with his wife again.

Then a year ago, Biogen Idec Inc. and partner Elan Corp. suspended sales of Tysabri after just three months on the market because of a link to a fatal brain infection. Barron will travel across the U.S. next week from his home in Arizona to join other patients demanding that federal regulators allow sales to resume and let patients choose whether to risk the side effects.

``I have friends in wheelchairs, using canes, committing suicide,`` Barron said in a Feb. 24 telephone interview. He plans to attend a Food and Drug Administration advisory panel meeting in Gaithersburg, Maryland. ``Most of us are pro-Tysabri because we failed all other therapies.``

The decision the FDA faces highlights the debate over patients` rights to a treatment with a severe side effect versus the agency`s responsibility to protect them, said bioethicist Arthur Caplan. Study results suggesting Tysabri is twice as effective as other treatments made it the best hope for multiple sclerosis patients in 10 years and a potential $3 billion-a-year seller for Biogen and Elan.

...

Patients Group

``There is no such thing as a perfect drug,`` said Barron, who founded MSpatientsforchoice.org to argue that the decision on whether to take the risk should be left to patients and their doctors. ``This drug is the closest thing there is to a cure for MS.``

Barron says his group, which is paying travel expenses for about 10 MS patients, holds fundraisers and takes no money from Biogen, Elan or other pharmaceutical companies.

A survey of 800 MS patients released this week by the National Multiple Sclerosis Society and Harris Poll found most would consider using Tysabri under certain conditions, such as if their current treatment wasn`t working or a reliable test existed for PML. The Society plans to release detailed results after the FDA advisory panel`s meeting.

The companies say Tysabri should be cleared again because the treatment reduces multiple sclerosis relapses by more than two-thirds and delays disability. Current therapies, such as Biogen`s Avonex, reduce relapses by one-third, studies showed.

Risks

The risks can be managed, partly by advising patients with impaired immune systems not to take the drug, said Biogen`s Burt Adelman, the executive vice president in charge of medical research and regulatory affairs, in a Feb. 9 interview.

Tysabri also shouldn`t be taken in combination with other MS therapies, Adelman said. In two of the reported PML cases, the patients were taking Tysabri in combination with Biogen`s Avonex, a multiple sclerosis drug introduced in 1996.

PML occurs when an infection called the JC virus evades the body`s immune defenses and penetrates the central nervous system. There it eats away the protective coating of nerve fibers, called myelin, causing irreversible brain damage.

Multiple sclerosis is caused when an abnormal immune-system response attacks the myelin. Tysabri, an antibody-based medicine, was designed to prevent that assault by suppressing immune cells. Researchers theorize that Tysabri may subdue defenses meant to keep the JC virus out of the brain.

It`s a risk that Cheryl Bloom is willing to take. A 53-year- old landscape designer in Eagle, Idaho, who was diagnosed with MS in 2001, Bloom says she`s paying her own expenses to attend the FDA advisory panel meeting next week.

``This drug worked for me, and I want to be ab

[Birgit.Tersteegen]

18 - $23 --> MARCH 9 (100% APPROVE
by: hunglikeahorz (33/M/NC)
Long-Term Sentiment: Strong Buy 03/02/06 07:46 am
Msg: 934611 of 934672

New England Journal of Medicine is the best peer reviewed medical/scientific journal RESPECTED by 500,000+ doctors, neurologists, surgeons, etc. all over the world.

Who will FDA listen to? NEJM or ..

Knoberman, Krasner, Silver ????

Don`t be stupid Shorty! Cover now and GO LONG!

[Birgit.Tersteegen]

Heute kriegen alle Shorties,Krassners,Silvers und Tevas einen auf die Mütze!!!Das macht mir mehr als klammheimliche Freude!

[Birgit.Tersteegen]

DAVY SAYS ELAN SHOULD BE $18/SHARE
by: hunglikeahorz (33/M/NC)
Long-Term Sentiment: Strong Buy 03/02/06 08:47 am
Msg: 934737 of 934737

Elan`s Tysabri Editorial Backs Return To Mkt

Thursday, March 02, 2006 3:40:45 AM ET
Dow Jones Newswires

0733 GMT [Dow Jones] Elan`s (ELN) Tysabri data in the New England Journal of Medicine had already been presented, but this is the first time they are published in peer-reviewed articles, notes Davy Stockbroker analyst Jack Gorman. Says timing is good ahead of the FDA advisory committee meeting next week, pointing out the editorial accompanying the articles supports the return of the drug to market. Keeps $18 target price. Shares closed at EUR10.89 Wednesday. (EXB)


http://www DOT newratings DOT com/analyst_news/article_1218452.html

[Poppholz]

Ordervolumen in London bereits 1,4 mio Aktien.

[Poppholz]

wenn die Zahl stimmt, dann haben wir heute hier den größten Umsatz des Jahres.

(ich denke mal, dass dort ein Kommafehler enthalten ist)

[[KERN]Codex]

13,53 +4%

[Birgit.Tersteegen]

na also!

13,60

[shareholder4]

[Birgit.Tersteegen]

My God Major News
by: o01tac
Long-Term Sentiment: Strong Buy 03/02/06 09:45 am
Msg: 934872 of 934877

VOL. IN LONDON

BUY = 1.36M SELL= 127K


Someone is grabbing all they can get over here, I have never seen anything like it before.

[Birgit.Tersteegen]

"Suspended MS drug found safe in 3 ..."
by: tekn0wizz (38/M/NL)
Long-Term Sentiment: Strong Buy 03/02/06 09:49 am
Msg: 934882 of 934882

Here is how the Buffalo News summarised the story:

"A promising multiple sclerosis drug that was suspended from the market because three people developed a rare brain disease now appears relatively safe and quite effective, three studies found."

Now that is what I call a GOOD short summary
Those who want details can read the NEJM (clearly not this paper).

[ http://www.buffalonews.com/editorial/20060302/4036942.asp ]
"
National/World

NEW YORK CITY
Suspended MS drug found safe in 3 studies

3/2/2006

NEW YORK (AP) - A promising multiple sclerosis drug that was suspended from the market because three people developed a rare brain disease now appears relatively safe and quite effective, three studies found.
The research in today`s New England Journal of Medicine comes days before government hearings on whether to allow sales of the drug, Tysabri, to resume.

Tysabri (pronounced ty-SAH-bree) was withdrawn a year ago by Biogen Idec and Elan Corp. PLC, only months after it had been approved. The Food and Drug Administration last month agreed to allow testing to resume after the company said no more cases of the brain disease had emerged.

The new studies found that Tysabri alone or with standard interferon treatment cut the rate of relapse by as much as two-thirds after two years and reduced the number of people whose MS got worse, compared with those on a dummy treatment or interferon alone.

Multiple sclerosis, a disease of the central nervous system, afflicts about 350,000 Americans and is more common among women than men.
"

[Birgit.Tersteegen]

here comes the turnaround ..ready
by: darrelldemello 03/02/06 10:15 am
Msg: 934953 of 935024

for blast-off?

After forced margin selling due to a sudden raise in the margin requirements to 100% at many brokerages .... (to help out friends and return favors) ... it appears that margin selling is over ....


It looks like the turnaround is here and the pps is ready for blast-off ....

Today`s close nearer to $14.00 if not more than $14....

again JMHO....

ps: off to work ... HOLD THOSE ELN SHARES....

[Birgit.Tersteegen]

unbedingt anhören


ty news
by: odz500 (46/M/N. Ireland)
Long-Term Sentiment: Strong Buy 03/02/06 11:01 am
Msg: 935084 of 935086

http://wm.world.mii-streaming.net/media/whdh/windowsmedia/fe… ging_ms.wmv

[loseit]

Hallo Birgit,

Läuft bei mir nicht - was Wichtiges?

Gruss Loseit

[Birgit.Tersteegen]

[posting]20.468.982 von loseit am 02.03.06 17:15:35[/posting]nicht Neues -aber GUT!
Gehe übers Yahoo-Board drauf;falls Du einen Media player hast.Gruss!

[loseit]

Habe ich, macht aber Zicken...

(wieder so ein frauenfeindlicher Ausdruck)

Gruss Loseit

[mankoll]

Ein Optimist !
Ich denke, hier ist zunächst einmal Vorsicht angebracht.
;-)

[Nostarowie]

Achterbahn fahrn is fein.

[Birgit.Tersteegen]

[posting]20.470.792 von Nostarowie am 02.03.06 18:13:22[/posting]und es geht immer wieder nuff!!

[nic1977]

kennt jemand die aktie SOLCO, habe gehört das demnächst in diversen aktien zeitschriften der wert empfohlenwird, und dann steigen bestimmt auch die fonds ein, also jetzt kaufen, denn so billig bekommt man den wert nicht wieder, soll die neue dyesol sein.

WKN: a0dnx0

[Birgit.Tersteegen]

[posting]20.471.016 von nic1977 am 02.03.06 18:21:31[/posting]spam?
Re: It still is puzzling and frustrating
by: hey_watchiss (45/M/FL)
Long-Term Sentiment: Strong Buy 03/02/06 12:15 pm
Msg: 935263 of 935268

Only Wall Street crooks control(manipulate) the price. We private investors have little control over the price unless we buy in mass quantities. The people setting the price on any given day are crooks who just love to screw small investors. It`s easy for them to scare small timers into selling for less than what a stock is really worth. The pros obviously make a lot of money when the price goes down. They make the most money when the price goes up, down, up, dow, up, down, up, down, up, down, just like screwing small investors.

Small investors make money when the price goes way up but in the meantime the pros make truck loads of cash by the price basically going nowhere. Up a little, down a little, up a little, down a little, etc... If the Hedge Funds could keep ELN pps in the range of $13-$16 forever they would be perfectly happy about it and make tons of money.

[mankoll]

...und auch wieder runter

[Birgit.Tersteegen]

[posting]20.471.400 von mankoll am 02.03.06 18:34:37[/posting].....hier musst DU ja nicht dabei sein--wer´s nicht mag lässt es eben!

[mankoll]

bin momentan short. Ach übrigens, schöne Grüße an aktienwind

[Birgit.Tersteegen]

[posting]20.471.673 von mankoll am 02.03.06 18:44:58[/posting]Danke schön--Du hast uns hier richtig gefehlt ,wäre ja sonst zu nett hier....vergiss das Covern nicht bis Montag!

sonst trägts Dich davon...!(will ja nur Dein Bestes,ist klar,oder...?!)

[Birgit.Tersteegen]

Ciao,bis morgen

[mankoll]

Danke für die guten Wünsche.
Warte erst mal ab, bis wir heute $12,89 sehen-
RTQ 13,14/13,16
und.... happy trading

[hechtbarsch]

wo ist die party heute??

nächste woche wird alles besser.
hb

[mikel_ann]

SK 12.81 <=> 10.65 € mir DE Abschlag etwas weniger.

Bitte vergesst nicht die Psyche des Normalos. Das Risiko
ist nicht unerheblich, dass es Probs bei der Zulassung
geben könnte. U.U. auch fremde wirtschaftliche Interessen.

Krimi halt, wie glube ich Poppi geschrieben hatte.

Was passiert ? Worst case Zulassung versagt -> 4 $ ..
Zulassung verschoben -> 8 $ .. Zulassung erteilt ->
Hochzocken auf 16 $ und Gewinnmitnahmen 12$.

In einem halben Jahr kann die Welt völlig anders aussehen.

Also mit Zu/Verkäufen einfach warten.

Momentan eine Richtung verherzusagen ist m.E. nicht wirklich möglich.

Aber wir sollten nicht vergessen, das es nur eine Aktie ist.

Schönen abend und Grüne Zeiten

[zenman]

mikel, du sagst es

[Birgit.Tersteegen]

Realize the Difference.............
by: rxdudette
Long-Term Sentiment: Strong Buy 03/02/06 04:57 pm
Msg: 935847 of 936039

it is important for everyone that is long to realize the difference from today and November `04.......

* The competition had ABSOLUTELY NOTHING to "hang their hat on" with regard to countering the safety and efficacy of the miracle drug Tysabri.

* The Wall Street manipulators jumped on board with ELN because they KNEW the revenue prospects of Tysabri (they ignored the AAB-001 and Nano side of Elan`s business).

* The longs were far and away AHEAD of everyone on the long term prospects of the SCIENCE, R&D, and the associated revenues for
ELN.

2005 provided a big opportunity............

* for the competition to say "AHAAA" now we have what we need to KILL this miracle drug Tysabri that will substantially reduce our marketshare and revenues (never mind the unmet need of the patients and btw we aren`t GREEDY, we are just protecting the safety of our patient population).

* Wall Street obtained yet some more bruises and broken noses. BM truly pissed some of them off in a big way.

* The crooks, bashers, shorts, daytraders jumped on board with both feet to "ride the wave", have a little fun, make some bucks, spew some GARBAGE.

* The Cramers, Krasners, Lehmans, "back pocket" physicians, etc. etc. etc. jumped on board, collected more $$$$$ from the competitors, spewed more GARBAGE (all orchestrated by the competitors).....all the while buying, buying, buying Elan stock on the cheap.

* The true knowledgeable longs grew a little touchy, a little frustrated...but held steadfast to those VALUABLE SHARES.

* The uninformed, the WEAK, the NOT SO SMART sold their shares......maybe making a few bucks, maybe not......but they think they feel better about their decision.

2006 - The Train is about to arrive with the Gnus..........

* The data is all there for EVERYONE to peruse............

WHAT DOES EVERYONE SEE IN 2006?????????

* Those that sold........feel sick.
* Those that hold........feel very happy!
* Those that are short are afraid.
* Those that compete with Tysabri are scrambling to figure out HOW IN THE HELL they will counter this MIRACLE DRUG!!!!!

Tysabri is NOT the END ALL AND BE ALL of MS drugs, however, it is the BEST therapy available to MS patients - FAR MORE SAFE - FAR MORE EFFICACIOUS - HALTS DISEASE PROGRESSION - RESTORES QUALITY OF LIFE (stay tuned for Tysabri 2).


WHERE ARE YOU IN 2006????? Do you own Elan stock.....if you don`t my friend, time is running out and if you do, you are one smart cookie and you will be rewarded im"e"o.

THE DIFFERENCE IN 2006 - the data is all in and if you don`t get it by now.....BYE NOW, or is that BUY NOW????????????

[flow_solver]

Das waren noch Zeiten, als alle davon träumten, dass Tysabri bereits im Sommer 2005 wieder auf den Markt kommen sollte. Ich bin etwas vorsichtiger geworden uns sehe die Kursentwicklung auch nach positiver Zulassung nicht sonderlich positiv. Es lässt sich immer was negatives finden solange Elan und BIIB nicht die Wiedereinführung mit starken Verkaufszahlen untermauern und das kann noch ein halbes bis ein Jahr dauern!

CEO Kelly Martin sagte folgendes bei der Hauptversammlung am 26.5.2005 in Dublin:

" We have multiple things that we are focused on with Tysabri. We are very, very focused on its return to the marketplace in the US for MS patients. We are as focused on its continued regulatory advancement in Europe for both Crohn’s and Multiple Sclerosis. We are focused on its regulatory advancement in the US for Crohn’s. And in addition to those specific therapeutic areas, we are also continuing to Tysabri’s use in other autoimmune diseases such as ulcerative colitis, asthma, organ transplant, and others."

Das liest sich sehr zuversichtlich, so dass man auf die Entwicklung bis zum Jahresende gespannt sein darf. Falls Ty wieder vermarktet wird (MS in US) und die Zulassung in Europa erteilt wird (MC und MS) sowie diejenige für MC in US, dann ...ja dann, scheint mir ein Kurs gröseer 30$ sehr wahrscheinlich.

[flow_solver]

Mich wundert vor allem die schwache Performance von BIIB.

http://www.genengnews.com/news/bnitem.aspx?name=1182250XSL_N…

[welke91]

Elan Tysabri Gets Upbeat Editorial

Thursday, March 02, 2006 6:45:30 AM ET
Dow Jones Newswires



1024 GMT [Dow Jones] Elan`s (ELN) suspended MS drug Tysabri gets an upbeat editorial in The New England Journal of Medicine alongside saftey review details and 2-year clinical data, says NCB Stockbrokers. NCB says this supports its own view that Tysabri will be relaunched, but says Elan`s stock will be influenced by market commentary ahead of the FDA decision on the drug. Maintains at buy.

[Birgit.Tersteegen]

Guten Morgen @all

Neuer Tag-neues Spiel!

[Poppholz]

Business Wire
TYSABRI(R) Ergebnisse von zweijähriger Phase III-Studie zu Multipler Sklerose sowie Sicherheitsbewertung werden im "New England Journal of Medicine"
Donnerstag 2. März 2006, 18:53 Uhr

CAMBRIDGE, Massachusetts, und DUBLIN, Irland 2. März 2006
TYSABRI wird derzeit von der US-amerikanischen und europäischen Zulassungsbehörden geprüft

Die Biogen Idec (NASDAQ: BIIB) und die Elan Corporation, plc (NYSE: ELN) gaben heute bekannt, dass zum ersten Mal Ergebnisse der beiden Phase III-Studien zu TYSABRI(R) (Natalizumab) sowie die Daten der umfassenden Sicherheitsanalyse des Produktes in der aktuellen Wochenausgabe des "The New England Journal of Medicine" veröffentlicht werden. Die Ergebnisse der beiden Studien wurden über einen Zeitraum von zwei Jahren ermittelt, bewertet wurde die Wirksamkeit von TYSABRI(R) bei Patienten mit rezidivierender Multipler Sklerose (MS). Die Ergebnisse der beiden Phase III-Tests waren zuvor, im Verlaufe des Jahres 2005, bei internationalen medizinischen Kongressen und bei Kongressen in den USA vorgestellt worden.

Bei den beiden Phase III-Studien handelte es sich um die Studie AFFIRM, bei der ausschließlich TYSABRI verabreicht wurde, und um die Studie SENTINEL, bei der TYSABRI zusammen mit AVONEX(R) (Interferon beta-1a) verabreicht wurde. Die Erkenntnisse aus diesen Studien waren zusammen mit der Sicherheitsbewertung des Produkts im Rahmen eines zusätzlichen Antrags auf Zulassung als biologisches Präparat im September 2005 bei der US-amerikanischen Bundesbehörde zur Überwachung von Nahrungs- und Arzneimitteln ("Food and Drug Administration/FDA") eingereicht worden. Dieser Antrag ("Biologics License Application/sBLA") wird jetzt in einem beschleunigten Verfahren ("Priority Review") geprüft, und die Unternehmen gehen davon aus, dass die FDA Ende März reagieren wird. Vergleichbare Informationen sind auch bei europäischen Zulassungsbehörden eingereicht worden.

Die heute veröffentlichten Daten der Phase III-Studie AFFIRM zur Monotherapie mit TYSABRI zeigten als ersten Endpunkt, dass die Behandlung mit TYSABRI die Gefahr des Fortschreitens der Krankheit um 42 Prozent (p<0.001) verringern kann. Gleichzeitig wurde im Vergleich mit einem Placebo eine Senkung der jährlichen Rückfallrate um 68 Prozent (p<0.001) beobachtet. Die Behandlung mit TYSABRI hatte auch eine anhaltende und statistisch signifikante Verringerung der fortschreitenden Hirnverletzungen zur Folge, was mit kernspintomographischen Verfahren nachgewiesen wurde. In der Phase III-Studie SENTINEL konnte auch gezeigt werden, dass die Behandlung mit TYSABRI in Verbindung mit AVONEX im Vergleich zur alleinigen Behandlung mit AVONEX signifikante Auswirkungen hat auf das Fortschreiten der Krankheit, die Rückfallrate und die mit kernspintomographischen Verfahren abbildbaren Hirnveränderungen durch die Krankheit.

Die Biogen Idec und Elan haben mit führenden Fachleuten für MS und progressive multifokale Leukoenzephalopathie (PML) zusammengearbeitet, um für über 3.000 Patienten, die TYSABRI erhalten hatten, eine Sicherheitsbewertung vorzunehmen. Ein unabhängiges Entscheidungsgremium, das als ein Element der Sicherheitsbewertung gegründet worden war, hat heute seine Ergebnisse veröffentlicht. Die Fachleute gaben an, dass neben den drei von den Unternehmen benannten Fälle keine bestätigten Neuerkrankungen mit PML bei Patienten aufgetreten sind, die mit TYSABRI behandelt worden waren.

"Die Daten aus der AFFIRM- und der SENTINEL-Studie, mit die umfassendsten Phase III-Studien zu MS, die jemals durchgeführt wurden, liefern überzeugende Beweise für die Wirksamkeit von TYSABRI. Die derzeit verfügbaren Therapien für MS können den Krankheitsverlauf bei vielen Patienten oft nicht entsprechend beeinflussen, so dass ein deutlicher, nicht abgedeckter Bedarf besteht. Hier kann TYSABRI ansetzen. Es ist sehr ermutigend, dass Zulassungsbehörden die Daten aus den klinischen Studien sowie die umfassende Sicherheitsanalyse einer Prüfung unterziehen, um das Risiko-Nutzen-Profil von TYSABRI bei MS zu klären", erklärte der Mediziner Dr. Chris Polman, Versuchsleiter der AFFIRM-Studie, Professor für Neurologie am medizinischen Zentrum der Vrije Universiteit und klinischer und wissenschaftlicher Direktor des Zentrums für Multiple Sklerose am medizinischen Zentrum der VU, Amsterdam.

Entscheidungsgremium Sicherheitsbewertung

Das Entscheidungsgremium ("IAC") wurde als ein Element der Sicherheitsbewertung gegründet und soll möglichen Fällen von PML nachgehen. Dem IAC sitzt Dr. Eugene Major vor, Leiter des "Laboratory of Molecular Medicine and Neuroscience" am "National Institute of Neurological Disorders and Stroke" der nationalen Gesundheitsinstitute der USA. Die wichtigsten Ergebnisse des IAC waren:

-- Die Sicherheitsbewertung wurde entwickelt, um die Teilnehmer der klinischen Studie zu TYSABRI und Berichte über mögliche Fälle von PML bei Patienten, die TYSABRI erhalten, zu erfassen. Von den 3.826 Teilnehmern der klinischen Studien, die an MS, der Crohns Krankheit (CD) und rheumatischer Arthritis (RA) litten und für die Bewertung in Frage kamen, nahmen 3.389 (89 Prozent) teil (2.046 Patienten mit MS, 1.343 Patienten mit CD und RA).

-- Von den teilnehmenden MS-Patienten wurden 97 Prozent mittels kernspintomographischer Verfahren oder neurologischer Verfahren innerhalb von drei Monaten nach der letzten Medikamentengabe untersucht, 91 Prozent der Patienten mit CD und RA wurden hingegen innerhalb von 6 Monaten nach der letzten Medikamentengabe untersucht.

-- Insgesamt wurden 44 Patienten an das IAS zur Bewertung verwiesen, das zu der Schlussfolgerung gelangte, dass keiner der genannten Fälle die diagnostischen Voraussetzungen für PMI erfüllt.

Über die Studien AFFIRM und SENTINEL

Die AFFIRM- und die SENTINEL-Studie wurden entwickelt, um die Wirkung von TYSABRI auf den Krankheitsverlauf und die Zahl der klinischen Rückfälle bestimmen zu können. Grundlage war dabei eine Verschlechterung um mindestens einen Punkt auf der EDSS-Skala ("Expanded Disability Status Scale"), die über einen Zeitraum von drei Monaten beobachtet wurde. Die randomisierte, multi-zentrierte, placebo-kontrollierte Doppelblind-Studie AFFIRM lief über einen Zeitraum von zwei Jahren, es nahmen 942 Patienten an 99 Standorten weltweit teil. Die Patienten der Monotherapie-Studie AFFIRM wurden willkürlich ausgewählt, um alle vier Wochen entweder eine Infusion von 300 mg TYSABRI (n=627) oder ein Placebo (n=315) verabreicht zu bekommen. An der randomisierten, multi-zentrierten, placebo-kontrollierten Doppelblind-Studie SENTINEL nahmen 1.171 Patienten an 124 klinischen Standorten weltweit teil, die mit AVONEX behandelt wurden. Die Studie lief über einen Zeitraum von zwei Jahren. Die mit AVONEX behandelten Patienten, bei denen die Krankheit weiter voranschritt, wurden nach dem Zufallsprinzip in zwei Gruppen unterteilt: Die eine Gruppe erhielt TYSABRI (n=589) und die andere Gruppe ein Placebo (n=582) zusätzlich zu ihrer Dosis AVONEX.

TYSABRI Phase III Sicherheit

Die Nebenwirkungen, die im Rahmen von AFFIRM der Behandlung mit TYSABRI im Vergleich zu einem Placebo am klarsten zugerechnet wurden, waren Müdigkeit und allergische Reaktionen. Nebenwirkungen, die bei SENTINEL auftraten und der Zusatztherapie im Verhältnis zur alleinigen Behandlung mit AVONEX zugerechnet wurden, waren Angstgefühle, Rachenkatarrh, Verstopfung des Sinus und periphere Ödeme. Das Auftreten ernsthafter Nebenwirkungen wich im Vergleich zwischen den beiden Behandlungsgruppen der jeweiligen Studien nicht signifikant voneinander ab. Die häufigste, nicht gewünschte ernsthafte Wirkung war bei allen Studien ein MS-Rückfall. Bei SENTINEL wurde PML als eine der ernsthaften Nebenwirkungen diagnostiziert, eine seltene und potentiell tödliche demyelinisierende Erkrankung des zentralen Nervensystems. Noch bei einem zweiten Patienten wurde PML diagnostiziert, er starb während der Erweiterungsphase der Studie. Beide Fälle von PML wurden bei den Patienten beobachtet, die mit TYSABRI plus AVONEX behandelt worden waren. Der Anteil der Patienten mit leichten und ernsthaften Nebenwirkungen und der Anteil dieser Erkrankungen waren bei AFFIRM und bei SENTINEL bei beiden Gruppen ähnlich.

Über die Biogen Idec

Die Biogen Idec setzt neue Behandlungsstandards in den Bereichen Onkologie, Neurologie und Immunologie. Als einer der weltweiten Marktführer bei der Entwicklung, Herstellung und Vermarktung neuer Therapien setzt Biogen Idec wissenschaftliche Erkenntnisse in innovative Produkte zur Gesundheitspflege um. Pressemitteilungen und weitere Informationen sind auf der Website des Unternehmens unter http://www.biogenidec.com abrufbar.

Über Elan

Die Elan Corporation, plc ist ein Biotechnologie-Unternehmen mit neurowissenschaftlicher Ausrichtung und strebt danach, das Leben der Patienten und ihrer Familien zu verbessern. Das Unternehmen setzt sich dafür ein, wissenschaftliche Innovationen für ernsthafte, nicht gelöste medizinische Probleme nutzbar zu machen, da diese nach wie vor weltweit anzutreffen sind. Die Aktien von Elan werden an den Börsen in New York, London und Dublin gehandelt. Weitere Informationen über das Unternehmen sind unter www.elan.com abrufbar.

Safe Harbour-Erklärung/Vorausschauende Aussagen

Diese Pressemitteilung enthält vorausschauende Aussagen über das Potential und den zulassungsrechtlichen Weg von TYSABRI. Das kommerzielle Potential und der zulassungsrechtliche Weg von TYSABRI unterliegen einer Reihe von Risiken und Unwägbarkeiten. Zu den Faktoren, aufgrund derer die tatsächlichen Ergebnisse in starkem Maße von den derzeitigen Erwartungen des Unternehmens abweichen können, gehören das Risiko, dass wir nicht in der Lage sein könnten, während der zulassungsrechtlichen Verfahren adäquat auf die Bedenken oder Fragen der FDA oder der europäischen Zulassungsbehörden zu reagieren, dass sich aus den zusätzlichen Daten oder Analysen Bedenken ergeben könnten oder dass die Unternehmen mit anderen, unerwarteten Verzögerungen oder Hürden konfrontiert sind. Es gibt keine Garantie dafür, dass die Unternehmen in der Lage sein werden, den Vertrieb und den Verkauf von TYSABRI aufzunehmen. Die Entwicklung und die Vermarktung von Medikamenten beinhalten ein großes Risiko. Ausführlichere Informationen über die Risiken und Unwägbarkeiten in Verbindung mit der Medikamentenentwicklung und anderen Aktivitäten der Unternehmen sind in den Berichten enthalten, die die Biogen Idec und Elan regelmäßig bei der US-Börsenaufsichtsbehörde "Securities and Exchange Commission" eingereicht haben. Die Unternehmen übernehmen keine Verpflichtung, vorausschauende Aussagen zu aktualisieren, sollten sich neue Informationen, Ereignisse o. ä. ergeben.

Kontakt

Pressekontakte:
Biogen Idec
Amy Brockelman, [phone]
oder
Elan
Davia B. Temin, [phone]
oder
Elan
Elizabeth Headon, [phone]
oder
Kontaktperson für Anleger:
Biogen Idec
Oscar Velastegui, [phone]
oder
Elan
Emer Reynolds, [phone]
oder
Elan
Chris Burns, 800-252-3526

[Poppholz]

bin sehr froh, dass ich schon so lange drin bin.

So macht mir das gedrücke nicht so viel aus. Steigende Kurse wären aber auch zum jetzigen Zeitpunkt eine schöne Sache.

[flow_solver]

Hier ein nettes Video mit einer Kaufempfehlung

http://www.forbes.com/video/?video_url=http://www.forbes.com…

[Birgit.Tersteegen]

Ich bin nach wie vor sehr zuversichtlich in bezug auf die weitere Entwicklung......wie gehts Euch??

The only reason we went down to day
by: f7fighter (35/M)
Long-Term Sentiment: Strong Buy 03/02/06 10:36 pm
Msg: 936320 of 936538

is ameritrade and e-trade forcing margin traders to abandon their positions do you think the wanted to sell? NOOOOO Way. we would have gone back to at least 14 and crept up to 15 by the 7th. if these b-houses wouldn`t have forced a sale. that only benefited shorts and cash players long. Also institutions got more cheap shares on one of elns best news days. The sad part is that once we pop from 11 to 17/18 on the 9th those poor retail small guys will have been forced to miss out on that gain due to less shares. Total bullshit. Its their choice to risk it all and apparently eln was good enough yesterday for 30% margin and with a clean bill of health from the NEJM why change requirements now?. Funny bull shit timing if youa ask me I smell a shit house rat.

[flow_solver]

@Birgit,

ich erwarte eigentlich eine weitere Short-Attacke, zu viel Angst und Unsicherheit ist noch in der Luft. Leider gibt es noch kein vernünftiges Monitoring für PML, das hätte die ganze Sache wesentlich vereinfacht. Ich habe mir nochmal viele alte Beiträge angesehen, es ist nicht leicht jetzt in der Aktie zu bleiben und die Short-Attacke zu widerstehen.

[mankoll]

http://clearstation.etrade.com/cgi-bin/details?Symbol=eln&Re…

[posimist]

Ob eine Short-Attacke mehr oder weniger, oder ob Bollinger die Bänder zusammenhält,gut und schön.

Wichtig ist: Ende März spätestens kommt T wieder auf den Markt.Bis dahin warte ich gerne!

posimist

[flow_solver]

@All

Sehr gute Zusammenfassung von einem Analyst.

from Goodbody:

Elan (Buy, Closing Price $12.81)
Tysabri newsflow - keeping the pot boiling.

Analyst: Ian Hunter
After the AAN abstract on Tysabri`s effect on the immune system and yesterday`s articles in the New England Journal of Medicine reporting the two-year data of the two Tysabri trials plus the search for PML in the patient population, today sees the publication of a "comment" in The Lancet on the Tysabri trials. The thrust of today`s article is that those being prescribed Tysabri and those participating in clinical trials of relapse-remitting MS should be carefully diagnosed as having the disease and not other indications. It states that one of the three patients who died of PML in the trials did not, on autopsy, suffer from MS. The article also questions the use of any MS medication, but particularly those with questioned safety profiles, at the early stages of the disease, when the diagnosis may be erroneous. The implied loss of market to newly-diagnosed patients would not be a blow to Tysabri as it is targeting patients unsatisfied with existing drugs. The implication, however, that one of the three deaths may have been a non-MS patient greatly reduces the implied risk of the drug within the target patient population.

regs

[mankoll]

Allerdings ist dies leider nur die Sicht der irischen Analysten; wichtiger wäre ein upgrade durch amerikanische Broker.
Erwarte für heute eine weitere Abwärtsbewegung im Hinblick auf das Wochenende.
Meine gestrige Prognose von $12,89 wurde um 20:51 Uhr erreicht und unterschritten.
Grüße

[Poppholz]

[posting]20.483.631 von mankoll am 03.03.06 12:13:19[/posting]Gratuliere.

Hoffe Du konntest aus dieser Vorhersage ein wenig Profit schlagen.

(hätte ich nicht mehr mit gerechnet, auf jeden Fall nicht so exakt)

[Poppholz]

war schon der Meinung, dass mit unserem ELAN Baby hart umgegangen wird, habe jetzt aber auch mal bei unseren Freunden von MOLOGEN reingeschaut.

@Birgit, @Kern: hoffe Ihr seit gut davor.

(alles wird gut)

[Poppholz]

erster Kurs USA liegt bei

$12,90

[Birgit.Tersteegen]

[posting]20.486.002 von Poppholz am 03.03.06 14:05:41[/posting]PUH!Bin wieder da --musste bei Mologen nachlegen--habe jetzt 2 "Problemkinder"(erziehen die sich nicht angeblich gegenseitig??)

[Poppholz]

habe eben auf level2quotes gesehen, dass wir wieder eine dritte Plattform haben: AMAXM

Wer (wo) ist dass denn jetzt wieder?

[Poppholz]

[posting]20.486.632 von Birgit.Tersteegen am 03.03.06 14:29:08[/posting]im Moment bin ich echt froh, dass ich nicht weiter bei ELAN aufgestockt habe, bei MOLOGEN nicht eingestiegen bin und auch bei CEL-SCI an der Seitenlinie stehe.

[Poppholz]

USA

$12,50

[mankoll]

<Gratuliere.....
Danke.

Im übrigen bin ich z.Zt. nicht der Überzeugung, daß man unbedingt kaufen müßte; habe das auch noch nicht getan.

Na ja, warten wir die Amateurstunde in Amerika mal ab (bis ca. 17:00 Uhr). Zur Zeit scheint es jedenfalls sehr schwierig zu sein, den Trend zu treffen.

Grüße

[Poppholz]

bin gut im Plus, so dass mir der momentane Kursverlauf nicht so viel ausmacht.

So lange der Kurs über 5,- Euro bleibt. Danach bekomme ich auch ein paar Probleme.

[Poppholz]

10.000er Position bei $12,60 im ASK.

Teilweise wurde mit 20er Postitionen gedrückt.

Hoffentlich geht diese Drückerei nicht noch den ganzen März so weiter.

[Birgit.Tersteegen]

[posting]20.487.630 von Poppholz am 03.03.06 15:04:41[/posting]Poppi,wenn alle Aktien die gleiche Richtung haben ist es so richtig übersichtlich....nur meine Zockerpositionen laufen gut....

Bei Molo scheint die Wende geschafft-bei unserem Schätzchen hier bis Mittwoch,gell Mankoll,dann bleibst Du uns weiter erhalten,oder?

[Poppholz]

[posting]20.490.290 von Birgit.Tersteegen am 03.03.06 16:23:02[/posting]ist halt alles nicht so einfach.

Bin auf die nächste Woche gespannt.

Ist Frankfurt vom Kursaussetzen nächste Woche auch betroffen?

Hatte in den Mitteilungn nur von USA, London und Irland gelesen.

[Poppholz]

die $12,50 Marke scheint zu halten, obwohl ständig neue Postitionen nach geschoben werden, um den Kurs unten zu halten.

[Birgit.Tersteegen]

[posting]20.490.512 von Poppholz am 03.03.06 16:30:13[/posting]Ich denke bei uns wird auch kein Handel stattfinden---wohin sie den Kurs wohl noch drücken wollen??

[Poppholz]

[posting]20.490.796 von Birgit.Tersteegen am 03.03.06 16:38:00[/posting]ich weiß es auch nicht.

Normalerweise müßten wir bei ca. $16,- stehen, um dann nächste Woche auf $18,- und bis Ende März auf 20,- zu steigen.

Warten wir die nächsten Wochen mal ab. Wenn wir Ende März bei $20,- stehen wäre das ja auch so in Ordnung.

[Poppholz]

in der ersten Stunde 3,3 mio Aktien gehandelt.

ist schon beeindruckend.

[zenman]

sorry leute

hier drückt keiner
die leute ham schiss und steigen lieber erstmal aus
ihr habt gesehn was en downgrade bewirkt hat
wenns mit ty verzögerungen gibt ....
FDA sacht
sie braucht für beurteilung des risikos mehr daten
was kann das bedeuten ?
das ergebnis der AD wird nicht eindeutig glasklar sein
da gibts kein uneingeschränktes yes
und so
hat die FDA das letzte wort
und DAS erst ENDE märz
solange is UNSICHERHEIT
der markt HASST unsicherheit

das is das wahrscheinlichste szenario
es wird kein schwarz oder weiss geben
ein mischmasch wird rauskommen

wahrscheinlich ein ja, aber

und dieses aber is der unsicherheitsfaktor

manche analysten ham gesacht
ty kommt 2007 auf den markt

das wär tatsächlich denkbar


dass es keinen abschlusshype gegeben hat
wie ich gehofft/vermutet habe
zeigt wie sehr den leuten noch die angst in den knochen sitzt

sorry, so seh ichs inzwischen

[Birgit.Tersteegen]

Da bin ich anderer Ansicht.

Guck Dir das Orderbuch an--ganz oft gleiche ungerade bid/asks

Positionen mit 3 cent Unterschied.

Zum anderen hat die FDA meines Wissens nicht gesagt ,sie brauche mehr Zeit,Daten--weil es bei Mono KEINEKEINE PML Fälle gab,die man weiter,länger,intensiver hätte untersuchen können.

Die folgende Zusammenfassung finde ich sehr treffend!


The Last Mile
by: okz45 03/03/06 11:14 am
Msg: 937090 of 937113

Some of you seem to forget when it was $3, $4,$5,$6,$7,$8,$9.$10,$11 and $12 and only want to remember $13,$14,$15,$16 and $30.

For you traders, you really can only say it is a stock that beats to its` own beat.

The worse thing they ever did to this security is put it in the option market. Professional traders use it as a
teaser to control the market. Tough scenario to figure. The time factor can kill you because MONEY talks and most retail pissants are dealing in a short
position in that stuff where the big guys can use the dates to squeeze. Right now they are squezzing you because they know most traders want to be out before the halt.

As far as we longs are concerned. Unless you used margin and didn`t leave yourself a buffer you should be able to stay invested and go this last mile.

The market is telling you more than the sell-side analyst are telling you. Think about that one.

Try and ignore the whining cry babies, because they put themselves in the position they are in. They will blame everyone for that position except the real culprit. themselves.

As far as the FDA decision. I don`t think there is any doubt about the ultimate outcome. I don`t think there is any doubt about the ultimate uptake of the drug.
Seriously, why would an MSer or Neurologist based on the safety and efficacy profile not at least investigate its` usage. I hear the comments about exposing the patient, but in reality monotherapy. so far ,outdistances current therapies by a large
margin.
How many are not happy with current therapies? How many have no therapy? It is enough of a start to where MSers themselves will make Tysabri a blockbuster if for but one reason. One Infusion a month and better results. For someone who takes three shots a day. I can tell you that the once a month gang will be growing by leaps and bounds

Don`t worry be HAPPY
The MSers and stakeholders are in
the last mile of a trying but triumphant
ride.

[mankoll]

<Bei Molo scheint die Wende geschafft-bei unserem Schätzchen hier bis Mittwoch,gell Mankoll,dann bleibst Du uns weiter erhalten,oder?....

Na mal sehen, kann schließlich nicht immer auf 2 Hochzeiten tanzen ;-)
sieht momentan so aus, als würden die MM Elan zwischen denn entsprechenden 3-er Blöcken (Level2) nach unten ziehen.
Ein Einstieg unter 10 € wäre eine Überlegung wert.

PS haben bisher noch nicht im 11$-Bereich geschlossen, wäre heute Premiere.

[Birgit.Tersteegen]

THE FDA DOCKET SAYS ....
by: cyberhunkie
Long-Term Sentiment: Strong Buy 03/03/06 12:03 pm
Msg: 937219 of 937219

1) That 5,000 patients in the clinical trials can now have Tysabri and enjoy it for a long time. FDA noted that from wheelchair-bound, they can now bike 10 miles and smile.

2) NEJM, the most respected medical journal, has articles that favor Tysabri`s return due to efficacy and safety and that the FDA respects NEJM`s published articles as the most scientific results of Tysabri to date.

3) FDA docket also says that they will play the video of Lauren and Audrey and how Tysabri has helped them. And that these are just a few of the greatest testimonies on March 7 and 8 that Tysabri is the next miracle drug.

http://www.mspatientsforchoice.org./index.htm

[Birgit.Tersteegen]

Longs the end of the tunnel is in sight
by: COBRAGENE
Long-Term Sentiment: Strong Buy 03/03/06 12:09 pm
Msg: 937242 of 937243

Its been a long weary fight since BM.
The scum hasn`t let up on their non stop attack of missinformation about Tysabri.
One more Trading day.
The TEVAs and SERs know whats coming,
SER is for sale, TEVAs big profit comes from $1.176 billion
in Copaxone sales, and they are shi#ing their pants and
pulling out all the stops.
If the American FDA system works, Tysabri will be back.
You gotta believe.

[mankoll]

If the American FDA system works, Tysabri will be back.
You gotta believe.

not if but when (KM)- das gilt im übrigen auch für die FDA
;-)

[Birgit.Tersteegen]

Even doubting ML now says:
by: COBRAGENE
Long-Term Sentiment: Strong Buy 03/03/06 02:00 pm
Msg: 937548 of 937557

Merrill Lynch analyst Eric Ende, in a research note earlier this week, said he believes an FDA panel will recommend that Tysabri be reintroduced for patients who have failed prior treatments. He projected sales of $750 million by 2010.

My how the tide is changing, I guess they stole all the
shares they need now

[welke91]

@ zenman

FDA Panel machte eine Final Decision!

Endgültig!
und yes wird die Antwort sein!

grüße

[welke91]

AAHH sieht schon gut aus nur Mut

12,47$ die mit schwachen Nerven sind raus wir sind drinne und werden ernten

[welke91]

jetzt lernen wir den sprint

[Birgit.Tersteegen]

[posting]20.496.710 von welke91 am 03.03.06 21:08:25[/posting]

[hechtbarsch]

yepp, lass uns ernten nächste woche

schönes WE

[Birgit.Tersteegen]

[posting]20.496.763 von hechtbarsch am 03.03.06 21:11:29[/posting]Wenn das klappt Jungs--dann PROST!

[welke91]

versetzt euch doch mal in die lage. ihr habt den chefsessel inne bei Elan!

Seit zwar auch aufgeregt aber wisst das es nur gut gehen kann:
denn weltweit beste ergebnisse
2 year data mehr als gut
geht mal auf verschiedene MS- Seiten jeder Patient will selbst entscheiden zu welche Therapie er nehmen will.
Mit Tysabri haben viele ein neues Leben gefunden!

So und so als Chef muss man es eben wagen können, weil viele früh rein sind wie wir, die zu ködern!

nehmt das geld jetzt und stabilisiert den kurs in den höheren Rängen wenn ihr später zurückkauft!

Die die ich nicht loswerden kann sind eben Hart im Nehmen und habens verdient!

oder so...

[Birgit.Tersteegen]

running out of time
by: pinvestment 03/03/06 03:43 pm
Msg: 937831 of 937848

i am glad that a resolution is at hand for MS sufferers - everybody has been able to say whatever they want up til now - next week the data gets to speak - and the way i see it the data is a monster - for those of you who ask " how come i couldn`t see the approval coming?" - my ansjavascript:smilie(``)
javascript:smilie(``)wer would be - you didn`t look at the data and give it a high enough value - the data is what drives the decision - not the opinions of a bunch of TEVA paid doctors hell bent on making more money by destroying peoples lives by forcing an inferior medication on them and trying to limit their therapeutic choices

[Birgit.Tersteegen]

MARKET PSYCHOLOGY AND COMMON SENSE
by: delta_squared
Long-Term Sentiment: Strong Buy 03/03/06 01:28 pm
Msg: 937438 of 937868

First premise: NEJM confirms that Tysabri will be a blockbuster drug in a multibillion dollar market.

Second premise: FDA will approve Tysapri remarketing this month.

Third premise: Big Money investors will increase their holdings of Elan

Fourth premise: Big Money is able to control and manipulate the share price of Elan over reasonable periods of time

(Note: in the very particular case of Elan, private investors are in posession of a disproportionately large number of shares)

QUESTION: How can Big Money induce private investors to sell their shares??

Possible option?: to give the private investor a profit by paying a little bit more for the shares DOES NOT WORK WHATSOEVER!..This approch is totally counterproductive....as the price goes up the private investor WILL BUY MORE SHARES, HE WILL NOT BE SELLING THE SHARES HE HAS in a stock that is increasing in price and making money for him..the increase in price is doubly counterproductive in that it provides the private investor more margin dollars with which to purchase even more shares in competition with Big Money. obviously this option CAN NOT AND DOES NOT WORK!

The ONLY way to purchase the shares that are currently held privately is to force the share price down...(and in light of the overwhelming positive shift of Elan fundamentals and the immediacy of the situation, A GREAT DEAL OF FORCE AND MANIPULATION IS REQUIRED)....
by forcing the price down, shares will be relinquished by private investors and can be bought at a favorable price for the following reasons:

first: rational and experienced private investors will readily sell an issue that is losing them money in favor of purchasing another stock that is increasing in value (and there are many to choose from)

Second: inexperienced investors can be readily be frightened into selling shares as the price is dropped, in order not to lose more money.

third: investors who are overweighted in a high risk issue are reminded of the wisdom of rebalancing their portfolio

fourth: investors who own shares on margin are forced to sell in order to meet margin calls

fifth: if the price is dropped sufficiently, stop loss orders are automatically triggered.

For these five reasons, droppin the share price by manipulaation is the ONLY HIGHLY EFFECTIVE AND ADVANTAGEOUS WAY to release and purchase the shares held by private investors

Next Question?: Why should anyone purchase or hold on to Elan shares:

First: on the basis of extremely sound understanding of the fundamentals of Elan, as can be learned from this board and other due diligence, comes the understanding of why Elan is currently substantially underpriced and the share price must rise within a time frame that will produce favorable investment return in the context of other readily available stock or other investment choices.

Second: on the basis of understanding and taking into account the mechanisms and motives of those forces that control price movement in the market

With all this being said, it also takes a great deal of guts, and Balls of Steel to deal in this market....

HANG ON TO YOUR SHARES. OR BIG MONEY WILL SOON OWN THEM!!!

and also

HANG ON TO YOUR BALLS OF STEEL, OR THEY WILL HAVE THEM TOO!!!

[Birgit.Tersteegen]

Schluss 12,50!

Re: running out of time/ PIN.
by: pinvestment 03/03/06 03:55 pm
Msg: 937875 of 937899

i trust one thing - THE DATA

everything else is opinion and hearsay - and i like to use the data to compare to history - find me a drug with the efficacy of tysabri - the unmet medical need of MS - a side effect profile indistinguishable from placebo - and no linkable risk of PML to monotherapy in immune competent patients

and tell me if any drug that looks like that was not approved by the FDA - it is impossible - thus tysabri will be back on the market and efficacy will drive sales higher than even the highest estimates - all MS patients might not be comfortable taking ty immediately but after disability then they will switch

[Birgit.Tersteegen]

Das Mantra bis Dienstag für die Longies--heisst inhaltlich die Daten sind sicher.....

NEW ELN MANTRA...TDIAM !!!!!!!!
by: stillholdun (40/M/Dallas TX)
Long-Term Sentiment: Strong Buy 03/03/06 04:16 pm
Msg: 937930 of 937933

The new mantra that we all need to chant from here on out is simple... TDIAM. It`s pronounced "teh-dee-am". Say it outloud - I know you can.... "teh-DEE-am.

It stands for, courtesy of our friend pinvestment, The Data Is A Monster !!!!!!

TDIAM, baby... look out.

[mankoll]

Schönes Wochenende und
don´t get to excited - oder so.

[eliasesteban]

wann am dienstag kommen denn die ergebnisse???????

[Birgit.Tersteegen]

Keine Ahnung--ich schätzs Mittwoch?

[Birgit.Tersteegen]

THE NUMBERS FOR TODAY
by: scubapop2
Long-Term Sentiment: Buy 03/03/06 04:39 pm
Msg: 937981 of 937991

5743600 BUY
4769300 Sell
1841400 ?

AFTER HOURS.. 21300 buy 600 sell.

[welke91]

Dienstag oder Mittwoch

auf jedenfall an beiden Tagen wird nicht gehandelt!

Birgit haste genug Merlot im Hause falls nicht?

[Birgit.Tersteegen]

[posting]20.498.483 von welke91 am 03.03.06 22:43:55[/posting]so oder so:Si klaro---haste noch ne Weinempfehlung für besondere Anlässe

[welke91]

[posting]20.498.546 von Birgit.Tersteegen am 03.03.06 22:48:15[/posting]Sicher Merlot?

Marco Felluga 2003 Anbaugebiet Collio!

spitzenwein!

[Birgit.Tersteegen]

[posting]20.498.655 von welke91 am 03.03.06 22:55:58[/posting]kann ich den so kaufen-oder kann ich ihn bei Dir bestellen?

[welke91]

[posting]20.498.683 von Birgit.Tersteegen am 03.03.06 22:57:54[/posting]uuuhh wird schwer an den ranzukommen!

jedenfalls bei euch habt ihr strom?

wenn not am mann/frau ist kann ich mal schauen was geht so ein Kartönchen oder? für dich mach ich spitzenpreis$

1 Elani gegen 1 Merlot oder so

[Birgit.Tersteegen]

Super Atikel von Ken Kam mit den Verwicklungen der "Schweinebande" in die Elanstory


Ken Kam on Elan- PT2
by: viz_sla
Long-Term Sentiment: Strong Buy 03/03/06 04:44 pm
Msg: 938000 of 938409

Strategy Lab Posting March 3, 2006

Buy 200 ELN at Market

Sell 50 BIIB at Market

One way to tell whether the hype about a new drug is warranted is to look at the reaction of its competitors. From the competition`s perspective, the year that Tysabri has been off the market has been a gift. Now that Tysabri appears poised to return to the market, Elan`s competitors are acting as though they are preparing for the worse.

The stakes are high. Tysabri has the potential to completely change the competitive landscape in a $4B market. Every day it seems like there are articles or reports both positive and negative on Tysabri and Elan is in a quiet period.

Teva Pharmaceutical`s (TEVA) Copaxone generated almost $1.2 billion of revenue in 2005 -- about 25%% of their total revenue and more of their profits. In January, Teva acquired IVAX pharmaceuticals, a generic drug manufacturer. To finance this transaction Lehman Brothers and Citigroup underwrote a $1.25 billion debt offering. The folks at Teva and the clients of Lehman and Citigroup who bought the debt cannot be excited at the prospect of Copaxone¹s sales being impacted by Tysabri`s return.

On Tuesday, Bloomberg reported that Teva Pharmaceuticals paid a marketing agent to publicize an abstract of an as yet unpublished article comparing Tysabri`s effect on the human immune system to AIDS. The way the media reported the story made it sound like Tysabri gave patients AIDS-like symptions. I think the authors of this paper would be aghast to see their research used in this way. It`s true that both Tysabri and AIDS suppress the immune system. Tysabri suppresses your immune system when its beneficial to do so such as when you have an autoimmune disease like MS. AIDS suppresses your immune system to your detriment.

Teva`s investment bankers have been active as well. Citigroup, you may recall, has a Sell rating on Elan that they reiterated about a month ago. Lehman Brothers also has a Sell on Elan which they updated on Thursday to state they expect 50 - 100 additional cases of PML in the next couple of years if Tysabri returns to the market.

[Birgit.Tersteegen]

Schaeffers report on Elan
by: keefer_lit 03/03/06 05:23 pm
Msg: 938071 of 938410

Apologies if posted, I just woke up and its the first thing I read. Happy Saturday.

-------

On Wednesday, a safety evaluation published in the New England Journal of Medicine reported that Elan`s (ELN: sentiment, chart, options) multiple sclerosis (MS) drug, Tysabri, used as a monotherapy cut the risk of disability progression by 42 percent. Remember that Tysabri was pulled from the shelves in February 2005 after it was linked to three cases of an often fatal brain infection. Since then, an independent committee, whose findings are published in the Journal, noted that there were no new confirmed cases of the infection from Tysabri.

So why was there heavy activity on ELN`s March 12.50 and March 10 puts? There was a press release on Tuesday stating that trading of ELN`s securities on the Irish Stock Exchange, the London Stock Exchange, and the New York Stock Exchange will be suspended as a Food and Drug Administration (FDA) advisory committee meets on March 7 to decide whether Tysabri can return to the full market. My guess is that this is the major reason why so many people have piled into ELN puts this afternoon. Moreover, Jim Cramer noted on his Mad Money show that he is bearish on the company, adding insult to potential injury for ELN.

The company has dropped quite a bit in response to the news; in fact, it has lost more than three percent today alone. What concerns me a bit is the fact that the shares have dropped below peak put open interest for March at the 12.50 level. If ELN is able to demonstrate a little late strength, it may be able to reclaim this level and its support. I am also a tad concerned about the fact that the stock has lost the support of its 20-week moving average. What should concern those ELN bears out there is the fact that it could easily reclaim this level of support if Tuesday`s news from the FDA is good.

Another thing that should concern Cramer and his ELN bearish brethren is the equity`s 10-month moving average. Yes, ELN has had its fair share of problems in the past, but notice that one constant has been its 10-month moving average. If it hadn`t been for the sizeable drop in February 2005, the shares might not be enjoying new-found support at this level. In fact, when I look at a monthly chart I see a bit of symmetry. Notice the two bottoms set by the stock in March 2003 and March 2005. What follows? The correct answer is a rally along its 10-month moving average. As ELN seems to have stagnated at the 12 level, this trendline is rapidly approaching to provide a push.

Pessimism teems from the options pits when it comes to ELN. The company`s Schaeffer`s put/call open interest ratio (SOIR) of 1.05 is at its highest point in the past 52 weeks.

The speculative options crowd`s bearish sentiment is echoed by Cramer, his minions, and analysts as well. According to Zacks all eight of the analysts covering ELN rate it a "hold" or worse. This configuration leaves the door wide open for upgrades to push the shares higher.

ELN could receive a further boost from a short-covering rally. More than six percent of the company`s total float is sold short, which could provide the fuel necessary for a short-covering rally as bears run away from their pessimistic bets. What could possibly provide that kind of good news? That`s right, an FDA approval for return to the market.

Keep an eye and an ear out for news from the FDA on Tuesday. If the news is good, the move higher could be substantial, considering ELN`s Schaeffer`s Equity Scorecard rating of 8.0.

h**p://www.schaeffersresearch.com/commentary/observations.aspx?ID=15453&obspage=2

[Birgit.Tersteegen]

GREAT ARTICLE ! MS DRUG SAFE AFTER ALL
by: hunglikeahorz (33/M/NC)
Long-Term Sentiment: Strong Buy 03/03/06 05:59 pm
Msg: 938101 of 938430

Do Over: New MS drug may be safe after all

Nathan Seppa

An experimental drug for multiple sclerosis (MS) that was approved in 2004, then abruptly yanked off shelves last year because of safety concerns, may get a second chance.

Two studies show that the drug can curb MS symptoms and slow progression of the autoimmune disease over 2 years, the longest tests of this drug to date. A third investigation finds no further cases of the often-fatal complication that sidetracked the drug last year, beyond the three patients who fell ill at that time. All three papers appear in the March 2 New England Journal of Medicine.

The drug, natalizumab, was pulled 4 months after its approval by the Food and Drug Administration. Three patients in clinical trials had developed progressive multifocal leukoencephalopathy (PML), a rare nervous system disorder caused by a virus that attacks people with suppressed immunity. The withdrawal came after doctors had written roughly 7,000 prescriptions for natalizumab for MS, rheumatoid arthritis, and an intestinal ailment called Crohn`s disease. The drug was marketed as Tysabri by Biogen Idec of Cambridge, Mass., and Elan Corp. of Dublin, which both funded the new studies testing the drug`s effectiveness.

The drug combats MS by binding to a protein called alpha-4 integrin on the surface of white blood cells, interfering with their entry into the brain. This thwarts the brain inflammation and nerve damage that these immune system cells trigger, says neurologist Richard A. Rudick of the Cleveland Clinic.

Starting in 2001, Rudick`s U.S. team randomly assigned patients to get a monthly infusion of either natalizumab or a placebo. In 2002, researchers in the Netherlands began a similar trial. Together, these tests included 1,859 MS patients. In the U.S. study, all patients also received interferon-beta 1a, a current MS drug.

Over 2 years, the annual relapse rate in patients getting natalizumab was one-third or less in both studies, compared with more than three-fourths among patients getting a placebo.

Natalizumab`s relapse suppression "was more robust than that for currently available drugs," says Chris H. Polman, a neurologist at Vrije University Medical Center in Amsterdam.

Magnetic resonance imaging showed that patients in the trials getting natalizumab were less likely to develop MS-type brain lesions than were those getting a placebo or a placebo plus interferon-beta 1a.

In the third study, researchers at the National Institute of Neurological Disorders and Stroke in Bethesda, Md., looked for signs of the virus that causes PML in 3,116 people who had taken natalizumab as part of the two new MS trials and several other trials.

No one aside from the three patients already identified had the disease, says virologist Eugene O. Major of the institute. The new findings indicate that the risk of developing PML while using natalizumab is roughly 1 in 1,000, he says.

All three patients who developed PML were taking natalizumab with other drugs and might have had overly suppressed immune systems, says Allan H. Ropper, a neurologist at Caritas St. Elizabeth`s Medical Center in Boston. Natalizumab alone "seems fairly safe, and it`s quite potent," he says.

http://www.sciencenews.org/articles/20060304/fob1.asp

[mikel_ann]

Morgähn ? 9.70 in FFM ??

[mikel_ann]

Und gleich mit Stückzahlen raus ..

10000 zu 10
rd. 5000 zu 9,70

Das sind ca. 0,70€ unter SK USA.

Wird langsam Zeit Geld zu sammeln für Elanies.

[mikel_ann]

Shares of Elan (nyse: ELN - news - people ) should see a heavy pickup in trading volume on Monday as the Irish drugmaker and marketing partner Biogen Idec (nasdaq: BIIB - news - people ) await the start of an advisory panel meeting on Tysabri. A U.S. Food and Drug Administration committee will meet over two days to discuss the fate of the multiple sclerosis drug, which was pulled from the market in early 2005 on safety concerns. Elan shares, which often react violently to news, will be halted during the entirety of the panel meeting, set for March 7 and 8. Research firm A.G. Edwards maintained a "hold" rating on Elan late Friday and predicted a favorable outcome for the company. "If the committee recommends against Tysabri`s return, we would expect Elan to trade down about $6 and Biogen Idec down around $3 to $5," it said. "We believe a positive outcome is assumed at current prices, but both stocks could move up on a positive recommendation

[Birgit.Tersteegen]

[posting]20.502.893 von mikel_ann am 04.03.06 11:32:40[/posting]tja-viele Menschen haben viel Angst--und mit der Angst machen wieder viele ein gutes Geschäft....an der Börse und in der Pharmaindustrie....that´s life...Eigentlich sollte Teva jetzt Antidepressiva an verängstigte (ehemalige) Elanaktionäre verkaufen-könnten sie ihre zukünftigen Mindereinnahmen an MS-Medikamenten mit kompensieren!

[mikel_ann]

Sollen Sie mal machen ! Da bin ich auch drin ! und die haben am Freitag -4% gemacht

Also sind die Elan-Aktionäre noch nicht verängstigt genug.

[Bachalor]

bin ein wenig entäuscht von euch
ich hatte euch angeboten kerni fragen zu geben bezüglich fda zulassungen usw
nicht einer hat es gemacht
kerni wird euch bestätigen,dass unser biophan mann bei der fda euch allen hätte sehr helfen können
aber kerni wird es privat sicherlich geholfen haben

[welke91]

[posting]20.511.863 von Bachalor am 04.03.06 18:41:06[/posting]genau, und auf dem Mars wachsen Schilfblumen,...

FDA bekommt ja erst am 7 März mitgeteillt ob es was wird!

grüße

[fred4]

<FDA bekommt ja erst am 7 März mitgeteillt ob es was wird!...
hi, rechne eher mit 08. März
long and strong
fred4(german)

[welke91]

[posting]20.513.770 von fred4 am 04.03.06 20:34:41[/posting]Gratuliere zu deinem ersten Posting un gleich bei Elan gelandet.
Bist du investiert?

sicher denn 2 Tage sperre im Aktienhandel also Mittwoch wirds öffentlich gemacht!

Das Panel unterrichtet am Dienstag ja die FDA und erst dann könnte Bachalors Friend uns was mitteilen aber dafür würde er sicher in USA lebenslänglich bekommen.

grüße

[Birgit.Tersteegen]

[posting]20.513.770 von fred4 am 04.03.06 20:34:41[/posting]Hi Fred 4 German-schön dass Du auch im deutschen Board gelandet bist--im Moment können wir hier Unterstützung gebrauchen...

Bacha-was sollen wir denn fragen wollen??Ausserdem habe ich davon nichts mitbekommen;und wenn Kernie etwas wichtiges weiss,wird er es mitteilen...

Some of the reasons I did not sell
by: ipar4s2
Long-Term Sentiment: Strong Buy 03/04/06 08:45 am
Msg: 938487 of 939042

going into the AC are related to a tremendous amount of due dilligence I have performed, with the assistance of many here, that leads me to several likely profiatble conclusions.

Tysabri Monotherapy will be given the green light sans a black box.

Tysabri HT production will be perfected, and Elan and Biogen will need the additional capacity quite soon.

KM is presenting at the Cowan and Co. Conference on March 9th. I imagine Biogen will announce the same soon. I anticipate them to tell the world a slightly different story on the potential Tysabri uptake. Actually, KM will stay the course, Mullen will update to match.

Elan as a Corporate entity has undertaken an about face. This supplement approval will allow them to compete effectively in the Global market once again.

Aab-001 PIII will probably be enrolling in conjunction with a "Fast Track" FDA road this year. Excitement is building at WYE and ELN.

ELN is on track to return to her glory years. This time with additional momentum.

Bioworld is where millionaires are made now days. The 3M`s, GE`s, etc...are solid for the person wanting 5%. I want much more, and am willing to take an educated risk.

The list could go on and on. Feel free to add. This next Tuesday and Wednesday have been waited on since February of last year. We finally have our day in court. No more, no less. Will the Judges agree with the Companies? That`s the ultimate question. This investor believes they will.

March 9th is payday.

Von meinen Elanies hat keine Eine die Besitzerin gewechselt....

Schönes WE!Birgit

[Birgit.Tersteegen]

Data Talks In This Business & BS Walks
by: stockhound4 03/04/06 07:46 am
Msg: 938469 of 939060

Appology to Pinvestment for repeating this mantra but the thruth is the truth.

The competition is in a tizzy over the data. Their market and market share which in 2005 was worth just over 5,200,000,000$ is at immediate risk of going away to the new kid on the block with an annual growth rate of rougly 17.5% in 2006 and 20% in 2007 this market ballons out to roughly 8,000,000,000$ in 2009. Will Tysabri grab 5%-10%-15%-20% of this market...Time will tell.

Will they scream fire in a theater...you bet!

Will they look to intimidate and influence the outcome....We have alrady seen it first hand this week.

Will they try to scare and people away comparing the drug to AIDS/HIV....?

Will they say the drug is dangerous and have respected/recognized professionals get up and say "Warning Will Robinson"...Hellow Steinman and Lnager-Gould.

Will the "ANAL"ysts that have been totally asleep at the wheel who now could not tell day from night stand up and say that the product is only a niche product that docs won`t prescribe and patients won`t take it...Hello Dick Sliver

What self respecting MS patient if given a choice to have a treatment that is roughly 2X more effective in preventing relapses and for 54% of patients taking the product showed that there was a complete halt in disease progression.

But back to the data.

Two-year AFFIRM Phase III monotherapy data published today showed that treatment with TYSABRI reduced the risk of disability progression by 42% (p<0.001), the primary endpoint of the study, and led to a 68% reduction (p<0.001) in the annualized relapse rate compared to placebo. TYSABRI treatment also resulted in sustained and statistically significant reductions in brain lesion activity as measured by MRI. The two-year SENTINEL Phase III data also demonstrated that treatment with TYSABRI in addition to AVONEX had a significant effect on disability progression, relapse rate and brain MRI disease activity compared to AVONEX alone.

Read it....Learn it....Respect it..This is powerful stuff.

Hound

[Birgit.Tersteegen]

Dies Video müsst Ihr Euch ansehen--total optimistisch was die Zulassung betrifft...


**WATCH THIS NEW VIDEO ON TYSABRI ***
by: hunglikeahorz (33/M/NC)
Long-Term Sentiment: Strong Buy 03/04/06 09:44 am
Msg: 938533 of 939064

There will be a short video advertisement on the weather (you need to watch that for a few seconds), then then news on MS patient taking Tysabri follows automatically.

" target="_blank" rel="nofollow ugc noopener">http://www.wndu.com/video/player.php?vid=781

[Birgit.Tersteegen]

Accumlative NBV / Predictions?
by: darrelldemello
Long-Term Sentiment: Strong Buy 03/04/06 09:28 am
Msg: 938521 of 939065

Here is an abbreviated message (from someone I respect as a SENSEI) that I woke upto this morning and it has some really interesting facts and and assumptions based upon which IMO one can make real strong predictions...
-------------------------------------------

For the last 8 months, there were 3 T/A breakouts as follows:



Breakout #1 was on 11/11, subsequently the pps moved from $9 to $11 on NBV of 21.09M shares. It took roughly 10M shares of NBV to move $1 in the pps.



Breakout #2 was on 12/07, subsequently the pps moved from $11 to $14 on NBV of 16.63M shares. It took roughly 6M shares of NBV to move $1 in the pps.



Breakout #3 was on 1/10, subsequently the pps moved from $14 to $16.8 on NBV of 24.29M shares. It took roughly 8M shares of NBV to move $1 in the pps



"Therefore based upon the average of the last 3 T/A breakouts, we expect it takes 8M shares of NBV to move $1 in Elan`s pps."



What is the accumulative Net Buy Volume now? Answer: Excluding the coming Monday, the NBV beats the last 3 breakout numbers by a wide margin and stands at 43.79M shares.
(is this a surprize? No. No. and again NO..)



What does this NBV implies?
Answer: In all likelihood, if NBV analysis is proven true and a good indicator of future happenings, Elan`s pps will jump at least $5 after the AC.



Is it a wild guess? are we pulling this out of our Top Hats?
Answer: Heck no!

Behold the following cold calculation:

Expected pps jump = 43.79M / 8M = $5 plus



Please note that based on Volume Analysis, T/A has already predicted:


***1.Ty will be approved with flying colors


***2.The pps will jump at least $5 after AC from today`s close of $12.50.


This is the first time we are forecasting a measured move in the pps based upon accumulative NBV.


Many of the posters on this message board have repeatedly questioned the usefullness of T/A and NBV as they state that T/A (and NBV) only reflects the past.

IMO a good read of the past history/ behaviour can help predict the likelihood of happenings/ trends in the future....

again IMO ... the increasing ACCUMULATIVE NBV ... now upto a total figure of 43.79 million shares is refective of the OBVIOUS ACCUMULATION via a MASTERFUL strangelhold MANIPULATION of the trading and the pps ... that has resulted in many retail shareholders either selling out (because of nervousness) or FORCIBLY being sold out (STOP LOSS ORDERS and MARGIN).

Via phone calls and email discussions many of you have asked a question as to what would be the Institutional holdings now ...

IMO Institutional holdings have crossed the 50% mark from approx 30% at the end of last quarter and the retail holdings have decreased ..... and will keep decreasing ... as retail takes profits or become over-leveraged.





This analysis is being posted to the EYMB because it appears that many nervous longs need re-assurance and many NAKED SHORTS need a forewarning that even KY jelly will be of no help ....

I have made changes in the mesage as I have seen fit, including a warnings to both over-leveraged longs and NAKED SHORTS.

now I await your responses ... many of which will be hostile, filled with ridicule and some filled with either good critiques and /or good comments ... all are WELCOME...

We are still trying to understand the importance of NBV and it`s usefulness as a predictor of news and pps rises or falls....

HAVE A GREAT WEEKEND FOLKS!!!

ELN`S/TYSABRI GOOD AND BETTER DAYS ARE COMING...

[welke91]

[posting]20.517.121 von Birgit.Tersteegen am 05.03.06 00:28:28[/posting]Please FDA please reacted!

Say yes for all `MS Patients!

grüße

[Birgit.Tersteegen]

March 09th = white + green Thursday ...
by: darrelldemello 03/04/06 12:35 pm
Msg: 938758 of 939073

you ask: "Could March 09th be another BM?"

First of all .. March 9th is a Thursday ...

and in al likelihood the AC will recommend to the FDA approval to re-commercialize Tysabri ...

IMO: March 9th will be a very WHITE THURSDAY with a HUGE WHITE CANDLE ... snd a very strong GREEN THURSDAY WITH A PPS rise of approx +$5 at least ....

JMHO.

[welke91]

[posting]20.517.146 von Birgit.Tersteegen am 05.03.06 00:37:10[/posting]I hope so but i think anyone after the approval would not sell his shares under 20 dollars!

is good for us!$$

[welke91]

Also Leute absolute Entscheidung:

Meanwhile, the biotech sector will catch the spotlight as Biogen (BIIB : and Elan take part in a meeting with the Food and Drug Administration on Tuesday to decide on whether the multiple sclerosis drug Tysabri should return to the market and what limits should be set on its use if it does. The stocks are expected to be halted on Tuesday and Wednesday.

Yes or NO? das is hier die Frage

[welke91]

http://www.marketwatch.com/tools/quotes/options1.asp?symb=el…

Bin mal gespannt wie sich die Optionen am Montag verändern werden!

[welke91]

hey ihr schlafmützen

zu Montag:

Shares of Elan (nyse: ELN - news - people ) should see a heavy pickup in trading volume on Monday as the Irish drugmaker and marketing partner Biogen Idec (nasdaq: BIIB - news - people ) await the start of an advisory panel meeting on Tysabri. A U.S. Food and Drug Administration committee will meet over two days to discuss the fate of the multiple sclerosis drug, which was pulled from the market in early 2005 on safety concerns. Elan shares, which often react violently to news, will be halted during the entirety of the panel meeting, set for March 7 and 8. Research firm A.G. Edwards maintained a "hold" rating on Elan late Friday and predicted a favorable outcome for the company. "If the committee recommends against Tysabri`s return, we would expect Elan to trade down about $6 and Biogen Idec down around $3 to $5," it said. "We believe a positive outcome is assumed at current prices, but both stocks could move up on a positive recommendation."

[Birgit.Tersteegen]

MOIN
Re: Pin Lets Talk PML
by: pinvestment 03/04/06 04:26 pm
Msg: 938977 of 939082

first of all I would like someone to explain to me the risk of PML in immune competent monotherapy patients

then i would like someone to explain to me the goal of zero risk for tysabri when the FDA allows remicade and many others to be sold that lead to death at much higher rates

or why herceptin and avastin are considered such great drugs when they are actually quite dangerous and have never been able to prove that they provide any survival benefit because of the rate of serious or fatal side effects

this comes down to a question of (1) can anyone prove that there is PML risk in monotherapy? ( the answer is no) - (2) if there is no measurable risk and only one case overall in ty mono at all ( immune suppressed patients) how can you ever prove a monitoring plan works if there are no cases - **** how can the FDA prove that lipitor does not increase the chance of someone getting hit by lightening *********
(3) it seems that the FDA has a much higher risk tolerance for many other drug - hence why do people think that ty risk have to be reduced to absolute zero by monitoring

the whole thing is a gross example of beauracratic masturbation while MS patients suffer - nobody is being forced to take the drug - approving a worthy drug just gives them a needed additional choice

[Birgit.Tersteegen]

Über den User "Pinvestment"der die qualifizierten Beiträge (s.o.)geschrieben hat

Pin does not like to blow his own horn, but he is a double doctor in Medicine & molecular biology, doing research at a major university and has been involved with taking drugs though the approval process.
He is also an astute assessor of biotech investments.

[Birgit.Tersteegen]

SUNDAY TIMES GOOD ARTICLE
by: elanguru2000 (32/M/Dublin) 03/04/06 07:08 pm
Msg: 939102 of 939331

Special report: Market lays bet on Tysabri verdict

LAS VEGAS may be the home of gambling in America, but action at the Holiday Inn in Gaithersburg, Maryland, this week is attracting the attention of some high-rollers indeed.
The hotel’s ballroom is getting a final clean this weekend ahead of the US Food and Drug Administration’s (FDA) two-day public meeting on Elan’s and Biogen’s multiple sclerosis drug, Tysabri, which was withdrawn from the market 12 months ago on safety grounds. The panel’s recommendation should prove pivotal as to whether the FDA will allow the drug to be relaunched. Trading in shares in both companies will be suspended during the meeting.
Elan and Biogen are not the only ones having another roll of the dice. The spread-betting firm WorldSpreads says that it has seen a marked pick-up in punter interest in Elan ahead of the meeting.

“Just two weeks ago, we were only dealing with two or three trades in Elan a week. It’s now 15 or maybe even 20 a day,” said David Lynch, a senior dealer at the firm. “It’s mainly small or medium players that are trading it and there are definitely one or two among them that were badly hit a year ago.”

The 70%, one-day slump in Elan’s share price last February left ordinary shareholders licking their wounds, but it was those who had taken out spread bets or contracts for difference who felt most pain. These fellows, after all, had effectively borrowed up to 90% of the money that punted on the stock.

This time round punters are not being allowed to take on such risk. WorldSpreads is demanding 60% of the money up front from clients betting ahead of this week’s crucial meeting. “Some of our competitors are calling for 100% up front,” said Lynch.

While the market has become increasingly jittery, with Elan shares having swung between €10.16 and €12.14 over the past two weeks, Lars Ekman, the group’s head of research and development, has been the epitome of coolness.

“I believe the drug will be approved because of its unparalleled efficacy and overall safety profile,” said Ekman.

Elan and Biogen have agreed to pitch Tysabri as a treatment on its own, rather than for use alongside other immunosuppresant drugs. The three clinical patients who developed an extremely rare brain infection — progressive multifocal leukoencephalopathy, or PML — after using Tysabri had also been on Avonex, another Biogen drug. Two of the patients died.

“No patient has yet (developed) PLM on monotherapy. That’ll be very clear on the label,” said Elman, whose team spent last summer conducting an extensive safety review on the treatment.

The two drug-makers received a boost in the middle of last month when the FDA gave them the go-ahead to resume clinical trials for Tysabri.

[Birgit.Tersteegen]

SUNDAY TIMES GOOD ARTICLE P2
by: elanguru2000 (32/M/Dublin) 03/04/06 07:08 pm
Msg: 939103 of 939338

While advisory panel meetings are normally one-day events, it has been extended to two days to allow for the large number of patients who want to make testimonials on the need for Tysabri to be returned to the market. It is also understood, however, that the widower of one of the PML fatalities will argue for restricting access to the drug.

Analysts largely expect the FDA to give Tysabri the thumbs-up by the end of this month — albeit with restrictions on its use — but nobody is pegging the $3.5 billion (€2.9 billion) peak sales target that was bandied about when the drug was first launched.

Opinion on sales is more divided now. While some Dublin analysts are pencilling in peak sales in the region of $1.8 billion (€1.5 billion), some US brokerages, such as giant Lehman Brothers, believe that they would barely hit $500m.

Ekman is too smart to be drawn in on the peak sales debate. “We have not given a number. We have said which patients should benefit — about 100,000 in Europe and the US that have been on and left other therapies. There is nothing left for them.”

Does the group have a plan-B should Tysabri be rejected by the FDA? “If you take Tysabri out of Elan’s fourth-quarter results last year, it was still Ebitda (earnings before interest, tax, depreciation and amortisation) positive.”

Tysabri, in fact, was a spin-off of Elan’s Alzheimer’s programme. Elan and partner Wyeth hope that one of their treatments for the degenerative disease — AAB-001 — will move into phase three clinical trials later this year. They expect their second drug — ACC-001 — to progress to phase two, and clinical trials to start on a third later this year.

Goodbody Stockbrokers recently forecast that the first two drugs could account for half of what it predicts will be a $10 billion drug market within the next 10 years. It is currently worth $3 billion.

Ekman is even more bullish. “A $10 billion market? That`s conservative. I think the companies who are out first with a disease-modifying drug (for Alzheimer’s) will have an outstanding opportunity. We are very well positioned to become that first company.”

More hype, more hope? Conservative investors might be inclined to have next week’s high-stakes event out of the way before laying their chips on the table to have a punt on the Alzheimer`s programme.

[Birgit.Tersteegen]

TYSABRI MONO 100% APPROVAL - NO PML !!!
by: dddctech (35/M/dddc headquarters)
Long-Term Sentiment: Strong Buy 03/04/06 07:03 pm
Msg: 939094 of 939339

This is what Biib has been saying last week.

This is what Pin has been saying.

THIS IS WHAT WE WANT !

This is WHAT PATIENTS WANT !

Tysabri Monotherapy is safe, effective, and the BIGGEST BLOCKBUSTER DRUG ever for MS !

[Birgit.Tersteegen]

Pinn or anyone a QUESTION...
by: boughtelanat2 (45/M/Fort Myers,FL)
Long-Term Sentiment: Strong Buy 03/04/06 07:22 pm
Msg: 939115 of 939339

BIIB and Elan pulled TY off the market on their own..Tysabri was not pulled off the market by the FDA manadory like Vioxx...Why are we going thru this process?..When we were not given a directive by the FDA to pull the drug?TY Mono is safe..PERIOD...Why can`t we just resume commercialization at our own risk without this bullshit..

Re: Pinn or anyone a QUESTION...
by: pinvestment 03/04/06 07:39 pm
Msg: 939126 of 939339

BIIB could have just asked for a re-instatement but they had excellent two year data on both trials and they wanted to put that on the label so they would need to submit a BLA to get that done


Posted as a reply to: Msg 939115 by boughtelanat2

[Birgit.Tersteegen]

Label ready to go.....
by: till_tomorrow_2004 03/04/06 08:22 pm
Msg: 939164 of 939339

“No patient has yet (developed) PML on monotherapy. That `ll be very clear on the label," , whose team spent last summer conducting an extensive safety review on the treatment.

There you go a slight tip of the hat and how do you do.

Tick, tock time is up.

[Birgit.Tersteegen]

Re: The Times
by: ipar4s2
Long-Term Sentiment: Strong Buy 03/04/06 08:56 pm
Msg: 939189 of 939341

Let`s see now, ipars says no black box for monotherapy. Youkei talks about zero gravity jaws. Lars Eckman says probably and zero. Yet there will be traders and gamblers insisting that just the opposite is likely. Now, whom should we think has a better handle on next week? LOL These board "traders" remind me of kids with a computer and $10,000. No wonder wall street is filthy with all the easy money there is to be had.

[Birgit.Tersteegen]

Now time to sit back and wait
by: deferoy7 03/04/06 02:04 pm
Msg: 938884 of 939346

The time for trading or arguing the merits is essentially over. For longs, its now a case of fastening the seat belt and waiting for wednesday afternoon. Following is my prediction of what the committee will say.


The Committee will note;

- the high efficacy of Tysabri
- the unmet clinical need
- the high patient acceptability of Tysabri
- the considerable patient demand
- the fact that it cannot be excluded that Tysabri itself is the cause of the PML cases
- that risk is about 1:1000 after two years and difficult to predict longer term
- the possibility that interaction with other drugs may play a role in the development of PML and that therefore the risk may be reduced by avoiding them
- the fact that our knowledge on PML is lacking


and will conclude;

- the efficacy is such that the drug should be on the market.
- a programme be put in place to alert neurologists and patients to the possibility of PML
- that patients should be registered and monitored
- that initially at least patients with more active MS be considered fotr Tysabri treatment
- that Tysabri should not be used with immunosuppressants and immunomodulators (steroid rescue with caution)
- that more research is necessary on PML in general.


Good luck to all!!!!

[Birgit.Tersteegen]

Re: just in time - new treatment of PML
by: elanaddict 03/04/06 02:29 pm
Msg: 938907 of 939348

if the perfect efficacy is 1 and we assume ty =1 no matter what the dose and avonex =1/2 no matter what the dose, then
ty + avonex = 1 1/2 which is too much modulating of the immune system and leads to pml.
doesnt this seem the logical conclusion instead of concluding that somehow avonex causes ty cange to a factor of 1 1/2 and avonex becomes 0?
also, why do we assume that the prob is that that avonex causes the body to retain ty and cause pml. this is not logical either.
pretty simple. avonex is good, ty is better but both together is too much.
(like alcohol and valium).
so not only is ty still pure as the driven snow,but according to pin, we may have a cure for pml.
do you think this logic is lost on the ac and fda. if a pissant can figure it out, i assume they can too.
this is a done deal folks. i expect monday morning their will be one more attempt ot take your shares and then the smart money will be buying with both hands into the close.
dont let them take your shares.
ant

[Birgit.Tersteegen]

Der Markt/die Grossen und die Kleinen....

Re: what do I miss?
by: cyberhunkie
Long-Term Sentiment: Strong Buy 03/05/06 01:05 am
Msg: 939321 of 939370

stigerbid ...

You keep referring to "the market" ...

You said `the market is more reasonable than all strong buys`.

YOU DON`T KNOW SHIT ABOUT THE MARKET.

Talk to any real pros on Wall st. And they will tell you that the Institutional Buyers don`t influence the market - THEY ARE THE MARKET.

The best indicator that you have been played by the market is NBV. Net Buy Volume says that there are more buyers than sellers, yet the prices are going down ... HOW`S THAT ?

Well the MARKET, as you refer to it, just manipulate a small fish like you and you gave in. Big money can have a SELL account on one hand and a BUY account on the other. They sell/dump 5,000,000 shares in one account for $13.00 to force PPS down immediately and buy all 5,000,000 shares in the other account for $12.50. All the while they are trying to accumulation an additional 2 million shares from the small fishes at $12.50 instead of $13, because small fishes are scared. Hence, NBV is positive due to net accumulation.

Know the market manipulation before trusting `market`. The market is fooling you.

[leiro1]

Hallo Elaner!
Ich hab gelesen, daß es für nächste Woche DI und MI keinen Handel in USA, GB und Irland geben wird.
Wie schauts eigentlich mit dem Handel in Frankfurt aus?

Ich bin wirklich gespannt was nächste Woche auf uns zukommt und hoffe, daß wir good news erhalten werden, denn dann wirds richtig rund(rauf)gehen, aber wenn nicht - dann schau ich mir den Kurs erst wieder in einem Jahr oder so an....

Schönes Schneeschaufeln!!! - das lenkt wenigstens ab.

Leiro

[Birgit.Tersteegen]

[posting]20.522.433 von leiro1 am 05.03.06 15:57:57[/posting]willkommen leiro 1!

Hier wird der Handel sicher auch angehalten sein...es wird spannend und super für Elan Aktionäre....wir arbeiten auf diese Tage ja schon lange hin....

Frohes Schaufeln!Gruss!

[eliasesteban]

hallo Birgit,nabend,hoffe das wir dieser tage positiv überrascht werden,besser gesagt ich weiss dass es so sein wird,hab ne kristallkugel und die...........wenn es anderst kommen sollte muss ich neu anfangen,das wäre mir unlieb!
sag mal,was isst denn mit der geplanten party,bräuchte mal ne ausszeit?
hasst dich auch bei MTC eingeloggt,gutes board,nicht wahr?
schönen abend noch
gruss
Eli:

[Birgit.Tersteegen]

[posting]20.525.059 von eliasesteban am 05.03.06 19:33:24[/posting]Hi Eli!

Ich glaube Deine Kristallkugel hat recht....

Von mir aus steht der Partytermin--aber ich dachte wir warten wie die nächsten Tage sich entwickeln und Ende der Woche müssen dann mal ALLE was verbindliches sagen...

Das MTC-Board ist spannend,schnell und "gewöhnungsbedürftig"für jdm.wie mich,die bisher nur selten "gedaytradet"hat--hast Du eigentlich eine spezielle Software (BIS o.ä.?)

Die letzten 2 Tage hatte mein Depot über Elan,VEM und Mologen einen eindeutigen (teuren)drive Richtung Süden....hoffe die Richtung ändert sich nächte Woche!

Fühle mich Ty,den MSlern und der Forschung von Elan sehr verbunden mittlerweile und will meine 3900 Stück eh länger halten--aber die Buchgewinne sahen im Depot immer so schön grün aus...

ALLES WIRD GUT -und das Leben ist schön...

Gruss Birgit

[eliasesteban]

eine software ,nein ich trade schon länger,ab und zu bisher grün ,das depot,MTC kenn ich schon länger,hab mich aber erst vor kurzem registriert,find es voll gut,die noggerT tips laufen - nicht alle aber ziemlich.da verkaufen sich anfangs die board und mailleser gegenseitig die shares,ich versuche schnell zu sein,10 % und ich bin wieder raus,verpass ich oft den sauberen aufstieg aber -lieber den spatz in der hand als die taube auf dem dach.
molo isst ja ziemlich abgeschifft,hab ich nur am rande mitgekriegt,warum eigentlich
sag mal,deine heimat,das Münsterland ist das überwiegend grün,alte gehöfte,kaltblüterpferde,traditionell,burgen-stell ich mir spannend vor.
gruss
EE

[Nostarowie]

Hi an alle Elanifanten.

Das Ding wird schon geschaukelt werden.
Ist doch nicht nur Ty im Topf.
Die manipulierte Massenhysterie wird sich legen so oder so, ob ja oder nein von der FDA. Auf jeden Fall herrscht dann klarheit.

...wird wo es erst ma runter gehen bei njet jedoch nach besinnung is up angesagt, sonst brauch die Hexe nen guten Schuldenberater -und ich nen Psychiater.

schönen restsonntag

[Birgit.Tersteegen]

[posting]20.525.589 von Nostarowie am 05.03.06 20:36:31[/posting]nosta,vielleicht kriegen wir dann Psychiater-Mengenrabatt?

[Birgit.Tersteegen]

Moin!

Die Spannung steigt!

Hier ein offener Brief des CEO der MSvereinigungan die Mitglieder









An open letter to the membership of the National Multiple Sclerosis Society from Joyce Nelson, President & CEO

March 5, 2006—People with multiple sclerosis must have more choices for safe and effective treatments. The National MS Society is relentless in our pursuit of this goal.

It is our strongest hope that the FDA, after considering the safety issues associated with Tysabri®, will determine that such issues are manageable and that Tysabri can return to the market.

To that end, the National Multiple Sclerosis Society has worked on multiple fronts to assist the FDA with its work:

* We advocated for the speediest possible review of Tysabri. As a result, the FDA accelerated the process to the fastest extent the law would permit.

* In order to assure that the FDA received feedback from every individual who wished to be heard on this issue, we dedicated a month-long front-page link from our website, which attracts over 14.5 million visits a year, to the FDA comment page. We also provided information on submitting testimony and participating in the hearings in person. As a result of the outpouring from all comments received, the FDA extended its hearing proceedings from one day to two, and expanded its usual one to two hour public comment period to six.

* In order to make sure that the hopes and concerns of people with MS were being heard in the FDA process, in December 2005, the National MS Society commissioned an online survey of people with MS to better understand their views concerning Tysabri and its possible return to market. The Society shared the comprehensive results of that survey with the FDA, who will include these results in their deliberations.

* In order to assure that the best possible reviewers serve on the FDA panel, the National Multiple Sclerosis Society met with FDA officials and submitted a recommended list of reviewers who, in our opinion, bring to the table a comprehensive and balanced understanding of the issues associated with the return of Tysabri to the market. We do not know if any of these candidates will ultimately sit on the review panel, but the FDA accepted these recommendations for consideration.

* Dr. John Richert, Vice President of Research and Clinical Programs, will present testimony at the hearings March 7-8 and will attend the full deliberations, along with other Society officials. Dr. Richert`s statement will be made available on our website after his testimony on March 7.

Since Tysabri`s initial introduction to the market and its subsequent recall, the Society has provided the most current and comprehensive information available to its membership on this important issue.

During this time, a number of Society members have become actively engaged in advocating for specific outcomes. We encourage and support each of our members in their right to take an individual stand on this issue, and we support the rights of members to form ad hoc groups to support their opinion.

We have maintained respectful communications with these members. For example, as a result of the work of MS Patients for Choice, Society members had the opportunity to register for the webcast of the hearing at a fraction of the full cost.

The Society has a responsibility to give voice to all people affected by MS—those hoping for more effective treatment and those concerned with having safe treatment choices. Thus, despite the urgings of individuals, industry representatives and ad hoc groups representing all points of view on this matter, the National Multiple Sclerosis Society has not, and will not, dictate to the FDA what its answer should be.

Having provided the best possible information and feedback to the FDA, we support the process that has been designed to review Tysabri. If, after this safety review is complete, the FDA recommends Tysabri`s return to the market, we will applaud the addition of this treatment to our arsenal. If the FDA does not approve Tysabri`s return to the market, or if it does so with significant restrictions, we will work tirelessly to find ways to satisfy the safety concerns so that more effective treatments can be readily available for the benefit of people with MS.

[Poppholz]

Guten Morgen miteinander,

so haben wir den letzten Tag vor der Kursaussetzung zu packen. Heute ist schon alles möglich (-10% und +10%), je nach dem, wer schneller kalte Füße bekommt.

Ich bin weiterhin postiv bei unserem Baby eingestellt und gehe von einem schönen Wochenausgang aus.

[eliasesteban]

ich kauf noch ne portion!!

[bernie55]

@alle

..jetzt bin ich mal ein Woche " on the road" und schon geht es hier im Board wieder drunter und drüber.....

....also - ich bleibe dabei !! - ohne wenn und aber.....
....und ich frage mich wirklich, was diese Hektik vor der möglichen Zula von Tysabri soll...

...ich weiß,dass ich nichts weiß....
.... aber ich weiß, dass ich mich von den " Unkenrufen irgendwelcher Möchte-gern-Superoberchecker" nicht verrückt machen lasse, zumal die Ausgangslage im Vergleich zum letzten Jahr eindeutig besser aussieht....


...oder sehe ich das falsch ???

... Ich bin und bleibe , ebenso wie Poppholzer, Birgit und Co., weiterhin sehr postiv zu ELAN eingestellt......


Grüße bernie55

[bernie55]

[posting]20.530.346 von eliasesteban am 06.03.06 10:17:50[/posting]..denk an deine Kalorien.....


Grüße bernie55

[Poppholz]

Dow Jones
Wettlauf um bestes Multiple-Sklerose-Mittel geht in neue Runde
Montag 6. März 2006, 11:48 Uhr

DÜSSELDORF (Dow Jones)--Der Wettlauf um das beste Medikament gegen Multiple-Sklerose (MS) geht in eine neue Etappe: Am Dienstag und Mittwoch berät die US-Zulassungsbehörde FDA darüber, ob das Medikament "Tysabri" der Unternehmen Biogen Idec und Elan wieder auf den Markt kommt. Wichtig ist das vor allem für die Wettbewerber Schering und Serono, deren umsatzstärkste Produkte ebenfalls MS-Mittel sind. Auch die Konzerne Sanofi-Aventis und Teva haben mit Copaxone eine wichtige MS-Arznei, sind von ihr aber weniger abhängig als die beiden Konkurrenten.

Analysten rechnen nun zwar mit einer erneuten Zulassung für den neuen Wettbewerber - aber mit Einschränkungen, die den möglichen Umsatz begrenzen. Das Medikament war nach einer kurzen Prüfphase Ende 2004 in den USA auf den Markt gekommen, musste dann aber im Februar 2005 überraschend wieder zurückgezogen werden, weil sich bei Patienten ein Virus zu einer lebensbedrohlichen Infektion ausgeweitet hatte, an der ein Mensch starb. Die Arznei hatte das Immunsystem so stark unterdrückt, dass es sich nicht gegen die Infektion wehren konnte.

Der Rückruf hatte nach Einschätzung von Analysten die Stimmung für die gesamte Biotech-Branche getrübt, denn das Mittel ist ein biotechnologisches Produkt, ein so genannter monokonaler Antikörper. Die bisherigen Untersuchungen zeigen jedoch auch, dass das Mittel sehr wirksam ist. Klinische Studien mit dem Medikament sind nun bereits wieder erlaubt.

Die Investmentbank Lehman Brothers erwartet, dass Tysabri nur bei Patienten eingesetzt werden könnte, deren Zustand sich rasch verschlechtert. Bei ihnen überwiege der Vorteil das Risiko. Vermutlich werde die FDA zusätzliche Warnhinweise fordern. Auch die Analysten von J.P. Morgan rechnen damit, dass das Mittel wieder zugelassen wird. Es werde wahrscheinlich im zweiten Quartal wieder auf den Markt kommen. Es sei zudem unwahrscheinlich, dass die FDA weitere Studien anfordern werde.

Für Biogen Idec, die sich den Umsatz mit dem Entwicklungspartner Elan teilen, sieht J.P. Morgan im Jahr 2010 einen Erlös von über 1 Mrd USD. Bei Goldman Sachs sind die Analysten ebenfalls zuversichtlich, dass Tysabri wieder auf den Markt kommt.

Auch Biogen Idec selbst ist optimistisch. Hans Peter Hasler, Senior Vice President, erklärte gegenüber Dow Jones, es gebe bei Multipler Sklerose einen ungedeckten medizinischen Bedarf und man sehe einen wirklichen Vorteil, wenn Patienten mit Tysabri eine weitere Behandlungsoption hätten. Ein erfolgreiches MS-Mittel, Avonex, hat der Konzern bereits entwickelt, es hat einen Marktanteil von rund einem Drittel wie auch das Produkt von Sanofi-Aventis und Teva.

Den Gesamtmarkt für MS-Medikamente schätzen Analysten auf 7 Mrd EUR. Die Wettbewerber wappnen sich nun zur Verteidigung ihrer Marktanteile. Schering hatte den Umsatz der Arznei "Betaferon" im vergangenen Jahr um 11% auf 876 Mio EUR gesteigert und rechnet auch für 2006 mit weiter zulegenden Erlösen. Der Marktanteil von rund 15% soll jetzt durch eine erweiterte Indikation ausgebaut werden. So hatten Menschen mit ersten Anzeichen der Krankheit, wenn die Diagnose noch gar nicht bewiesen ist, das Mittel erhalten und davon profitiert. Zudem prüft Schering die Wirksamkeit einer höheren Dosierung.

Analyst Marcus Konstanti von Sal. Oppenheim rechnet dennoch damit, dass sich Tysabri zu einer ernsthaften Konkurrenz für Interferone wie Betaferon entwickeln könnte. Er erwarte bei einer Rückkehr des Mittels auf den Markt zwar zunächst nur verhaltene Verschreibungen. Mit jedem weiteren Quartal ohne Zwischenfälle könnte der Umsatz aber zulegen. In seinen Prognosen für Betaferon habe er die mögliche Konkurrenz bereits berücksichtigt: Ab 2007 rechne er mit einem zurückgehenden Umsatzwachstum.

Für das Schweizer Unternehmen Serono, das weitgehend von dem MS-Medikament Rebif abhängig ist, steht noch mehr auf dem Spiel. Nach Einschätzung von Analysten hätte eine Rückkehr von Tysabri einen Einfluss auf die gesamte Zukunft des Unternehmens. Im vergangenen November hatte Serono die Investmentbank Goldman Sachs beauftragt, nach strategischen Alternativen, sprich einem Käufer, zu suchen.

Bisher hatte es offenbar keinen Interessenten gegeben, und bei einer neuen Konkurrenz für das Hauptprodukt wäre Serono noch weniger interessant. Analysten rechnen für 2006 bei Rebif in den USA mit einem Umsatzrückgang von 5%, wenn Tysabri wiederkehrt - 2005 hatte der Umsatz noch um fast 32% angezogen.

- Von Richard Breum, Gangolf Schrimpf und Stefanie Weitz, Dow Jones Newswires, +49 (0) 211 - 13872 15, [e-mail] DJG/rib/jhe

[bernie55]

....no comment !!!!

[bernie55]

....no comment !!!!!

[bernie55]

...no comment !!!!!

[bernie55]

..ELAN goes up and up and up....

[Poppholz]

Biotec Aktien sind halt nichts für schwache Nerven.

Mologen und ELAN sind auf jeden Fall keine langweiligen Aktien.

(aber wer möchte schon "langweilige" Aktien haben)

[bernie55]

...wir doch nicht, Poppie , oder ???

[24littlehours]

[posting]20.532.436 von Poppholz am 06.03.06 12:16:59[/posting]ne kaufempfehlung steckt da aber keine drin

[Poppholz]

allerdings ist dieser Bericht wesentlich positiver, als die Meldungen die im deutschsprachigen Raum bisher rausgekommen sind.

Es wird davon ausgegangen, dass das Medikament wieder zugelassen wird und auch die Konkurrenz gehe davon aus.

[Poppholz]

zu einer Kaufempfehlung wird sich heute kein Analyst mehr hinreißen lassen.

[Poppholz]

erster Kurs in USA:

RT: $12,70

[Poppholz]

320 Stück bis $15,00.

[Birgit.Tersteegen]

Hi Ihr Lieben!

Bin froh über die Qualität dieses Threads hier.Bei WO gibt es jede Menge (sorry,ich muss es mal sagen)SAUBLÖDER FREILAUFENDER WÜRSTCHEN,gerade im Mologen thread hautnah zu erleben..,tausend Vermutungen werden angestellt von denen die noch billiger einsteigen wollen--aber keiner weiss irgendwas.
Ich habe eben dort angerufen und bekam Auskunft....

Muss mich abregen!

Freue mich auf die Entwicklung unseres Babies hier in den nächsten Tagen.

Grüsse

PS.Manchmal merke ich dass ich Sternzeichen"Löwe" bin

[Poppholz]

Deiner Laune nach zu urteilen bist Du noch in MOLOGEN investiert.



Ist schon erschreckend, wie sich eine "gute" Aktie in wenigen Tagen verändern kann.

Elan ist es in der letzten Zeit ja auch nicht besser gegangen, nur dass der Kurssturz sich über mehr Tage hingezogen hat, als bei MOLOGEN.



(alles wird gut)

[Poppholz]

über 10.000 Stück zu $14,75 im ASK.

wäre doch nicht schlecht, wenn die heute noch bedient werden.

[Poppholz]

BID füllt sich langsam in den USA:

11.000 zu $12,55
13.000 zu $12,60



(sollten die "richtigen" heute kalte Füße bekommen?)

[Birgit.Tersteegen]

[posting]20.534.422 von Poppholz am 06.03.06 14:13:09[/posting]

[Poppholz]

Tysabri focus obscures another Biogen Idec advance
Drug`s use OK`d for rheumatoid arthritis
By Jeffrey Krasner, Globe Staff | March 6, 2006

This week, the biotechnology world is focused on Tysabri.

A Food and Drug Administration advisory committee will meet for two days, starting tomorrow, to consider the fate of Biogen Idec Inc.`s multiple sclerosis drug, which was withdrawn from the market in February 2005 after two patients developed rare brain infections.

But the Cambridge company is concerned that the focus on Tysabri is taking attention away from another one of its products, Rituxan. The drug, which has been used to treat some forms of lymphoma, last week received FDA approval as a treatment for rheumatoid arthritis.

``We think it`s a big deal," said Biogen Idec`s chief executive, James C. Mullen. Rituxan ``changes the way this disease is treated," he said. ``It`s a brand new approach."

Rheumatoid arthritis is an autoimmune disease in which the body`s defenses attack the lining of joints, causing inflammation and -- in serious cases -- swelling, deformity, and loss of motion.

Some doctors share Biogen Idec`s enthusiasm for Rituxan.

``Any time you have drugs that take patients who are running out of options and give them new options, it gives an exciting opportunity to help those who otherwise wouldn`t get better," said Dr. Robert Shmerling, a rheumatologist at Beth Israel Deaconess Medical Center.

Rituxan uses a different method than existing rheumatoid arthritis treatments to interrupt the chain of events that lead to damaged joints. It targets white blood cells called B-cells, which are thought to play a role in identifying foreign invaders and triggering other cells to attack. The drug binds only to B-cells with a protein associated with rheumatoid arthritis, reducing their number and preventing the start of inflammation and injury.

While about 2 million Americans are believed to suffer from rheumatoid arthritis, Rituxan will be targeted at a much smaller population, about 220,000, according to an analysis by JPMorgan. Only patients who have failed initial treatments to reduce inflammation, and have also failed second-line treatments, will be eligible for the new treatment, according to its FDA-approved label.

Also, Rituxan will face competition from Orencia, a new drug to treat rheumatoid arthritis. Orencia, made by Bristol-Myers Squibb Co., was approved in December to treat the same group of patients who have not responded to existing therapies.

And there is something else complicating the outlook for Rituxan: The drug, which went on sale in 1997, was developed by Idec Pharmaceuticals before it merged with Biogen in 2003.

Facing extreme financial pressures, Idec signed a copromotion deal with biotechnology giant Genentech Inc. of South San Francisco, Calif. Under the agreement, Genentech keeps about 69 percent of US Rituxan sales, according to JPMorgan, and Biogen Idec and Genentech split a 20 percent royalty on European sales. That limits Biogen Idec`s potential revenue.

Rituxan will cost around $9,000 for each course of treatment, Biogen Idec said. Patients will receive two lengthy infusions two weeks apart. Most will require two courses of treatment in a year, a total of four infusions.

Still, some on Wall Street consider the new indication for Rituxan an important opportunity for Biogen Idec.

``Biogen Idec has a $2.4 billion revenue base, and this will provide an incremental 10 percent on that," said Eric Schmidt, an analyst with S.G. Cowen. ``Over time this could be a bigger drug in [rheumatoid arthritis] if it were to be approved for first-line treatment. It could also be used to treat other autoimmune diseases."

An analyst at JPMorgan, Geoffrey Meacham, estimates that the new indication will increase Rituxan`s annual sales growth in the United States to 26 percent annually, from 19 percent.

He predicts total sales to treat rheumatoid arthritis will increase from $83 million this year to $1.44 billion in 2010.

``Certainly the movement of Rituxan into the [rheumatoid arthritis] setting will be a positive for Biogen Idec," Meacham said.

``The question is, how much is already priced into the stock?"

Biogen Idec shareholders are also interested in the answer to another question, he said:

How will Tysabri affect the company`s fortunes if FDA advisers this week signal the multiple sclerosis drug`s return to the market?

Jeffrey Krasner can be reached at [e-mail].

© Copyright 2006 Globe Newspaper Company.

http://www.boston.com/business/technology/biotechnology/arti…

[Poppholz]

Restricted Tysabri Wouldn`t Hit Serono Rebif

Monday, March 06, 2006 7:01:11 AM ET
Dow Jones Newswires

1046 GMT [Dow Jones] Aurel Leven doesn`t see a significant impact on Serono`s (SRA) Rebif prescriptions if Elan`s (ELN) Tysabri returns to market with a restricted label. Sees AstraZeneca (AZN) as a possible suitor for Serono, after CEO David Brennan said last week it has enough resources to buy a mid-sized company. However, highlights the probable existence of a change-of-control clause with Pfizer (PFE), which markets Rebif in the US. Such a clause could be worth CHF100 a share. AstraZeneca +0.4% at 2,650p, Serono -0.1% at CHF928.5. (EXB)


Contact us in London.
[phone]
[e-mail]

Copyright (c) 2006 Dow Jones & Company, Inc.




(wenn die das so sehen, dann wird das bestimmt stimmen)

[bernie55]

[posting]20.533.946 von Birgit.Tersteegen am 06.03.06 13:46:29[/posting]Manchmal merke ich, dass ich Sternzeichen" Löwe" bin

...dann würde ich sagen: " Gut gebrüllt, Löwin "....

[bernie55]

[posting]20.534.790 von Poppholz am 06.03.06 14:34:51[/posting]...jetzt mal im Enst !!!!!

...Kann es soviel Selbstignoranz überhaupt noch geben ?????

[Poppholz]

[posting]20.534.983 von bernie55 am 06.03.06 14:45:11[/posting]Bernie, die Jungs sind vom Fach.

Da verstehen wir doch gar nichts von.

[Poppholz]

Kurs geht schön hoch.

RT: $13,00

[Poppholz]

ALABS ist wieder da.

Mit 20.000 Positionen wollen die den Kurs wieder drücken.

[bernie55]

[posting]20.536.149 von Poppholz am 06.03.06 15:39:17[/posting]...erst der Anfang, Poppholzer....

[Poppholz]

ALABS:

34.000 zu 12.90

20.000 zu 13,02

im ASK.

Die versuchen es mit allen Mitteln.

[bernie55]

[posting]20.536.223 von Poppholz am 06.03.06 15:41:45[/posting]...da gibt es einfach was auf die Finger.....

[Birgit.Tersteegen]

[posting]20.536.249 von bernie55 am 06.03.06 15:42:56[/posting]Alles "Schweinebacken".Aber heute ist ihre letzte Chance billig einzukaufen....Gönnen wir se Ihnen.....

[bernie55]

[posting]20.536.318 von Birgit.Tersteegen am 06.03.06 15:46:41[/posting]..wieder mal " sozial " eingestellt...

...so kenne ich dich, Birgit....

[bernie55]

..oder lass doch einfach mal einen Brüller los....

[Birgit.Tersteegen]

[posting]20.536.390 von bernie55 am 06.03.06 15:49:19[/posting]Kommt noch;kann mich doch noch nicht verausgaben....

[bernie55]

[posting]20.536.494 von Birgit.Tersteegen am 06.03.06 15:54:39[/posting]....ok - bei ZULA darfst du Dich austoben.....

[Poppholz]

25.000 zu $12,51 von ALABS im ASK.

[Poppholz]

da soll mal ein Großer kommen und richtig die Hände aufhalten.

Kann doch nicht angehen.

[Poppholz]

$12,26

(wir waren vor 15 Minuten noch bei $13,06)

[Birgit.Tersteegen]

gnadenloses Gedrücke--bei Mologen auch...

[Poppholz]

an der momentanen Situation hat sich natürlich noch nichts geändert.

[bernie55]

[posting]20.536.684 von Poppholz am 06.03.06 16:02:09[/posting]YYEEPPP....

[Poppholz]

$12,10

Da müssen doch auch mal genügend Käufer sein. So viel Unsicherheit ist nicht zu begreifen.

[bernie55]

....heute halt noch einmal ein ZICK - ZACK - DAY....

[bernie55]

....jetzt wieder 12,44 USD....

[bernie55]

So viel Unsicherheit ist nicht zu begreifen.

.....und dass vor der ZULA von TYSABRI......

[bernie55]

[posting]20.536.775 von bernie55 am 06.03.06 16:06:05[/posting]...jetzt wieder 12,28 USD....

[bernie55]

...ich glaube, die machen sich selbst langsam nervös....

[eliasesteban]

hab auch nochmal zugelangt,die welt hält mich für verruckt,wenn das ma gut geht,zitterpartie,aber ich glaub dran,mann darf ja wohl ein bisschen zittern.
hab so das gefühl das was raus kommt womit keiner von uns rechnet.

[Poppholz]

Kurs ist wieder bei $12,70

[Poppholz]

$12,86

heute wäre ein schöner Tag zum Daytraden gewesen.



Von 12,50 auf 13,06 auf 12,10 auf 12,85.

(Börse ist so einfach)

[bernie55]

[posting]20.536.855 von eliasesteban am 06.03.06 16:09:59[/posting]MUT TUT GUT .

[bernie55]

[posting]20.537.333 von Poppholz am 06.03.06 16:30:19[/posting]DAYTRADEN....nein, Danke...

besser YEARTRADEN......

[Birgit.Tersteegen]

[posting]20.537.395 von bernie55 am 06.03.06 16:32:57[/posting]Ich hab´dann doch gebrüllt....und nun ist 12,92.(Bei molo mach ich mir wahrscheinlich Feinde fürs Leben....)

[Poppholz]

auf der Käuferseite ist die Zurückhaltung vorhanden, da viele hoffen, dass noch einmal eine Drückerkolonne vorbei kommt, damit die Aktien noch ein bischen günstiger eingekauft werden können.

Käufer sind genügend vorhanden, nur wollen die (verständlicher Weise) nicht zu viel bezahlen.

Wenn aber keine Drückerkolonne mehr kommt, dann explodiert der Kurs.



(wer mit im Boot sitzt, darf auch mitfahren)

[Birgit.Tersteegen]

Das haben sie gehört und DRÜCKEN---werd ja bald heiser-wie Du Bernie

[zenman]

WASHINGTON, March 6 (Reuters) - It is unclear whether Biogen Idec (BIIB.O: Quote, Profile, Research) and Elan Corp.`s (ELN.I: Quote, Profile, Research) (ELN.N: Quote, Profile, Research) multiple sclerosis drug Tysabri may raise the risk of a rare, life-threatening brain infection when used alone, U.S. Food and Drug Administration staff said on Monday.

"It is unclear for which patients the risk-benefit profile would be acceptable," the FDA staff said in a report released ahead of an advisory panel review of the drug that starts Tuesday. The companies should implement a mandatory program to monitor risks should the drug be allowed to return to the market, the staff recommended.

Tysabri sales were suspended in February 2005.

[Birgit.Tersteegen]

FDA docs look fine
by: pinvestment 03/06/06 10:10 am
Msg: 940754 of 940852

i am very happy with what i have read - is much more positive than other FDA opinions on drugs that got approved - not much difference between opinions - and FDA suppositions seem based on approvla be a bit of a given

[Bachalor]

bin heute bei meinen steckenpferden

sorry

[Poppholz]

[posting]20.537.423 von bernie55 am 06.03.06 16:34:01[/posting]bin auch nicht für das Daytraden geeignet.

Weder finanziell noch vom Nervenkostüm her.

Wenn ich mir den Kursverlauf so ansehe, dann scheinen einige Ihr Handwerk allerdings zu verstehen.

[bernie55]

[posting]20.537.634 von Bachalor am 06.03.06 16:43:47[/posting]...bei den Bratwürstchen ????....


Grüße bernie55

[Poppholz]

wieder über $12,90

vorhin kamen die Drückerpositionen bei $13,05.

und jetzt?

früher?

später?

gar nicht?

[Bachalor]

[posting]20.537.735 von bernie55 am 06.03.06 16:48:03[/posting]wollte freitag bei dir frühstücken auf dem weg nach münchen

warst aber lange nicht online

[Bachalor]

nur ein 2 sätze zu biph

sollte biph demnächst 2$ erreichen,solltet ihr euch welche zulegen.
dann könnte sehr schnell der börsenwechsel kommen
und news folgen

[bernie55]

[posting]20.537.757 von Bachalor am 06.03.06 16:49:04[/posting]Yepp...ich bin in der letzten Woche in Holland gewesen und erst am Sonntag nach Hause gekommen......

[Birgit.Tersteegen]

fast 13$

[Birgit.Tersteegen]

und wieder gedrückt...!

[Birgit.Tersteegen]

4.01pm NBV+++2.7049 million shares
by: darrelldemello 03/06/06 04:06 pm
Msg: 941678 of 941734

At 4.01pm pps $12.71

Buy Volume = 8,645,000 shares

Sell Volume = 5,940,100 shares

Indeterminate Volume = 2,514,700 shares

Total Volume = 17,099,800 shares

NET BUY VOLUME = NBV +2,704,900 shares

All th best for the two days of the AC ... God Bless to all participating in the AC and pray that those that need Tysabri the most ... the patients with MS ... get Tysabri back as soon as possible....

[Birgit.Tersteegen]

Moin

Super Artikel zur Notwendigkeit Ty zuzulassen von einem ehemaligen FDA Mitglied;LESEN!!



Patients vs. Paternalism Font Size:
By Dr. Henry I. Miller : BIO | 07 Mar 2006
Discuss This Story! (0) Email | Print | Bookmark | Save

Decisions about drug safety and efficacy are far from easy. Tysabri, a multiple sclerosis (MS) drug that was voluntarily withdrawn from the market last year after the appearance of a previously unknown side effect, illustrates some of the conundrums that exist in drug treatment.

In advance of the publication of three critical new studies on Tysabri in the current issue of the New England Journal of Medicine, a major news organization recently asked me, as a physician and former FDA official, whether I knew of examples of prescription drugs that have "efficacy but [also] serious safety issues." That is the rule rather than the exception, I responded.

Obvious examples include the antimetabolites used for traditional chemotherapy. Because these drugs are no more than poisons administered in a way intended to be more toxic to cancer cells than normal ones, it is not surprising that their side effects are often serious and even life-threatening. When I was a medical resident three decades ago, hospital gallows humor included referring to BCNU, an experimental cancer drug, as "Be seein` you." (Approved in 1977, it is still widely used.)

A more recent example is aldesleukin (also known as interleukin-2, or IL-2), a drug that has offered new hope to victims of kidney cancer and malignant melanoma. It is highly effective in a small proportion of patients but exhibits significant toxicity. The patient information booklet warns that those taking the drug "frequently experience serious, life-threatening, or fatal adverse events," including dangerously low blood pressure and reduced organ perfusion, impaired function of infection-fighting white blood cells, disseminated infection, and autoimmune disease.

Antibiotics are another class of wonder drugs that sometimes manifests significant toxicity. Chloramphenicol, a drug that is effective against a wide spectrum of bacterial infections, causes rare cases of fatal aplastic anemia, so it used only sparingly. The potent antibiotic gentamicin is often life-saving but can cause damage to the kidneys, nerves and ears. And significant numbers of patients are allergic to other important antibiotics, including the penicillins and cephalosporins.

But let us return to Tysabri, only the sixth medication approved -- and the first in several years -- for the treatment of MS, a common and debilitating autoimmune disease that affects the central nervous system. Following impressive results of the drug`s testing in clinical trials -- the frequency of clinical relapses reduced by more than half -- the FDA granted accelerated approval in 2004.

However, by the time that several thousand patients were being treated with Tysabri, three had contracted progressive multifocal leukoencephalopathy (PML), a rare neurological disorder caused by a virus. (Because the drug suppresses certain components of the immune response, regulators, clinicians and the product`s developers had from the beginning been sensitive to the possibility of infections as a side effect.) Precipitously -- some would say prematurely -- the manufacturers of the drug voluntarily halted production and distribution and withdrew Tysabri from the market. MS patients and many neurologists were bitterly disappointed.

The three clinical studies reported in the New England Journal of Medicine bolster our confidence about both the safety and efficacy of Tysabri. In a study of almost a thousand patients that compared Tysabri to placebo, the drug cut the rate of clinical relapses by 68 percent (from 0.75 to 0.24), reduced by 83 percent the number of new or expanding brain lesions found on MRI, and slowed the clinical progression of disease. (The other currently used drugs for MS lower the occurrence of acute relapses by roughly one third.) Similar results were obtained in a second trial which compared two-drug therapy with Tysabri plus interferon beta-1a to the interferon alone.

Finally, a third study found no additional cases of PML in more than 3000 patients (exposed to an average of 17.9 monthly doses) who had participated in clinical trials of Tysabri. The investigators concluded that the incidence of this serious side effect is approximately one in a thousand patients treated with the drug. However, it should be noted that all three of the original cases of PML occurred in patients treated with interferon beta or other immunosuppressive agents as well as Tysabri, so the risk might be significantly lower in patients treated with Tysabri alone. Many neurologists who are familiar with Tysabri in MS believe this will prove to be the case.

The "safety" of a drug is a relative thing. Safety and efficacy, the two criteria required for marketing approval of a drug, are inextricably linked. The judgments of regulators (and practicing physicians) require a global and often difficult calculation of risk and benefits, including consideration of what alternative therapies are available. We are willing to tolerate greater uncertainty and more severe side effects for a potential cure for pancreatic cancer or AIDS, for example, than for a new drug that treats heartburn. When FDA grants marketing approval, the drug is deemed to be sufficiently safe and effective to be used for the conditions on the label.

In light of previous studies and the new data published in the New England Journal of Medicine -- to which the FDA should have had access months ago -- the publicly available evidence certainly supports returning the drug to market, presumably with revised labeling, as quickly as possible. If that happens, physicians and patients will need to decide whether for a given individual the risk of the drug is acceptable in view of the possible benefits.

Even in view of the just-published data, one eminent neurologist who has long and extensive experience with Tysabri remains cautious: "I myself would only use the drug in patients who are `train wrecks,`" by which he meant patients who were severely symptomatic. He feels that it is only they who "can assume a 1/1000 risk of a fatal complication and for whom such a risk is reasonable. I know many in this category with MS, because of the nature of my practice. But I would not treat that hypothetical 20 year [old] sophomore on campus with early MS."

I have far less clinical experience than he, but given that Tysabri reduces the number of new or expanding brain lesions as measured by MRI, and that it slows the progression of the disease, it may be that some of the hypothetical 20 year old college sophomores with MS might opt to take the drug if it makes it possible for them to live more normal lives.

When an FDA advisory committee convenes this week to make recommendations about Tysabri`s fate, its members will likely confront a mishmash of testimony from patients, physicians and other experts, perhaps including even some mischief on the part of companies with competing products. As I learned during my own extensive service on advisory committees, there is astonishing variability in an individual`s -- even an expert individual`s -- interpretation of the data.

The FDA has the final say. Although society has designated the FDA as a gatekeeper between drug companies and the marketplace, the agency must beware of excessive paternalism and strive preserve the right of patients, in consultation with their physicians, to make informed individual decisions about the available therapeutic options. Inevitably, different people will have very different comfort levels about risks and benefits.

If our society permits citizens to make risk-benefit decisions about whether or not to have elective surgical facelifts and stomach-stapling operations for weight control, whether to buy the penis-expanders and weight-loss snake oil nostrums that are intensively advertised on TV, and whether to invest in certificates of deposit, equities or junk bonds, how can we prohibit patients from making life-and-death medical decisions about drugs that have been shown to be effective?

The notion that FDA should "err on the side of safety" sounds like a tautology, but it is an affront to patients with incurable or poorly treatable diseases: For them, there is no safety in the status quo, and we only damage them further with paternalistic public policy that prevents individuals from exercising their own judgment. If FDA must err, it should be on the side of patients` freedom to choose.

Henry I. Miller, a physician and fellow at the Hoover Institution and Competitive Enterprise Institute, headed the FDA`s Office of Biotechnology from 1989-1993. His most recent book, "The Frankenfood Myth," was chosen by Barron`s as one of the 25 Best Books of 2004.
Click here for more TCS Daily special coverage of this issue.

[welke91]

Hallo Leute,

grad heute muss Wo spinnen grad heute wenn wir uns alle gegenseitig helfen müssen diese beiden Tage durchzustehen.

Heute wird sicher noch keine einigung erreicht werden!

grüße

[Poppholz]

ich rechne eher mit einer Entscheidung am Mittwoch.

Ansonsten hätten die sich auch nicht die Mühe machen müssen, den Kurs zwei Tage auszusetzen.

Vielleicht "sickert" heute aber auch schon so ein wenig durch.



Ist aber auch egal. Jetzt haben wir schon so lange gewartet.

[mikel_ann]

Ist heute eigentlich noch Handel ?

[welke91]

Hey Poppholz wie stehts mit dir?

feuchte hände,schüttelfrost, dunkle Augenränder ober bist echt total gelassen?

ich denke schon verdammt positiv!!!

[Poppholz]

FOCUS:Panel Advises FDA Wed On Elan`s Troubled MS Drug
03-06-06 12:40 PM EST
By Quentin Fottrell
Of DOW JONES NEWSWIRES

DUBLIN -(Dow Jones)- The U.S. Food & Drug Administration`s advisory committee will make a long-awaited recommendation on Wednesday that will decide the future of Elan Corp. PLC`s (ELN) multiple sclerosis drug Tysabri.

The FDA will take on board the advisory committee`s recommendations and make the final decision by the end of March on whether Tysabri can be marketed again and under what labeling restrictions, an Elan spokeswoman said.

The debt-laden company`s future relies heavily on Tysabri: before it was suspended on safety concerns in 2005, analysts hoped the drug would generate annual sales of between $1 billion - double Elan`s existing turnover - and $2 billion.

"The advisory committee will not make the ultimate decision, but obviously its review of Tysabri will be a significant step and will play an important role in the FDA`s decision," an Elan spokeswoman said.

Elan and partner Biogen Idec PLC (BIIB) suspended their would-be blockbuster drug in the U.S. on Feb. 28 last year after three patients on combination therapy - including Tysabri - contracted a rare neurological disease called PML.

While most analysts now predict that Tysabri will be marketed, they say it will be sold under a restricted monotherapy label - excluding the higher-risk combination therapy - and for those who haven`t responded to other MS drugs. Such restrictions will inevitably reduce sales.

"It will certainly not be used in combination with other MS drugs," agrees NCB Stockbrokers` Orla Hartford, but she also said that there`s still a vast unmet medical need for Tysabri - as seen by its use by nearly 7,000 patients pre- suspension.

"It`s worth remembering that only around 25% of patients used it as a combination drug when it was previously marketed," Hartford added. "Combination therapy is very expensive and frequently does have side-effects."

At 1715 GMT Monday, Elan was up 42 cents, or 4.1%, at EUR10.63 on the Irish Stock Exchange; the stock reacts aggressively to all comments on Tysabri by stockbrokers or doctors.

Elan has said it expects Tysabri to be reintroduced to the market and that the MS drug could break even with around 20,000 patients, or annual revenue of $500 million, though it expects its market to far exceed that level.

Biogen has the manufacturing capacity for 100,000 patients and is working to increase this to about 300,000 over 2 to 3 years; together, the companies aim to spend $300 million a year on marketing.

But Anne Marieke Ezendam, who runs the global healthcare fund at Threadneedle Investments in London says Elan needs to cut these costs and that the company`s revenue projections for Tysabri are optimistic. Ezendam does not have a rating on Elan.

"I see it hitting annual revenue of $300 million or $500 million if people are really raving about it," Ezendam said. "But Elan`s management team needs to look at the cost base, otherwise it won`t be able to afford its planned R&D."

Elan`s Tysabri setback followed a long and arduous recovery, beginning with a change of senior management in 2002, when Elan`s late former CEO and Chairman Donal Geaney resigned amid accounting troubles and a falling share price.

The European Medicines Agency, or EMEA, is currently reviewing data from Tysabri`s 2-year Phase III, a final premarketing study; Elan expects a decision by the EMEA mid-2006.

Elan aims to reduce its net debt to less than $1 billion by year-end, from around $2 billion currently; $850 million is due in 2008, $250 million of which is convertible to equity at $7.42/share if the share price is over $11.

Apart from Tysabri, Elan is also pinning its hopes on an Alzheimer`s drug. Elan expects to know whether its monoclonal antibody AAB-001 will move into Phase III toward year-end, and has said it is hopeful, given the data so far.

Elan`s stock will be suspended at 1300 GMT Tuesday in London, Dublin and New York to coincide with the start of the advisory committee`s meeting. "It`s nerve-racking," one observer said, "it`s like the calm before the storm."

Company website: http://www.elan.com

-By Quentin Fottrell, Dow Jones Newswires; [phone]; quentin.fottrell&# 174;dowjones.com


(END) Dow Jones Newswires
03-06-06 1240ET
Copyright (c) 2006 Dow Jones & Company, Inc.

[Poppholz]

[posting]20.548.212 von welke91 am 07.03.06 08:41:45[/posting]stehe der momentanen Situation positiv gegenüber.

Im schlimmsten Fall wird die FDA weitere Testergebnisse verlangen (allerdings besteht hierzu kein Grund, da die Ursache für die PML Fälle bekannt ist und entsprechend reagiert werden kann).

Ich gehe davon aus, dass die Sicherheitshinweise auf der Packung erscheinen werden und die Patienten ein entsprechendes Beratungsgespräch mit dem Hinweis auf die Risiken erhalten werden (ist auch sinnvoll, aber die Betroffenen werden wahrscheinlich sehr genau wissen worauf sie sich einlassen).

Alles wird gut.

Wir brauchen auf jeden Fall keine Angst vor einer Abzocke haben, wie sie momentan bei MOLOGEN durch gezogen wird (ganz miese Geschichte läuft dort)

[Poppholz]

[posting]20.548.122 von mikel_ann am 07.03.06 08:38:37[/posting]heute und morgen soll kein Handel statt finden.

[eliasesteban]

moin,in frankfurt schon 288 stück,kurs 10,37,das zum thema handel!

[Poppholz]

Irland und London sind auch fleißig am Handeln.



Mir ist es aber auch egal.

So können noch einige Glückliche einsteigen bzw. aufstocken.

[flow_solver]

Wer lesen kann ist im Vorteil.

Der Handel in London und Europa wird heute um 13:00 GWT
eingestellt! Bis dahin kann man natürlich noch handeln.

[welke91]

[posting]20.549.326 von flow_solver am 07.03.06 09:31:46[/posting] Risiko.......ab 13 Uhr na wollen noch welche raus....

Wer sein Leben so einrichtet,
daß er niemals auf die Schnauze fliegen kann,
der kann nur auf dem Bauch kriechen.

H. Riesenhuber

Unser Baby will laufen!

[Poppholz]

DRX.IR Uhr:9:59 Kurs:10,80 +0,20 +1,89% Menge:28.282 BID:10,60 ASK:10,80
ELA..L Uhr:9:49 Kurs:10,84 +0,19 +1,78% Menge:8.174 BID:10,65 ASK:10,82
DRX..F Uhr:9:36 Kurs:10,50 +0,15 +1,45% Menge:829 BID:10,52 ASK:10,70
EAN..F Uhr:9:00 Kurs:10,41 +0,05 +0,48% Menge:000 BID:10,66 ASK:10,82

auf der Insel haben die Käufer "mehr Mut"

[Birgit.Tersteegen]

ob ich noch ein bisschen aufstocke....habe ja durch meinen verlustreichen Mologenverkauf wieder etwas frei....??

[Poppholz]

UPDATE:FDA Asks Panel To Weigh Benefits, Risks Of Tysabri

03-06-06 12:24 PM EST
(Updates with Biogen`s comments in the seventh paragraph and additional material from the FDA starting in the eighth paragraph.)

By Jennifer Corbett Dooren
Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration will ask an outside panel of medical experts this week to make recommendations about whether the multiple sclerosis drug Tysabri should be allowed to return to the market.

Biogen Idec Inc. (BIIB) and Elan Corp. (ELN) pulled the drug off the U.S. market in February 2005 after two patients developed a rare brain disorder. A third patient was later discovered to have the disorder, known as progressive multifocal leukoencephalopathy, or PML. Two of the three patients died.

In briefing documents posted to the FDA`s Web site Monday, the FDA said it will ask the advisory committee to "reassess the risks and benefits of natalizumab (the generic name of the Tysabri) and advise FDA on the possible return of...(Tysabri) to the marketplace."

Tysabri was approved by the FDA in November 2004 and was only on the market for about three months when the companies pulled the drug.

The panel is set to start meeting Tuesday, but won`t make any recommendations until Wednesday. The trading of both Biogen and Elan`s stocks will be halted both days.

The FDA usually follows its panel`s advice but is not required to. The agency is expected to make a final decision on Tysabri by March 29. Most analysts expect the FDA to allow the drug back on the market with restrictions.

Biogen, in its briefing document posted to the FDA`s Web site, urged the FDA to allow Tysabri to return to the market, saying it "provides substantial clinical benefit...and that the risk-benefit profile warrants its reintroduction to patients." Biogen and Elan have proposed a risk management program that would, among other things, allow the companies to keep studying patients on Tysabri for at least five years.

The FDA panel is being asked to address up to 11 questions about Tysabri including whether MS patients should be required to first try other MS treatments such as Biogen`s Avonex, and whether Tysabri should be reserved only for those with more advanced cases of MS. The panel will also be asked whether patients who might take Tysabri should avoid Avonex. The two cases of PML in MS patients were in patients taking both Avonex and Tysabri.

The FDA raised some concerns about Tysabri`s proposed risk-management plan, but said the companies have agreed to make changes.

One recommendation the FDA had was that all patients taking Tysabri be followed for at least five years, not just smaller groups of patients that would be followed in post-marketing clinical trials, as originally proposed by Biogen and Elan.

The FDA noted that multiple sclerosis is a serious, often disabling disorder that afflicts approximately 300,000 patients in the U.S. MS is a progressive disease that affects the spinal cord and brain and involves damage to nerves that control muscles and vision

"Currently available MS treatments provide only modest benefit and are not tolerated by many patients," the agency said. "Therefore, there remains a substantial and urgent need for new treatments that are more effective in controlling the clinical manifestations of MS."

Clinical studies of Tysabri suggest the drug is an effective treatment. One study showed it cut the rate of clinical relapses by 68% and reduced by 83% the number of new or growing brain lesions that are found in MS patients after an average of two years.

The FDA said the magnitude of treatment with Tysabri in reducing the MS relapse rate "appears to be twice the benefit of currently available first-line treatments for MS," which also include Serono SA`s (SRA) Rebif, Betaseron, by Berlex Inc., a U.S. unit of Schering AG (SHR) and Teva Pharmaceuticals Industries Ltd.`s (TEVA) Copaxone.

But the FDA said it could not definitively make an assessment about the risk of PML associated with Tysabri because the currently available data are " insufficient." The agency noted that many MS patients have a relatively benign disorder and that treatment with Tysabri with the risk of PML "may be unacceptable."

"Primarily because the risk of PML, which is not well quantified, it is unclear for which patients the risk-benefit profile would be acceptable," the FDA said.

Last month the FDA lifted a "clinical hold" on Tysabri and said the companies could make the drug available to patients who were receiving the drug as part of preclinical studies. Biogen and Elan said they would begin a new clinical study and it would be open to patients who participated in the earlier clinical studies of the drug.

Biogen and Elan filed for permission to return Tysabri to the market in September. The FDA granted so-called priority review status to the application, which is usually reserved for drugs the agency deems would be a "significant improvement" compared to existing treatments if the product were to be approved. It cuts about four months off of the typical 10-month review period for a drug.

- By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; [e-mail].


(END) Dow Jones Newswires
03-06-06 1224ET
Copyright (c) 2006 Dow Jones & Company, Inc.


http://news.morningstar.com/news/DJ/M03/D06/200603061224DOWJ…

[Poppholz]

ein VIDEO auf FORBES:

http://www.forbes.com/video/?video_url=http://www.forbes.com…

[Poppholz]

Tysabri`s Fate Set to Be Determined

By Althea Chang
TheStreet.com Staff Reporter
3/6/2006 2:58 PM EST

Regulators are set to consider in the next two days whether Tysabri, the multiple sclerosis drug from Biogen Idec (BIIB:Nasdaq - commentary - research - Cramer`s Take) and Elan (ELN:NYSE ADR - commentary - research - Cramer`s Take), is safe enough to return to the market.

The drug was withdrawn from the market last year after three cases of a rare brain disease -- progressive multifocal leukoencephalopathy -- were linked to Tysabri. In two of the cases, the patients died.

This Tuesday and Wednesday, an advisory committee to the Food and Drug Administration will convene to look at the drug`s safety and effectiveness and to hear statements from patients who want the drug to be available as a treatment option.

Positive data on Tysabri`s effectiveness were published in the New England Journal of Medicine last week and appear to be too compelling for regulators not to at least strongly consider the drug`s return. Still, concerns have surfaced that Biogen and Elan haven`t adequately assessed the risk of PML that patients on Tysabri could face.

The advisory committee is expected to weigh the risks and benefits of the drug and discuss its ability to stop the development of physical disabilities in MS patients. The panel will also debate whether to approve the drug`s re-entry into the market with its use limited to a specific subset of patients. Additionally, the medical experts will try to determine if the drug may be used in combination with other so-called immunosuppressive agents.

According to FDA briefing documents posted on the agency`s Web site Monday, the committee might also request additional data or further studies on the drug. Tysabri was granted an accelerated review by the FDA on the basis of its efficacy and its potential to provide patients with a more effective MS drug than those already on the market.

Advisory committee meetings usually last only one day, but the FDA extended its meeting on Tysabri to two days in order to hear from patients and the general public. Trading in shares of Biogen and Elan will be halted during the meeting.

Biogen shares were lately down 32 cents, or 0.7%, at $45.18, while Elan was higher by 30 cents, or 2.4%, to $12.80.

http://www.thestreet.com/_tscrss/stocks/biotech/10271980.htm…

[Poppholz]

2nd UPDATE:FDA Panel To Weigh Benefits, Risks Of Tysabri

03-06-06 02:49 PM EST
(Updates with FDA comments on comparing clinical trials in 14th paragraph.)

By Jennifer Corbett Dooren

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration will ask an outside panel of medical experts this week to make recommendations about whether the multiple sclerosis drug Tysabri should be allowed to return to the market.

Biogen Idec Inc. (BIIB) and Elan Corp. (ELN) pulled the drug off the U.S. market in February 2005 after two patients developed a rare brain disorder. A third patient was later discovered to have the disorder, known as progressive multifocal leukoencephalopathy, or PML. Two of the three patients died.

In briefing documents posted to the FDA`s Web site Monday, the FDA said it will ask the advisory committee to "reassess the risks and benefits of natalizumab (the generic name of the Tysabri) and advise FDA on the possible return of...(Tysabri) to the marketplace."

Tysabri was approved by the FDA in November 2004 and was only on the market for about three months when the companies pulled the drug.

The panel is set to start meeting Tuesday, but won`t make any recommendations until Wednesday. The trading of both Biogen and Elan`s stocks will be halted both days.

The FDA usually follows its panel`s advice but is not required to. The agency is expected to make a final decision on Tysabri by March 29. Most analysts expect the FDA to allow the drug back on the market with restrictions.

Biogen, in its briefing document posted to the FDA`s Web site, urged the FDA to allow Tysabri to return to the market, saying it "provides substantial clinical benefit...and that the risk-benefit profile warrants its reintroduction to patients." Biogen and Elan have proposed a risk management program that would, among other things, allow the companies to keep studying patients on Tysabri for at least five years.

The FDA panel is being asked to address up to 11 questions about Tysabri including whether MS patients should be required to first try other MS treatments such as Biogen`s Avonex, and whether Tysabri should be reserved only for those with more advanced cases of MS. The panel will also be asked whether patients who might take Tysabri should avoid Avonex. The two cases of PML in MS patients were in patients taking both Avonex and Tysabri.

The FDA raised some concerns about Tysabri`s proposed risk-management plan, but said the companies have agreed to make changes.

One recommendation the FDA had was that all patients taking Tysabri be followed for at least five years, not just smaller groups of patients that would be followed in post-marketing clinical trials, as originally proposed by Biogen and Elan.

The FDA noted that multiple sclerosis is a serious, often disabling disorder that afflicts approximately 300,000 patients in the U.S. MS is a progressive disease that affects the spinal cord and brain and involves damage to nerves that control muscles and vision

"Currently available MS treatments provide only modest benefit and are not tolerated by many patients," the agency said. "Therefore, there remains a substantial and urgent need for new treatments that are more effective in controlling the clinical manifestations of MS."

Clinical studies of Tysabri suggest the drug is an effective treatment. One study showed it cut the rate of clinical relapses by 68% and reduced by 83% the number of new or growing brain lesions that are found in MS patients after an average of two years.

While the FDA said comparisons of MS treatments in various clinical trials was "problematic," the agency said the magnitude of treatment with Tysabri in reducing the MS relapse rate "appears to be approximately twice the benefit of currently available first-line treatments for MS." Other first-line treatments include Serono SA`s (SRA) Rebif, Betaseron, by Berlex Inc., a U.S. unit of Schering AG (SHR) and Teva Pharmaceuticals Industries Ltd.`s (TEVA) Copaxone.

But the FDA said it could not definitively make an assessment about the risk of PML associated with Tysabri because the currently available data are " insufficient." The agency noted that many MS patients have a relatively benign disorder and that treatment with Tysabri with the risk of PML "may be unacceptable."

"Primarily because the risk of PML, which is not well quantified, it is unclear for which patients the risk-benefit profile would be acceptable," the FDA said.

Last month the FDA lifted a "clinical hold" on Tysabri and said the companies could make the drug available to patients who were receiving the drug as part of preclinical studies. Biogen and Elan said they would begin a new clinical study and it would be open to patients who participated in the earlier clinical studies of the drug.

Biogen and Elan filed for permission to return Tysabri to the market in September. The FDA granted so-called priority review status to the application, which is usually reserved for drugs the agency deems would be a "significant improvement" compared to existing treatments if the product were to be approved. It cuts about four months off of the typical 10-month review period for a drug.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; [e-mail]


(END) Dow Jones Newswires 03-06-06 1449ET
Copyright (c) 2006 Dow Jones & Company, Inc.

http://news.morningstar.com/news/DJ/M03/D06/200603061449DOWJ…

[Poppholz]

BOSTON CAPITAL
The value of Tysabri
By Steven Syre, Globe Columnist | March 7, 2006

Will Tysabri get a second chance? I`d bet on it.

A Food and Drug Administration advisory committee meets today to consider the fate of Tysabri, the powerful multiple sclerosis drug with a troubled record. The drug was withdrawn from the market a year ago after two patients developed rare brain infections. Now the two companies behind the drug, Biogen Idec Inc. of Cambridge and Ireland`s Elan Corp., are joined by some patients pushing the FDA to allow Tysabri back on the market. A final FDA decision is expected by the end of the month.

Concessions may be required to settle safety issues raised by the FDA staff yesterday. But in the end, it will be hard for regulators to refuse patients who want Tysabri on the basis of dangerous but rare side effects. Approval isn`t a slam-dunk, but the odds are good.

Now here`s another question, not for regulators or patients, but for investors: How much is Tysabri worth as a product? And the real question: What is Biogen stock worth?

Tysabri, once optimistically projected to become a $3 billion drug, poses lots of investment questions. What would happen if the FDA actually turns thumbs down on the drug`s return? How hard would safety plans make it for patients to get Tysabri?

Then there are the doctor questions. How would they view the risk of prescribing the drug?

Finally, there is the great unknown. What would happen if more patients suffered serious side effects?

The price of Biogen stock, which closed yesterday at $45.51, had approached $70 per share when hopes were high for Tysabri. Once cases of serious side effects emerged and Tysabri was pulled off the market, Biogen shares plunged below $35.

If the highs and lows of Biogen shares represent stock market fear and greed at work, projecting Tysabri annual sales at $3 billion in one instance and nothing in the second, what does the current Biogen stock price suggest? About $1 billion in Tysabri sales.

That`s a rough way to do the math, and I wouldn`t necessarily recommend it. A better way would be to assume the value of biotech stocks can be driven at a rate equal to about six times the sales of a drug. The difference between Biogen`s stock lows and its current value again suggests Tysabri revenue around $1 billion (split down the middle with Elan).

Morgan Stanley analyst Mark Schoenebaum goes through much more sophisticated calculations than that and concludes peak Tysabri sales of $1 billion a year implies a fair value of $47 for Biogen shares, about equal to the current price. Lower the sales bar to $500 million and his stock value slips to $38 per share; raise sales estimates to $2 billion and the stock price climbs to $64. Schoenebaum rates Biogen stock as ``underperform."

The problem: Few people project Tysabri sales at $1 billion in the foreseeable future. Most hope it can generate $200 million or so in revenues for a few years and eventually build a bigger following. So where can the stock go from here?

Rob Junkin, manger of the John Hancock Health Sciences Fund, isn`t interested in buying Biogen shares now. ``At $45, I don`t feel like I`m missing anything," he says. ``From a risk-reward standpoint, I don`t see it."

Many patients prefer Tysabri to alternative treatments, and it appears to produce truly amazing results among some MS sufferers. Any plan that makes Tysabri available to them and successfully protects others from terrible side effects would be a worthy medical accomplishment.

But investors expecting more big gains from their Biogen shares based on a return of Tysabri may be headed for disappointment. A very successful Tysabri comeback is already priced into their stock, and there aren`t enough good reasons to expect more.

Steven Syre is a Globe columnist. He can be reached at [e-mail].

© Copyright 2006 Globe Newspaper Company.

http://www.boston.com/business/technology/biotechnology/arti…

[fred4]

Hallo Birgit,
verfolge ymb, bzgl. neuestes von der Konferenz
Gruß

[Birgit.Tersteegen]

[posting]20.551.660 von fred4 am 07.03.06 11:08:14[/posting]na klar!

[Poppholz]

FDA raps Biogen`s plan to track MS drug`s safety
Still analysts expect agency will approve return to the market
By Jeffrey Krasner, Globe Staff | March 7, 2006

A day before the start of a crucial Food and Drug Administration review of the multiple sclerosis drug Tysabri, the agency released a report criticizing plans by drug makers Biogen Idec Inc. and Elan Corp. PLC to monitor the use of the drug and track the health of patients.

But analysts and doctors said the 13-page report appears unlikely to derail efforts to return the drug to the market, and another FDA report released yesterday showed Biogen Idec, of Cambridge, had already responded to some concerns raised by the agency`s Office of Drug Safety.

``Clearly the drug is going to come back," said William Tanner, an analyst with Leerink Swan & Co ``The drug safety people are not asking them to reinvent the wheel. They`re asking them to be more rigorous in their risk-minimization plan."

If the Office of Drug Safety had more serious concerns, Tanner said, it could have required an additional clinical trial, potentially delaying the reintroduction of the drug by years.

Tim Hunt, a Biogen Idec spokesman, said the company has been working with the FDA since February 2005, when Biogen Idec and Elan voluntarily withdrew Tysbari from the market after two patients taking it in a trial contracted a rare brain disease. Ultimately, three patients in trials were found to have the disease, and two died.

``Our risk-management plan will continue to evolve with the FDA, as it has in recent weeks," Hunt said.

Yesterday`s news did not seem to rattle investors. Biogen Idec shares gained one cent to close at $45.51 on a day when broad market indexes declined sharply. Elan shares gained 20 cents to close at $12.70.

Tysabri was considered an extremely promising treatment when it went on sale in November 2004. In some clinical trials, it seemed to show twice the benefit of other first-line treatments for multiple sclerosis, according to an FDA briefing for the meeting.

Two weeks ago, the FDA gave Biogen Idec permission to restart clinical trials of Tysabri. But the drug`s commercial fate rests largely on hearings scheduled for today and tomorrow. Patients, doctors, and others will have a chance to speak about whether Tysabri should be sold again. The meeting was extended to two days after numerous patients sought to speak at the hearing.

The advisory committee will vote after the sessions conclude and its recommendation will go to the FDA. Although it is not binding, such recommendations usually predict how the agency will act.

``I want Tysabri back," said Dr. Mark Gudesblatt, medical director of South Shore Neurological Associates, a large private practice in Bayshore, N.Y. ``There are people I take care of that are on every medication or combination you can think of, and they`re doing poorly. I want another option."

One issue the FDA wants addressed is how Biogen Idec and Elan will oversee patients and doctors if Tysabri is brought back. The Office of Drug Safety wrote that the original plan submitted by Biogen Idec ``does not adequately address the risk" of the rare brain disease, progressive multifocal leukoencephalopathy.

In that plan, Biogen Idec had proposed that doctors and patients sign up voluntarily for a registry to track their experience with the drug. The drug safety office said all patients should be followed, regardless of how long they use Tysabri. In a subsequent memo, Biogen Idec proposed as part of a risk program that the registry be made mandatory.

Other specific recommendations of the safety committee that were detailed in the 13-page memo included:

Steps to prevent doctors from prescribing Tysabri to treat diseases other than multiple sclerosis. For instance, Tysabri is still being studied as a possible treatment for Crohn`s disease, an intestinal ailment.

Closer control of Tysabri supplies, to ensure that only people participating in the risk program receive the drug.

Restricting Tysabri to certain multiple sclerosis patients, such as those who aren`t responding to existing drugs.

``It`s reasonable to insist that physicians register with the safety plan, that patients register, and that infusion centers register, so that patient is being followed and if anything happens to that patient, it is brought to the attention of the scientific community," said Dr. R. Philip Kinkel, director of the Multiple Sclerosis Center at Beth Israel Deaconess Medical Center.

``We need to closely monitor patients that go on treatment, and we need further information as to how to minimize the risk of PML or any other adverse outcome."

Jeffrey Krasner can be reached at [e-mail].

© Copyright 2006 Globe Newspaper Company.

http://www.boston.com/business/technology/biotechnology/arti…

[welke91]

[posting]20.551.660 von fred4 am 07.03.06 11:08:14[/posting]beginn heute um 14 uhr ende morgen nachmittag !

[Poppholz]

anscheinend möchte sich aber zum jetzigen Zeitpunkt kein Analyst mehr negativ zu Tysabri und ELAN äußern.

Macht auf jeden Fall alles einen sehr "objektiven" Eindruck.

[Poppholz]

[posting]20.551.828 von Poppholz am 07.03.06 11:16:21[/posting]die Kurse laufen langsam nach oben.

[Birgit.Tersteegen]

[posting]20.551.935 von Poppholz am 07.03.06 11:21:29[/posting]und dass, obwohl das die KRITISCHEN Kommentatoren hier sind...

[Poppholz]

[posting]20.551.968 von Birgit.Tersteegen am 07.03.06 11:23:07[/posting]sehe ich genau so.



hast Du eben noch 2.000 DRX nachgelegt?

[Poppholz]

Irland steht bei €11,07 (bezahlt)

[fred4]

Briefing/Ablauf siehe:
http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4208-in…

[fred4]

sollte ich verkaufen ?

[bernie55]

[posting]20.552.342 von fred4 am 07.03.06 11:39:52[/posting]...wenn man fred4 heißt, natürlich nicht....

[Birgit.Tersteegen]

[posting]20.552.342 von fred4 am 07.03.06 11:39:52[/posting]wehe!

Poppi--bin noch nicht zum Zuge gekommen ....

gruss und uns viel Glück Birgit!!

[Birgit.Tersteegen]

ELN in Dublin €11.20 or $13.46 at 6:04
by: tekn0wizz (38/M/NL)

[Poppholz]

London steht sogar bei €11,24

[bernie55]

ELN in FRANKFURT: 10,41 €

Geld
11,48
Brief
11,66


DRX in Frankfurt: 11,25 €
Zeit
07.03.06 12:09:04

[bernie55]

...tja, ich bezeichne das als " Kaufrausch ".....

[Bernd13090]

[posting]20.553.090 von bernie55 am 07.03.06 12:15:30[/posting]hy bernie und birgit,

habt ja gut auf elan aufgepasst, in vietnam hats grausam mit elan ausgesehen .

gruß aus dem saarland

[bernie55]

[posting]20.553.122 von Bernd13090 am 07.03.06 12:17:35[/posting]..Hi Bernd

..bei uns in Germany sah alles halb so schlimm aus....

...wieder back in town ????

[mikel_ann]

Nun wollen aber schnell noch welche rein

[bernie55]

[posting]20.553.207 von mikel_ann am 07.03.06 12:22:50[/posting]...vielleicht diejenigen, die am Freitag für 9,70 € geschmissen haben....

[Poppholz]

Irland
DRX.IR ELAN CORP 12:10 11,50 +0,90 +8,49%

London
ELA.L ELAN CORP 12:10 11,44 +0,80 +7,46%



(und wir haben es die ganze Zeit gewußt)

[bernie55]

(und wir haben es die ganze Zeit gewußt)

..geahnt, Poppie , geahnt.....

[Poppholz]

Frankfurt ist noch günstig.

[Poppholz]

[posting]20.553.266 von Poppholz am 07.03.06 12:27:00[/posting]solche Kurse werden am Donnerstag nicht mehr vorkommen

[Poppholz]

[posting]20.553.289 von bernie55 am 07.03.06 12:28:23[/posting]dann sagen wir doch "richtig interpretiert".

nur aufgrund einer Ahnung würde ich nicht so viel Geld investieren.

[Poppholz]

die letzten 15 Minuten laufen.

Wer noch "günstig" rein möchte, sollte jetzt zugreifen.

Anscheinend wollen ja auch nicht mehr viele verkaufen.



(es kann natürlich auch alles anders kommen als wir denken)

[Bernd13090]

hy bernie,
bin wieder im lande, gibts neuigkeiten oder warum zieht der kurs so an,

ist ja im moment alles spekulation.

gruß

[Birgit.Tersteegen]

[posting]20.553.739 von Bernd13090 am 07.03.06 12:53:07[/posting]Erwarte wunderbaren Reisebericht von Vietnam....Ich dachte Du kommst nach dem AC wieder?

Wir steigen weil die Zulassung in grosse Nähe rückt...

[bernie55]

[posting]20.553.314 von Poppholz am 07.03.06 12:29:51[/posting]nur aufgrund einer Ahnung würde ich nicht so viel Geld investieren.

Poppie, Ahnung kommt Ahnung !!!! und nicht nur von Vorahnung bzw. Nichtchecken...

RESUME:

...von nichts eine Ahnung haben..
..trifft bei uns WO-ELANNIES nicht zu !!!

..von Tuten und Blasen keine Ahnung haben..
..trifft bei uns WO-ELANNIES nicht zu !!!

..keine blasse Ahnung haben..
..trifft bei uns WO-ELANNIES auch nicht zu !!!


ALSO:

... wir wissen , was wir tun....oder auch nicht...

..egal ob mit oder ohne Ahnung..


Grüße bernie55

[bernie55]

[posting]20.553.604 von Poppholz am 07.03.06 12:46:12[/posting](es kann natürlich auch alles anders kommen als wir denken)

..Yepp, aber warum nur ???

[bernie55]

test

[Poppholz]

die ELAN Schlusskurse um 13.00 Uhr:

DRX.IR 11,65 +1,05 +9,91% 120.853 BID:11,30 ASK:11,65
ELA.L. 11,65 +1,00 +9,39% 189.798 BID:11,31 ASK:11,65
DRX.F. 11,40 +1,05 +10,14% 07.980 BID:11,55 ASK:11,75
EAN.F. 10,41 +0,05 +0,48% 000.000 BID:10,71 ASK:10,87

Mal sehen wie sich diese am Donnerstag verändert haben.

[Poppholz]

anscheinend wird in Irland immer noch gehandelt.

[bernie55]

HILFE.....was ist los mit WO ??????

[Birgit.Tersteegen]

[posting]20.554.359 von bernie55 am 07.03.06 13:29:16[/posting]WIESO?

[bernie55]

....es funzt wieder......

[Poppholz]

[posting]20.554.359 von bernie55 am 07.03.06 13:29:16[/posting]anscheinend haben die um 13.00 Uhr den Betrieb eingestellt.

[Poppholz]

auf ARCAEX und INET werden auch Orderbücher angezeigt.



Gibt es doch keine Kursaussetzung?

(ach ja, die Shorties müssen doch noch wieder rein kommen)

[bernie55]

Aktuell
11,60 €

Zeit
07.03.06 13:33:46

Diff. Vortag
+11,97%


...ich weiß nicht, ob das jemand schon reingepostet hat..

..mein WO spinnt wieder einmal..

.meine Postings erscheinen irgendwie zeitverzögert.....

[diddlhase]

[posting]20.551.251 von Birgit.Tersteegen am 07.03.06 10:50:02[/posting]Hi Birgit,

was denn, du hast Mologen verkauft, oder bist ausgestoppt worden?:O
Vielleicht solltest Du Dich bei einem Glas Wein mal zurücklehnen und überlegen, ob Du bei Elan aufstocken willst oder bei Mologen wieder einsteigen?! Bei welchem Wert hast Du größere Chancen Gewinne zu machen?!? Mal die Weisheit mit dem fallenden Messer.. außer acht zu lassen. Manche Messer sind schon mächtig gefallen und danach wieder in die Höhe gestiegen! In spätestens 4 Wochen bist Du schlauer!!
Elan wird übrigens immernoch gehandelt!!

[Poppholz]

inet hat den Handel mit ELAN eingestellt.

[Dennie]

Wird denn nun den ganzen Tag über gehandelt oder nicht ? Muss doch jemand hier genaueres wissen oder ?

[Birgit.Tersteegen]

FDA meeting started
by: defenderyou 03/07/06 08:35 am
Msg: 942773 of 942779

Biogen presenting the history of TYsabri now

[Birgit.Tersteegen]

BIIB says
by: zepsdaddy (43/M/Florida)
Long-Term Sentiment: Strong Buy 03/07/06 08:44 am
Msg: 942794 of 942811

monotherapy only! Stated twice already at meeting.

[bernie55]

....ja, das gibts doch gar nicht....


WO funktioniert ?????

[bernie55]

......schon wieder nicht !!!!!!!!

[Birgit.Tersteegen]

[posting]20.554.924 von Dennie am 07.03.06 14:18:22[/posting]Heute und Morgen nicht mehr!

[Poppholz]

[posting]20.554.924 von Dennie am 07.03.06 14:18:22[/posting]13.00 Uhr englische Zeit.

Somit hier um 14.00 Uhr.

[Poppholz]

die scheinen bei W O echte Probleme zu haben. Die Postings werden alle zeitverzögert angezeigt.

Ist halt ein wenig unstimmig, die ganzen Postings zu lesen.

Fragen auf Antworten, die bereits vor einigen Tagen eingestellt wurden.

[bernie55]

[posting]20.555.681 von Poppholz am 07.03.06 15:20:40[/posting]Fragen auf Antworten, die bereits vor einigen Tagen eingestellt wurden

...da gibt es wenigstens keine Diskussionen....

[Birgit.Tersteegen]

Aber wir haben uns wieder

Fight broke out at the AC !
by: coloncowboyu
Long-Term Sentiment: Strong Buy 03/07/06 09:18 am
Msg: 942878 of 942927

MS`s are beating the crap out Krasner ! They got him pinned down to the floor !


-----ob das stimmt??Ichwäre SOOOOOOOOOOOOOOOOO gerne dabei!

[bernie55]

...also heute zu posten - sinnlos !!!!!!


WO , haut mal in die Kerbe.....wir wollen uns mal wieder wohl fühlen....

[bernie55]

[posting]20.555.839 von Birgit.Tersteegen am 07.03.06 15:31:50[/posting]They got him pinned down to the floor !


UPS !!!!!

....das tut uns aber leid.....

[bernie55]

es fuuuuuunnnnzt wieder !!!!!!

[Birgit.Tersteegen]

Okay ...
by: paddystocks 03/07/06 09:41 am
Msg: 942958 of 942958

Looks like we`re talking mandatory monitoring/registration and a prominent label (not black box) and the drug to be re-introduced mainstream (no restrictions).

This means -block buster-.

[Poppholz]

ich würde so gerne mithören.

Hätte mich vielleicht krank melden sollen.



@Birgit: Bitte halte uns auf dem Laufenden.

[Birgit.Tersteegen]

[posting]20.556.180 von Poppholz am 07.03.06 15:48:35[/posting]Ich höre leider auch nichts.Im yahoo-board schreibt"romolus" aus der AC.
Wir Dussel hätten alle Teva-puts kaufen sollenIin 3 Tagen verdreifacht....

"We have designed plan w/o...
by: roymulus
Long-Term Sentiment: Strong Buy 03/07/06 09:48 am
Msg: 942981 of 942993

...unecessary burden to doctors or patients." FDA AC

[Poppholz]

von PUTS und CALLS verstehe ich leider so gar nichts.



Höre immer nur, dass damit "richtig viel" Geld gemacht werden kann.

[Birgit.Tersteegen]

ich auch nicht...

Recommend this Post Ignore this User | Report Abuse
Re: Dr. Rudick
by: zepsdaddy (43/M/Florida)
Long-Term Sentiment: Strong Buy 03/07/06 09:56 am
Msg: 943004 of 943005

He`s now outlining T benefit over other therapies. 1/3 vs 2/3 reductions in relapse rates.

[bernie55]

[posting]20.556.384 von Poppholz am 07.03.06 15:56:27[/posting]..aber auch " das ganze " Geld verloren werden kann.....


...ich handel auch nicht mit Optionsscheinen....

[bernie55]

...na, da sind wir drei uns ja wieder einig !!!

[bernie55]

...so, ich muss los.....see you, ELANNIES ....

[Poppholz]

[posting]20.556.434 von bernie55 am 07.03.06 15:59:05[/posting]ich denke auch.

Bei Aktien haben wir ja wenigstens etwas in der Hand.



Im Ernst: Hier ist das Risiko doch ein wenig überschaubarer, zu mal wir diese dann auch liegen lassen können.

[Birgit.Tersteegen]

"I believe Tysabri should...
by: roymulus
Long-Term Sentiment: Strong Buy 03/07/06 10:00 am
Msg: 943018 of 943079

...be used by fully informed patients in consultation with their doctors" FDA AC

[Birgit.Tersteegen]

Recommend this Post - This post has 5 recommendations Ignore this User | Report Abuse
Re: Dr. Rudick
by: youkei 03/07/06 10:04 am
Msg: 943031 of 943082

IMHO that he could not have done better. Confident, realistic, rational, not appealing for `the world`. I thought he massaged many nerves without `striking` them.

[Birgit.Tersteegen]

The difficult questioner wanted...
by: roymulus
Long-Term Sentiment: Strong Buy 03/07/06 10:20 am
Msg: 943082 of 943137

... to know, specifically, how many reductions in relapses and reductions in progression, per 1,000 patients WHEN COMPARED TO THE OTHER MS DRUGS! He said the Tysabri was, "unfortunately", compared to placebo rather than the other MS drugs 9 (the CRABS). Duh! So it is now "unfortunate" that drugs are first compared against placebos? Bias?

[Birgit.Tersteegen]

Tsybari comparisons
by: frankie8001 03/07/06 10:25 am
Msg: 943104 of 943143

Ty comparisons with placebo is known;

Other MS drug comparison with placebo is known;

On basis of the above, it is shown that Ty twice as effective as other MS drugs.

now that was not too difficult. Perhaps, Teva may hire a mathematician to refute the above.

[Birgit.Tersteegen]

e: Why did BIIB request strictest label
by: pinvestment 03/07/06 10:43 am
Msg: 943176 of 943192

because the FDA doesn`t want everybody in the world starting to use tysabri for crohns and other diseases right off the bat - that is why they want certain controls on its release - it not crohns patients failing therapy will try tysabri also and possibly do so with a ton of other immune suppressant they don`t need to take and might be dangerous

for now the FDA will try its best to only allow tysabri to MS patients - but i still think that ty market share in 2-3 years is 30-40% of insured market - that would be 3-4 billion in the US alone

[Birgit.Tersteegen]

edderdz
by: pinvestment 03/07/06 10:49 am
Msg: 943199 of 943258

i think i am just stating the obvious - you are taking copax - one day you go blind in your right eye? do you stay on copax or try a more efficacious drug?

one day you become incontinent - do you stay on copax or try a more efficacious drug?

one day you realize you cannot walk and a family member orders a wheelchairs for you - do you stay on copax or try a more efficacious drug?

one day you realize that over the last 3 years you cannot do most of the chores of daily living and suffer terrible fatigue - do you continue to take avonex or rebif and spend 2-4 days a week sick as a dog and watch the rest of your life slip away or do you take a more efficacious drug without the side effects

in time more people will realize what unmet medical need is - analysts might think unmet medical need refers to a drug stock that the analyst is not currently bashing or hyping - in time they will realize their folly